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Editorial on the Research Topic
The Clinical and Ethical Practice of Neuromodulation – Deep Brain Stimulation and Beyond
Neuromodulation is among the fastest-growing areas of medicine, involving many diverse
specialties and affecting hundreds of thousands of patients with numerous disorders worldwide. It
can briefly be described as the science of how electrical, chemical, and mechanical interventions
can modulate the nervous system function. A prominent example of neuromodulation is deep
brain stimulation (DBS), an intervention that reflects a fundamental shift in the understanding
of neurological and psychiatric diseases: namely as resulting from a dysfunctional activity pattern
in a defined neuronal network that can be normalized by targeted stimulation. The application
of DBS has grown remarkably and more than 130,000 patients worldwide have obtained a DBS
intervention in the past 30 years—most of them for treating movement disorders. These numbers
will grow further for several reasons. First, DBS is investigated for various novel neurological and
psychiatric indications. Second, current research suggests that stimulation may be more beneficial
if it is applied earlier in the course of the disease, especially for Parkinsonian patients. Third, the
number of countries, centers, and companies that get involved in this field is steadily increasing.
This Frontiers Research Topics provides an overview on the current discussion beyond basic
research in DBS and other brain stimulation technologies. Researchers from clinical disciplines
(e.g., neurology, neurosurgery, and psychiatry), neuroethics, social science, law, and economics
who are working on broader clinical and social issues related to DBS and related neuromodulation
technologies have contributed to this research topic. In the following, we provide a brief overview
on the content of the e-book on “The clinical and ethical practice of neuromodulation – deep brain
stimulation and beyond.”
The paper from Ineichen and Christen exemplifies the impressive publication activity in the
field. They analyzed more than 7,000 papers published between 1991 and 2014 on DBS using
quantitative methods. The study confirms known trends within the field such as the emergence
of psychiatric indications with a particular focus on depression and the increasing discussion of
complex side-effects such as personality changes. Other findings are more surprising, e.g., that
hardware-related issues are far more robustly connected to ethical issues compared to impulsivity,
concrete side-effects or death/suicide. This indicates that the bioethical discussion on DBS may
underestimate ethical problems due to DBS hardware.
The issue of complex side-effects are in the center of the opinion article of Cyron. He argues
that psychiatric side effects are an integral part of DBS for Parkinson’s disease. Particularly,
hypomania, reckless behavior, suicidality, changes in personality, and moral competence are issues
with a confounding ethical impact. He pleads for a sober and unprejudiced discussion about
neuropsychiatric effects of DBS for Parkinson’s disease.
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Kocabicak et al. address the vividly discussed question
whether there is still need for microelectrode recording, given
that the subthalamic nucleus can be well-visualized with MR
imaging. Based on the literature and their own experience, they
argue that intra-operative electrophysiology is not necessary to
find the STN. However, they have decided not to abandon
it, particularly because with multiple-electrode recordings, an
alternative trajectory is immediately available, if necessary.
Müller et al. broaden the view on psychiatric neurosurgery
in their contribution. They compare the rivaling paradigms
DBS and modern ablative procedures with microsurgery or
radiosurgery, and argue that none of the procedures is absolutely
superior. Rather, they have different profiles with respect to
advantages and disadvantages. They conclude, that the patients’
social situation, individual preferences, and individual attitudes
are crucial when deciding, which of the methods are preferable.
Crowell et al. describe their observations of the response
of patients with treatment-resistant depression to DBS. They
find that the typical time course consists of different phases,
beginning with changes in mood reactivity, followed by a
transient worsening prior to stabilization of response. The
authors hypothesize that this characteristic recovery curve
reflects the timeline of neuroplasticity in response to DBS.
Beeker et al. discuss the ethical concern that DBS for patients
with major depression might threaten their ability to make
autonomous decisions. The authors argue that DBS in these
patients might increase the patients’ autonomy by reducing
anhedonia and increasing energy, so that it can rather restore
than threaten autonomy.
A summary of the current state of the discussion on the
many facets of DBS is provided by the “Proceedings of the
Fourth Annual Deep Brain Stimulation Think Tank” from Deeb
et al. that took place in 2016 and gathered leading researchers
such as James Giordano, Helen Mayberg, Jens Volkmann, and
Michael Okun. The spectrum of addressed topics is very large and
includes research and clinical practice, policy issues such as the
formation of registries and novel technological innovations such
as closed-loop DBS. Readers gain an up-to-date overview when
consulting this contribution.
The contribution of Glannon provides a more philosophical
focus on the issue of neuromodulation. He pleads for a
non-reductive materialist model of the mind and brain
relation. He argues that the fact that DBS can modulate
dysfunctional brain circuits to make them amenable to cognitive-
behavioral therapy underscores the complimentary of brain-
based and mind-based techniques in controlling the symptoms
of psychiatric disorders.
Finally, Cabrera and Reiner have investigated the public’s
understanding of the proposed use of a non-invasive
neuromodulation technique: transcranial direct current
stimulation (tDCS). They investigated the use of tDCS for
enhancement by analyzing and comparing online comments
in key popular press articles from two different periods:
pre-commercialization and post-commercialization. They found
that the public’s attitude has shifted from misunderstanding to
cautionary realism—probably a common pattern when analyzing
the public reception of new neurotechnologies.
Overall, the contributions that form this eBook on clinical
and ethical practice of neuromodulation demonstrate the many
facets of a fascinating new research field that poses important and
challenging ethical and social questions. It is encouraging to see
that researchers from many different disciplines have begun to
tackle them.
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The enormous increase in numbers of scientific publications in the last decades requires
quantitative methods for obtaining a better understanding of topics and developments
in various fields. In this exploratory study, we investigate the emergence, trends, and
connections of topics within the whole text corpus of the deep brain stimulation (DBS)
literature based on more than 7000 papers (title and abstracts) published between
1991 to 2014 using a network approach. Taking the co-occurrence of basic terms
that represent important topics within DBS as starting point, we outline the statistics
of interconnections between DBS indications, anatomical targets, positive, and negative
effects, as well as methodological, technological, and economic issues. This quantitative
approach confirms known trends within the literature (e.g., regarding the emergence
of psychiatric indications). The data also reflect an increased discussion about complex
issues such as personality connected tightly to the ethical context, as well as an apparent
focus on depression as important DBS indication, where the co-occurrence of terms
related to negative effects is low both for the indication as well as the related anatomical
targets. We also discuss consequences of the analysis from a bioethical perspective,
i.e., how such a quantitative analysis could uncover hidden subject matters that have
ethical relevance. For example, we find that hardware-related issues in DBS are far more
robustly connected to an ethical context compared to impulsivity, concrete side-effects or
death/suicide. Our contribution also outlines themethodology of quantitative text analysis
that combines statistical approacheswith expert knowledge. It thus serves as an example
how innovative quantitative tools can be made useful for gaining a better understanding
in the field of DBS.
Keywords: deep brain stimulation, text analysis, network analysis, co-occurrence of terms, bibliometrics,
bioethics
INTRODUCTION
A characteristic of modern knowledge production is the enormous increase of the number of
scientific publications (original papers, reviews, conference abstracts, editorial material, etc.) that
is made accessible through digital technology. In neuroscience alone, it is estimated that more
than 100,000 papers a year are added to a text corpus that contains many millions of publications
(Grillner, 2014). This information overload poses a substantial challenge for researchers to keep
pace with the developments in their own fields; and it is well-known that the biomedical sciences are
especially vulnerable in this regard, since they are strongly oriented toward text-based knowledge
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sources (Hölzer et al., 2006). This problem certainly also holds
within the field of Deep Brain Stimulation (DBS) (Hariz et al.,
2013), that has experienced a substantial growth of publications
since the late 1990s (Müller and Christen, 2011). In this paper
we propose a way to handle this challenge by using quantitative
text analysis that combines statistical approaches with expert
knowledge.
Quantitative approaches using bibliometrics, scientometrics,
and text mining have gained popularity, as they may serve
as navigational prospects and orientation aids. They enable
researchers to identify relevant topics, trends, and publications
in a fast-growing text corpus. Among other methods, network
approaches, and data visualization techniques that aim to identify
connections between topics within a given text corpus are being
used (Popping, 2000, 2003; Ryan, 2007) and have shown to
be useful to grasp important concepts within a text of any
length. While being applied in a wide field, such approaches
have a long tradition in enabling researchers exploring possible
configurations of the unknown, shared visual representations
which may open new ways for channeling collective attention,
envisaging innovative interpretations and help us to make sense
of data at different scales (Okada et al., 2014). The ultimate
advantage of network analyses and their visual representation
in general is recognized from a wide and diverse field. Ideally,
the results of such a methodological approach will verify
conjectured trends within the field, enrich the discourse, and
support unconventional ideas or interpretations of the ongoing
scientific development. In the following, we will explore the
techniques of sized graphs in combination with sophisticated text
preprocessing in order to find features in the network structure of
the DBS text corpus which otherwise would be difficult to detect.
In general, a graph visualizes relations of a given set of data
and is composed of nodes and edges. Nodes typically represent
items or concepts whereas edges connect nodes according to
some association rules. Graphs are widely used for e.g., analyzing
social networks where people represent the nodes and edges
represent relationships between people. To convert information
(e.g., of text) into a visual representation can facilitate the
handling and perception of hidden structures from large data
sets. By following paths and detecting clusters of closely related
nodes, one may detect unique features of a given data set.
However, if the data set exceeds a certain level of magnitude, the
task of exploring, and navigating becomes increasingly difficult.
More specifically, there is extensive work on representing textual
data as graphs and the subsequent application of network text
analysis (e.g., Losiewicz et al., 2000; Grbic et al., 2013; James et al.,
2013; Guan et al., 2014) for gaining an increased understanding
of influential concepts, text’s meanings, and structure. Network
Abbreviations: ALIC, Anterior limb of internal capsule; BC, Betweenness
Centrality; DBS, Deep Brain Stimulation; ECT, Electro-convulsive therapy; ET,
Essential tremor; GP, Globus pallidus; GPi, Globus pallidus internal segment;
MDD, Major depressive disorder; STN, Nucleus subthalamicus; Nacc, Nucleus
accumbens; OCD, Obsessive-compulsive disorder; PD, Parkinson’s disease; PPN,
Pedunculo-pontine nucleus; QoL, Quality of life; SCS, Spinal cord stimulation; SG,
Subgenual cingulate; TS, Tourette syndrome; tDCS, Transcranial direct current
stimulation; VNS, Vagus nerve stimulation; Vim, Ventral intermediate nucleus; Zi,
Zona incerta.
analysis is therefore also suitable for linguistic comparative
analyses which focus on semantic relations between words, often
framed through the co-occurrence of terms (i.e., relevant terms
that more often appear in the same text are more likely to share
some semantic connection). By making use of the large number
of published DBS papers as well as a statistics driven quantitative
approach, a potential subjective bias may be diminished.
In the following, we will use graph analysis and visualization
techniques for investigating (1) most influential topics, (2) their
mutual connections as well as (3) the temporal development
of topics by retrieving the titles and abstracts of all published
publications from 1991 to 2014 in the field of DBS (see
Material and Methods for more specific information). We
expect to be able to reproduce known phenomena (e.g., an
increase in discussing psychiatric disorders in the DBS literature,
well-described anatomical targets for the treatment of various
disorders, or known treatment methods for various disorders)
which might become obvious in different ways (e.g., direct
connections or by reference to how e.g., anatomical targets
are being discussed). Additively, we are interested in detecting
how specific topics (e.g., lesioning-methods, personality, and
bioethics) develop over time and/or how they interrelate with
other topics. The original text corpus was composed of more
than 10,000 DBS publications, based on which 7154 texts (titles
and abstracts) containing more than 400,000 potentially relevant
words have been selected for analysis. Using the co-occurrence of
key terms as association rule, we conducted graph visualization
techniques, community analyses and quantitative metrics to get
insight into how DBS has been discussed during the last 23 years.
The results of this analysis are then reflected by referring
to issues that dominated the DBS literature. Beside others, we
are interested in how some topics that have been identified as
ethical focal points in the international practice of DBS (Christen
et al., 2014) are represented in this quantitative approach. In this
way we explore the potential of such quantitative approaches for
identifying subject matters that are of relevance from a bioethical
perspective. The study will conclude by a discussion of limitations
of quantitative approaches as heuristics to deal with information
overload.
MATERIAL AND METHODS
Textual data is complex due to syntactic (verb forms, declination,
etc.), semantic (homonymy, synonymy, etc.) and pragmatic
(context-dependency etc.) variation. Therefore, any quantitative
analysis based on textual data has to ensure appropriate
preprocessing of text data such that it can be correctly used
for statistical processing. In the following, we first describe text
preprocessing to generate the final word set that was then used for
trend and co-occurrence analysis, before we outline the network
analysis and visualization methodology. The aim of the study was
to obtain a comprehensive set of DBS publications as a set for
quantitative analysis. We restricted ourselves to papers published
since 1991, as earlier papers on DBS are rather sparse and do not
yet contain in all cases the string “deep brain stimulation” as a
simple identifier for a text that can be attributed to the DBS text
corpus.
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Text Preprocessing
Text preprocessing contained three steps as outlined in Figure 1.
The starting point was a search in the Web of Science Core
Collection database (the search was performed on December 5th
2014)1. We used the search string “deep brain stimulation” in
the “topics”-field, restricted to the time range 1991 to 2015. We
excluded the “Proceedings Citation Index,” because entries in this
database only contain the title of contributions without abstract.
This resulted in a set of more than 10,000 contributions and a text
corpus of almost 1.2 million words. In a first preprocessing step,
we deleted special characters (e.g., “(” or “?” including number
signs) as well as the search string itself (because it is unspecific),
we transformed all letters into lower case and wemerged frequent
word pairs (e.g., “informed consent” to “informedconsent”). This
last step was based on a word-pair statistics over the whole text
set to identify very frequent pairing of words (a cutoff value
of about 80% was chosen). We identified frequent word pairs
by selectively looking through potential word-pairs and decided
whether they should be merged based on our experience with the
DBS vocabulary (in total, 130 word pairs were merged).
In a second preprocessing step, we deleted standard stop
words2 like “the,” “is” etc., and we performed a lemmatization,
i.e., we transformed all nouns, verbs, and adjectives into their
ground form using standard lookup tables3; for example the
plural “brains” is replaced by “brain” or the past tense “came”
is replaced by “come”—the latter step served for removing the
amount of variability. We refrained from stemming (another
standard procedure in text processing), because a stemmer
operates on a single word without knowledge of the context,
and therefore cannot discriminate between words which have
different meanings depending on the text. Finally, we computed
the text length distribution and we deleted all short texts4. The
remaining text corpus consisted of 7154 texts and 597,474 words,
22,034 of which were distinct words.
Finally, a third preprocessing step was necessary due to
area-specific stop-words and terms that were not contained
in standard lemmatizing lists. We first deleted all words that
were present in less than 0.1% of the texts (i.e., that are
contained in maximal seven texts), because these rare words are
not suitable for statistical text analysis. Then, two raters (the
authors) independently assessed which words are considered to
be unspecific. If both raters independently rated the same words
as unspecific, they were deleted (1308 in total). In a similar
way, we identified 1380 replacement-pairs for area-specific
lemmatization5. In this way, we generated a set of 7154 texts that
1WoS, Thomson Reuters, access through https://webofknowledge.com/
2Available at: https://code.google.com/p/stop-words/
3Available at: http://www.lexiconista.com/datasets/lemmatization/
4The text length distribution displayed a peak for very short texts (e.g., editorial
material that is only present in the WoS database with its title). In the mean, there
were 36 texts per bin, the standard deviation was 57. Thus, the distribution was cut
where there were more than 36 + 57 = 93 texts per bin, which was the case for
texts that contained 11 or less words).
5In some cases, we also replaced verbs or adjectives with nouns; e.g., “painful”
was replaced with “pain,” because the number of words of one category was
considerably lower compared to the number of words of the other category.
FIGURE 1 | Scheme outlining the generation of the final text set for
network analysis.
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FIGURE 2 | Distribution of publication years of all texts of the final set
(7154 texts), indicating a steep growth in the number of DBS texts
since the late 1990s.
consisted of 411,655 words, consisting of 2591 distinct words.
This set was used for the quantitative analysis.
Figure 2 provides an overview of the text corpus in terms
of publication years which shows the quantitative basis for our
analysis and reflects the substantial growth of publication within
the field of DBS. Text size distribution and term frequency are
shown in Supplementary Figure 1.
Text Analysis
The text analysis consisted of an expert evaluation part and a
statistical part. The expert evaluation (performed by the authors)
aimed to identify terms that are characteristic for issues and
topics that are widely discussed in the field of DBS. For issue
identification, we also referred to earlier publications from us, i.e.,
we included issues and topics which were identified as relevant
based on an analysis of DBS conference contributions (Christen
and Müller, 2011) and a large review covering the literature on
DBS in the Nucleus subthalamicus (Christen et al., 2012). “Issues”
refer to overarching themes (such as anatomical localization),
“topics” refer to defined subject matters within an issue (such
as specified anatomical localizations), and “terms” refer to the
actual words that appear in the text. As outlined in Table 1, seven
issues containing 73 topics were chosen for further analysis, based
on the authors estimation of relevance (some topics could be in
more than one issue; e.g., pain as indication or side-effect). Topics
sometimes are composed of different terms (e.g., “accumbens”
and “nucleusaccumbens”). In that case, the terms describe the
same topic.
In addition, we analyzed ethical issues as a single topic
characterized by the terms “ethic,” “moral” and “social” because
we were interested in investigating on how ethical aspects are
being discussed in the literature. In total, we had 74 topics and
162 terms. For these topics, we performed a trend analysis, i.e., we
counted the appearance of terms belonging to different topics in
all texts of a single year starting from 2000 (due to the low number
of texts in the 1990s that contained topic terms). We always
normalized the trend data with the total number of publications
per year for detecting trends within the whole DBS publication
body.
Furthermore, we calculated the pairwise co-occurrence
C(X,Y) of two topics X and Y as:
C(X,Y) =
∣∣T(X,Y)
∣∣
min({|X| , |Y|})
Where
∣∣T(X,Y)
∣∣ denotes, how often the terms characteristic for
topic X and Y appear in the same text and |X| respectively |Y|
denotes, in how many texts these terms appear in the whole
set. C(X,Y) is between 0 (the terms of two topics never occur
in a same text) and 1 (the terms always occur in same texts).
The co-occurrence is used as similarity metrics for the network
analysis.
For visualizing the co-occurrence matrix, we used Gephi,
an open source software for analyzing graphs and networks6.
In the resulting graph, the thickness of the edges reflects the
co-occurrence, i.e., a higher probability that two terms appear
in the same text is reflected by a thicker and more saturated
connection.
The sizes of the nodes (= topics) reflect their betweenness
centrality (BC), which is equal to the number of shortest
paths from all vertices to all others that pass through
that node. The betweenness centrality BC(X) of topic X is
defined as:
BC(X) =
∑
X 6=Y 6=Z
σY,Z(X)
σY,Z
Where σY,Z is the number of shortest paths between topics Y
and Z, and σY,Z(X) is the number of shortest path between those
two topics that pass through X. For example, if there are three
different shortest paths between two nodes and a third node is
part of two of them, then the BC of this third node and for
this specific configuration is 2/3. As a result, nodes with higher
BC are more influential, because they functions as junctions for
“communication” within the network (Freeman, 1977; Brandes,
2001). Terms with high BC are therefore hypothesized to play the
most important role in establishing the meaning for the text and
its interpretation.
We visualized the whole network of all topics as well as
the networks that only contained topics of two issue classes
(we performed six specific visualizations in total: anatomical
targets-indication, indication-side effects, anatomical targets-
side effects, technological issues-indication, economic issues-
indications, positive-effects-anatomical targets. In the following,
we display the three of them that yielded the most interesting
results.
In some cases, we also looked at Page rank values of each
node in order to make a statement about the importance of the
term. Page rank is an algorithm that was originally developed
to measure the relative importance of web pages. It formed the
basis for ranking results when using the Google search engine
and was named after Larry Page (Brin and Page, 1988; Page
et al., 1999). Today, Page rank is a common tool in network
analysis aiming at assessing linked documents based on their
6Available at http://gephi.github.io/
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TABLE 1 | Issues and associated topics, characterized by terms that were contained in the final set.
Issue Topics associated with issue (in brackets: terms that characterize the topic)
Anatomical localization 15 topics:
{accumbens, nucleusaccumbens}, {alic, limb}, {amygdala}, {caudatenucleus}, {centromedian, centromedianparafascicularcomplex},
{cingulatecortex}, {cingulum}, {globuspallidus, globuspallidusexternus, globuspallidusinternus, pallidus}, {hippocampus}, {pallidum},
{pedunculopontine, pedunculopontinenucleus}, {stn, subthalamicus}, {subgenual, subgenualcingulate, subgenualcingulatecortex}, {vim},
{zonaincerta}
DBS indication 20 topics:
{addiction, alcoholism, smoke}, {alzheimer}, {anorexianervosa, eatingdisorders, obesity}, {anxiety}, {ataxia}, {bradykinesia}, {chorea,
huntington}, {clusterheadache, headache}, {depression}, {dyskinesia}, {dystonia}, {epilepsy}, {essentialtremor, tremor}, {hypomania, mania},
{memory}, {obsessivecompulsive, ocd}, {parkinson}, {schizophrenia}, {sclerosis}, {tourette}
Positive effects 3 topics:
{qualityoflife, wellbeing}, {alleviation, relief, remission}, {enhancement}
Negative effects 18 topics:
{safety}, {aberrant, adverse, adverseevents, complication, decline, deterioration, distress, impairment, perseverative, sequela, sideeffect},
{apathy}, {ataxia}, {character, personality}, {death, die, suicide}, {dysarthria}, {dyskinesia}, {fluency, language, speech}, {hemorrhage,
hemorrhage}, {hypersexuality}, {hypomania, mania}, {impulsecontrol, impulsivity}, {infection, inflammation}, {memory}, {pain}, {psychosis},
{psychosocial}
Methodological issues 15 topics:
{ablation}, {radiosurgery, ultrasound, gammaknife}, {capsulotomy}, {cingulotomy}, {pallidotomy}, {subthalamotomy}, {thalamotomy},
{psychosurgery, lobotomy, leucotomy}, {computertomography, diffusiontensorimaging, eegfmri, electrocorticography, electroencephalography,
fmri, magnetoencephalography, mri, tomography, transcranialsonography, ventriculography, pet, spect}, {spinalcordstimulation},
{transcranialdirectcurrentstimulation}, {transcranialmagneticstimulation}, {vagusnervestimulation}, {electroconvulsivetherapy}, {dopamine,
dopaminereplacementtherapy, duodopa, ldopa}
Economic issues 3 topics:
{commercial, cost, costeffectiveness, economic, expensive, financial, inexpensive, market, socioeconomic, expenditure}, {industry,
manufacture, manufacturer, medtronic, kinetra}, {effectiveness}
Technological issues 3 topics:
{battery, cable, device, electrode, hardware, implantablepulsegenerator, lead, pacemaker, recharge, rechargeable, stimulator, wireless},
{closedloop, responsiveneurostimulatorsystem}, {program}
Remind that Lemmatizing in step 3 has mapped most of the different manifestations of topics (e.g., abbreviations) on a single term (e.g., the abbreviation “PD” on “parkinson”). The
topics ataxia, dyskinesia, (hypo)mania, and memory are present in two issue classes.
connectivity structure. The principle of this measure can be
explained as follows: the more links (in our case connections)
refer to a site (in our case to a node/topic), the more weight a
given site receives. As a consequence, the more weight a given
site/node acquires, the bigger its importance. If one interprets co-
occurrence of topics as a measure of “linking” two topics, then
the page rank value would determine the order of “search results”
in the network determined by the topics chosen by us. Since we
are only rarely referring to page rank, we refrain from describing
the mathematical basis of this algorithm in detail and refer to the
original work by Brin and Page, to a brief description by Chen
et al. (2007 p. 9) and to an in-depth review by Langville and
Meyer (Brin and Page, 1988; Langville and Meyer, 2004; Chen
et al., 2007).
Graphs were represented by use of a Force Atlas 2 algorithm
(Jacomy et al., 2014). This algorithm is used to spatialize the
network: nodes repulse each other similar to charged particles
whereas edges attract their nodes like springs. The specific
spatial distribution of each node therefore depends on the nodes’
connections to other nodes. As a result, the specific coordinate
of one single node cannot be interpreted on its own but has
to be analyzed in combination with other nodes (Jacomy et al.,
2014). Since edges are weighted, we added the “Edge Weight
Influence” δ (δ = 3.0, a pre-programmed selection option)
to the visualization in order to prevent edge weights to be
ignored.
RESULTS
Trend Analysis over Time
The trend analysis of potential anatomical DBS targets over
time suggests a crosscurrent tendency: while the discussion of
psychiatric DBS indications such as addiction, major depressive
disorder (MDD), schizophrenia, Tourette syndrome (TS), and
obsessive-compulsive disorder (OCD) (among others) are
increasingly being discussed, the discussion of conventional,
motor-related indications such as Parkinson’s disease (PD)
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and essential tremor (ET) recedes (see Figure 3A). Dystonia,
on the other hand, shows a surprisingly stable pattern over
time. In confirmation of the above, the trends for anatomical
DBS targets mainly match the ones depicted in the DBS
indication analysis: while traditional anatomical targets used in
movement disorder therapy decline over time—globus pallidus
(GP), ventral intermediate nucleus (Vim), subthalamic nucleus
(STN) –, a marked increase of “psychiatric” targets—e.g., nucleus
accumbens (Nacc) or subgenual cingulate (SG)—is visible (see
Figure 3B). Interestingly, the increase of psychiatric targets is less
pronounced than the one for psychiatric indications, suggesting
that psychiatric indications have become per se an emerging
topic within the DBS literature. The above described pattern is
again partly backed when including the trend analysis for lesion
methods (including radiosurgery, capsulotomy, gammaknife,
pallidotomy, to name a few) specifically: the discussion of such
alternative techniques in the context of motor disorders decreases
substantially. Interestingly, there is no trend in the case of
psychiatric indications (see Figure 3C).
In line with these results is the fact that overall, the trend
analysis for negative effects shows an increased emphasis in
discussing “psychiatric” phenomena (including anhedonia,
hypomania, personality, and impulsivity among others)
whereas phenomena associated with traditional, motor related
indications (apraxia, ataxia, dysarthria, among others) are
consistently less often discussed. Surgery related issues (such
as hemorrhage, infection, and ischemia, to name a few) are
quite stable. The data also confirm earlier findings (Müller and
Christen, 2011) that general terms which indicate side-effects
non-specifically such as “aberrant,” “adverse,” “complication,”
“distress,” “impairment,” “sequel,” “sideffect” (among others), are
also less often mentioned.
FIGURE 3 | Trend analysis for selected topics. (A) Movement disorders vs. psychiatric indications; (B) DBS targets for movement disorders vs. targets for
psychiatric indications; (C) mentioning of lesion methods in papers also mentioning movement disorders vs. psychiatric indications.
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Finally, technological terms associated with new stimulator
systems such as “closed loop,” “responsive neurostimulator
system,” “rechargeable,” and “wireless” have partly displaced
the discussion about conventional technological and hardware-
related terms which themselves are less often discussed (e.g.,
“battery,” “cable,” “electrode,” “implantable pulse generator,”
“lead,” “pacemaker,” and “stimulator”; data not shown).
Analysis of Whole Data Set
General Structure of the Graph
Overall, the aggregated graph (except the issue ethic which
was analyzed separately) consists of 73 nodes and 1908 edges
(Figure 4). We observe the average shortest path length to be
pretty small (1.3) (Jackson, 2008) (i.e., we can move from one
point in the network to another point quite easily, the graph is
therefore well-interconnected). The graph furthermore shows a
high number of influential nodes besides a high value of average
degree (i.e., a quite diverse text corpus). In general, degree is a
measurement of connectedness in graph theory whichmeans that
a specific node in a given network with high degree consequently
has many neighbors in that network. A high average degree
therefore means that the graph is highly interconnected. Because
of this high average degree, no contextual clusters have been
identified using the community detection algorithm of Blondel
et al. (2008).
Thematic Structure of DBS Publications
The betweenness centrality (BC) analysis reveals that apparently
five main topics dominated the DBS field in terms that they
occupied an exceedingly central space within the whole text
corpus. Those are effectiveness, safety, side-effects, and hardware
related issues apart from PD, the main indication for DBS
FIGURE 4 | Network of all 73 topics (except ethic). Color-code: Blue: indications; purple: anatomical targets; yellow: methods; green: positive effects; red:
negative effects; brown: economic issues; gray: technological issues.
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(equal BC values; see Figure 4 and Table 1 in Supplementary
Materials). Moreover, those topics are adjacent to most of the
words in the network and therefore function both as local hubs
(i.e., a node with many connections) and as important junctions
within the whole text corpus.
Apart from the five main topics, the topics including positive
effects (alleviation, relief, remission), MDD, imaging methods,
dopamine, quality of life (QoL), STN, dystonia, OCD, anterior
limb of the internal capsule (ALIC), pain, enhance(ment),
epilepsy, death, ET, and imagingmethods (with decreasing values
across sequence) also show high betweenness centrality. Concrete
side-effects appear at place 25 and 27 (dyskinesia and infection).
The topics personality (place 41), psychosocial (place 56)—
both inherently difficult variables –, subthalamotomy, alternative
therapies [such as electro-convulsive therapy (ECT), vagus nerve
stimulation (VNS), spinal cord stimulation (SCS), or transcranial
direct current stimulation (tDCS)] and hypersexuality [which
itself occurs quite rarely (in 19 abstracts only)] (place 72) receive
especially low BC.
A Google’s page rank analysis revealed the following
sequence of importance: PD, hardware related terms, side-effect,
STN, MDD, effectiveness, dopamine, ET, imaging-methods,
GP, OCD, safety, dystonia, and positive effects (alleviation,
relief, remission). The BC values of neuroanatomical targets
indicates a higher BC value for ALIC than for GP and a
higher one for Nacc than for Vim. However, this sequence
changes when conducting Page-rank analysis: highest values
are accredited to the STN, GP, ALIC, Vim, and Nacc.
Also, the lesional approaches (pallidotomy, subthalamotomy,
and thalamotomy) receive dramatically more weight (in the
middle field) when performing Page-rank (among lowest if
conducting BC).
Analysis of Specific Topics
Next we performed a co-occurrence analysis incorporating the
five terms (effectiveness, safety, side-effect, PD, and hardware)
with highest BC (see Table 2 in Supplementary Materials for
detailed information on all co-occurrence-values). Firstly, the
topic effectiveness is most often mentioned in combination
with the topics PD and hardware. Likewise, the second
topic safety is most often discussed in the context of PD
and hardware. Third, we were interested in the topic side-
effect, which shows to be, apart from PD, the topic with
most above-threshold co-occurrences (co-occurrences > 0.3,
determined by the authors based on distribution of the
data; see Table 2 in Supplementary Materials). It is most
often mentioned with hardware- and motor-related side-effects
but also includes side effects of the psychiatric/psychological
domain: infection, hemorrhage, dysarthria, apathy, speech,
psychosis, memory, mania, dyskinesia, psychosocial, anxiety,
hypersexuality, subthalamotomy, STN (among others, with
decreasing values across sequence). Fourth, the main indication
PD, is discussed to a greater extent with hypersexuality
(or more accurately; whenever there is a text including
the term “hypersexuality,” “parkinson” is most often also
present), bradykinesia, subthalamotomy, and apathy. Please
note that the term “hypersexuality” appears quite rarely
(in 19 abstracts only). The results therefore have to be
complemented and analyzed in combination with how often a
term actually occurs within the texts (for frequency distributions
see Supplementary Figure 1B). The last and fifth key-
topic with highest BC includes hardware-related issues which
is discussed most often with industry, hemorrhage, new
systems (terms: “closed loop,” “responsive neurostimulation
system”), program, infection, PD, and general economic-
topics (terms “cost,” “commercial,” “economic,” “financial”
among others).
Analysis of Interactions between Different
Issues
In order to investigate on potential interactions of different
issues, we conducted a co-occurrence analysis. First we outline
the co-occurrence of topics related to the issues indications,
anatomical targets, and side-effects.
Interaction between Indications and Side-effects
As for the combination of indications and side-effects (Figure 5),
the strongest co-occurrence connections yielded the following
results. The topic PD is most commonly discussed with
hypersexuality (as already stated above). Moreover, PD is
often discussed with apathy, dyskinesia, mania, impulsivity,
speech (and dysarthria), psychosocial, death/suicide, and
psychosis. ET, on the other hand, is most often discussed
with dysarthria. Of note is the fact that neither MDD nor
dystonia is strongly connected to any concrete side-effect.
Additionally, and as a side note, an intracategorial analysis
shows most often co-occurring side effects to be impulsivity and
hypersexuality.
Interaction between Indications and Anatomical
Targets
The combination of indications and targets (Figure 6) showed
strongest co-occurrence connections between PD and the STN,
followed by the pedunculo-pontine nucleus (PPN), the zona
incerta (ZI) and lastly with the GP. ET, on the other hand, is
clearly connected with the Vim. MDD is most often linked to
the SG, the cingulate cortex, and Nacc, while the indications
bradykinesia and dyskinesia show most frequent connections to
the STN. Finally, OCD is most often discussed with the Nacc and
schizophrenia with the hippocampus.
Interaction between Side-effects and Anatomical
Targets
Finally, the strongest co-occurrence connections between the
issues side-effects and anatomical targets (Figure 7) yielded the
following results: The STN is most often discussed with apathy,
mania, speech, dysarthria, impulsivity, death, and hypersexuality.
We found no robust co-occurrence between neuroanatomical
targets relevant for the treatment of psychiatric disorders and
concrete side-effects (such as infection and the like). Also no
marked co-occurrence of side-effects and anatomical targets
other than the STN were observed.
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FIGURE 5 | Network-Analysis for the issues indications (blue nodes) and side-effects (red nodes).
Additive Relationships
Additively, we were interested in potential connections between
topics from economic issues, technological issues, and positive
effects.
The topic industry is most often discussed with PD, imaging
methods, safety, and ET. Interestingly, terms like “costs,”
“economic,” “commercial” and the like are markedly linked to
the indication PD solely. The issue positive effects including the
topics alleviation, relief, and remission are most often associated
with PD, pain, and dopamine. The terms “quality of life” and
“wellbeing” on the other hand are most often connected to PD,
side-effect-related terms, psychosocial, and apathy while most
prominent connections with regard to the topic enhance(ment)
are PD, hardware, and STN. In particular, the strong connection
between QoL and psychosocial is important because it may
highlight an increased interest in psychosocial issues in the
context of QoL. Finally the topic program is most often discussed
with PD and STN whereas the topic of new-devices (terms:
“closed loop” and “responsive neurostimulation system”) is most
often connected to PD and epilepsy.
When integrating how methods other than DBS are discussed
within the DBS-literature, one finds the following outcomes:
Concerning indications, PD is most often connected to
subthalamotomy, dopamine, and pallidotomy. OCD on the
other hand is robustly connected to capsulotomy and to a
minor degree to cingulotomy whereas ET is mentioned most
often in combination with thalamotomy. Finally, MDD is
most often discussed with ECT, cingulotomy and still quite
often with tDCS whereas epilepsy is most often discussed
with VNS.
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FIGURE 6 | Network-Analysis for the issues indications (blue nodes) and anatomical targets (purple nodes).
Regarding side-effects, dopamine is apparently most often
discussed in combination with hypersexuality, impulsivity,
psychosis, apathy, and dysarthria. Psychosurgery on the other
hand, is mostly discussed in the context of cingulotomy
whereas pain (here probably meant as indication) most often
with SCS.
Associations with the Topic “Ethic”
There is a rich discussion which deals with ethical aspects in
the context of DBS. Ranging from personality changes and side-
effects (Christen et al., 2012) to topics taking up the debate of
human enhancement (Synofzik and Schlaepfer, 2008; Schermer,
2013) and research ethics (Fins et al., 2011), the discussion is
clearly multifaceted. Hence, ethical questions are a constant topic
of debate. Therefore, we were interested in how ethics-terms
interrelate with other terms of the text corpus. We therefore
investigated the co-occurrence of the topic ethics with all other
topics (see Figure 8). Apart from the rare topic psychosurgery
(present in only 52 texts) and the very frequent topic PD (present
in 3544 texts) which yielded the strongest co-occurrences, the
ethics-topic is most often linked to personality, psychosocial, side
effect, hardware, MDD, and hypersexuality. Of note is the very
rare connection between ethical issues to the GP (in only 3% of
the total possible co-occurrences) compared to the STN (in 14%
of the total possible co-occurrences).
DISCUSSION AND CONCLUSION
We will first outline some of the findings which underpin
the validity of our approach directly followed by discussing
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FIGURE 7 | Network-Analysis for the issues negative effects (red nodes) and anatomical targets (purple nodes).
findings acquired from the trend analysis over time and then
guide the discussion toward the graph analysis based on BC
and co-occurrence. Finally, we will outline pertinent ethical
questions.
Findings Corroborating the Validity of Our
Approach
We detected a multitude of findings which underpin the validity
of our approach, some of which we highlight in the following.
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FIGURE 8 | Interrelation of the topic ethics to all other topics with at least 5% co-occurrence (for color code see caption of Figure 4).
Chronic pain for example, is a well-described indication
suitable for spinal cord stimulation (Wolter, 2014). The findings
including indications and lesion methods also confirm known
connections as evidenced in the case of ECT, a well-known
therapeutic option for the treatment of MDD, besides others.
The relationship of epilepsy and closed-loop systems might
also underpin the robustness of our methodological approach
by bearing in mind that epilepsy characterizes a promising
indication for the application of closed loop devices (Armstrong
et al., 2013; Krook-Magnuson et al., 2013; Paz et al., 2013;
Nagaraj et al., 2015). Regarding anatomical targets and side-
effects, we highlight a distinct connectivity between the STN
and impulsivity which has been described elsewhere (Zavala
et al., 2015). Regarding the detected intracategorial connection
between impulsivity and hypersexuality, a recent publication
confirms a tight connection between the two topics (Kor
et al., 2013). Hence, a multitude of identified co-occurrences
incorporating the different issues such as indications and
corresponding lesion methods, or indications and anatomical
targets among others, serve as validation of our method.
Trend Analysis
When analyzing the data set including DBS-indications and
relevant anatomical targets, one can identify a clear shift
away from motor-related neuroanatomical targets (GP, Vim,
STN) (even though numerically still predominant) toward an
emphasis on anatomical targets which are especially relevant in
psychiatric indications (Nacc, amygdala, hippocampus, SC) (see
Figures 3A,B). Such a tendency is indicative for the broadening
of the therapeutic spectrum of DBS. A multitude of scientific
publications highlighted this circumstance already (e.g., Hariz,
2012; Hariz et al., 2013; Christen et al., 2014, to name a few).
Even though we cannot make a qualitative statement about how
such topics are being discussed (i.e., the discussion may be
framed in a supportive, critical, or neutral way), the identified
increase may represent the seen utility in DBS for the treatment
of psychiatric indications. Questions about suitability of such
complex disorders for the therapeutic application of DBS and
the difficult search of anatomical loci for the treatment of such
indications (e.g., for MDD (among others): Nacc, ALIC, and
SG) may also be indicative for such an increase. Additionally,
the data highlights no standard locus for the treatment of MDD
(e.g., Hariz et al., 2013 for the unspecific use of neurostimulation
targets in the context of MDD, TS, and OCD; or Da Cunha
et al., 2015; Kocabicak et al., 2015). Finally, the trend analysis
incorporating negative effects (data not shown) completes the
picture; while motor side effects are less frequently discussed,
complex issues such as personality are increasingly the topic of
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the current debate. In the context of psychiatric disorders, such
phenomena seem to be prevalent to a greater extent.
The trend analysis involving lesion based therapy approaches
revealed that lesion approaches recede in the context of motor-
related disorders and are quite stable in the case of psychiatric
disorders. This might demonstrate—and under the assumption
that medication based therapy is still the most frequently used
therapeutic approach—that (1) lesions are still considered to
be an effective and reliable means for patients refractory to
drug-therapy and (2) that DBS was not (yet) able to replace
lesion-based therapy approaches in psychiatry. When talking
about an observed decline of the discussion of topics related to
lesion approaches, one has to emphatically point out that this
reflects how lesions are being discussed within the DBS-literature
only. This means that we are limited in our interpretation
of observations related to lesion methods and look with a
narrow “DBS-perspective” on relationships which are discussed
in these articles. Moreover, lesion approaches are still considered
therapeutic competitors and as suchmight receive little attention.
We have outlined elsewhere (Christen et al., 2014, but see
also Müller et al., 2015) the importance of ensuring alternative
therapeutic approaches which of course would not quantitatively
carry much weight when extracting abstracts from numerous
DBS-publications.
Network Analysis
Thematic Structure of DBS Publications
Our results suggest that the topics PD, side-effect, hardware,
safety, and effectiveness play a conducive role within the DBS
literature and this to a greater degree than other terms because
the relation of their influence to the total number of connections
was calculated to be highest (reflected in BC). One could say
that the backbone of any publication in the context of DBS
is composed of issues about safety, side-effects, effectiveness,
hardware, and PD. These junctions act as mediators within the
discursive field of the textual graph. The broader backbone of a
publication in the field of DBS can be inferred to be generated
through the mentioning of the remaining major topics: relief,
MDD, imaging methods, dopamine, QoL, STN, dystonia, OCD,
ALIC, pain, enhance(ment), epilepsy, death, ET, and TMS. This
furthermore means that by analyzing the top 20 terms and by
allocating those to the major topics, it is evident that indications
are most numerously represented (n = 7), followed by negative
effects (n = 4), methods (n = 3), and anatomical targets
(n = 2). As the discussion in the DBS literature is shifting
toward new and more specific questions, specific anatomical
targets tend to be less often associated with more general topics.
The strong representation of indications again reflects the trend
of broadening the therapeutic spectrum in the context of DBS.
Personality and Psychosocial Issues in DBS
Publications
The growing discussion about personality (trend analysis) is not
yet reflected in BC because the topic personality shows one
of the lowest BC-values. This can be explained by referring
to the low frequency of the topic itself within the whole
text corpus and may likely change as such issues have to
be addressed in the context of measuring pre-post-effects in
the case of psychiatric neurostimulation. The circumstance
of personality and psychosocial issues receiving low BC may
indicate that their associated concepts represent genuinely vague
and difficult variables and consequently are not utterly useful
for clinical research. As validated instruments to objectively
and qualitatively measure changes in the personality and the
psychosocial dimension are often missing or criticized for not
accurately measuring the topic under investigation, such much
needed concepts cannot easily enter clinical research (Dimitrov
and Rumrill, 2003). The fact that psychiatric indications are
increasingly being addressed by means of brain-stimulation, the
need for the accurate and thorough observation and measure
of psychosocial and personality-related issues (and also in the
context of movement and other disorders, Pham et al., 2015)
is obviously most important. Therefore, with more accurate
insights into the neuronal circuitries exerting maladaptive effects
on many disorders despite high complexity and limited means
of investigation (Rossi et al., 2015) and the eagerness to evaluate
results beyond short-term quality of life (Ooms et al., 2014),
indications for DBS should get more individually tailored (Galati
and Stefani, 2015). Additively, the accurate and longitudinal
measure of psychosocial issues has already been proposed also in
the context of movement disorders (Schüpbach and Agid, 2008).
Combined with the fact that the topic QoL is robustly connected
to the topic psychosocial, as well as the fact that a limited number
of scales for the measurement of personality- and psychosocial-
related issues do exist, the introduction of such instruments
combined with the eagerness to improve such instruments, is
greatly needed.
Economic Issues
The restriction of the discussion incorporating economic issues
to PD only, also poses questions. Given the increase of
psychiatric indications, economic considerations should be in
place and extended toward other indications in order to
adequately address socio-economic issues. The often observed
co-occurrence between the topic economic and ethic further
emphasizes this point.
Centralities of Neuroanatomical Targets and Their
Implications
The BC-values of neuroanatomical targets indicate a higher one
for ALIC than for GP and a higher one for Nacc than for Vim.
This may serve as another evidence for the growing importance
of neuropsychiatric topics in the literature of DBS. However, this
sequence changes when conducting Page-rank analysis: highest
values are accredited to the STN, GP, ALIC, Vim, and Nacc. Since
Page-rank puts an emphasis on the number of connections (e.g.,
“links”), the traditionalmotor targets STN andGPwould be listed
before ALIC within a given search result. Given the fact that GP
and Vim represent historically older topics in DBS and based on
the higher Page-rank values, the two are more densely linked
with other topics. However, ALIC and Nacc already are more
central concepts within the DBS-literature, presumably acting as
mediators of information to a greater extent than GP and Vim.
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MDD and Alternative Therapeutic Approaches
The execution of a Page-rank analysis also changes the sequence
of the most important topics: PD clearly is attributed the highest
value and MDD makes it into the “top 5.” In sum, one can
state that depression is the most discussed psychiatric indication
in the DBS literature. In light of MDD’s importance within the
DBS literature, it is from a bioethical point-of-view important to
emphasize that this indication has not yet received approval from
the U.S. Food and Drug Administration (FDA) as a standard
therapeutic treatment. Patients therefore should be well-
informed about the ongoing search of optimal neuroanatomical
targets, the challenging support without standardized guidelines
of patients along the whole treatment and beyond as well as the
complexities associated with the appropriate conduct of clinical
trials (Jimenez-Shahed, 2015) and the vulnerability of patients
(Bell et al., 2014).
When looking specifically at alternative therapeutic
approaches such as SCS, tDCS, ECT, and VNS, it becomes
obvious that they receive especially low BC. This circumstance
can be explained by highlighting that we specifically selected
scientific publications involving DBS. Presumably, those
publications have a low interest in advocating for alternative
therapeutic approaches. Furthermore, the co-occurrence analysis
shows that within the DBS-literature, ablative therapeutic
approaches such as pallidotomy, subthalamotomy, and
thalamotomy are most frequently discussed in combination
with terms from the topic side effect. While ablative therapeutic
strategies appear to a greater degree to be negatively connoted,
the latter also symbolize the still most direct competitors to
DBS, as already outlined within the trend-analysis. Interestingly,
the lesional approaches (pallidotomy, subthalamotomy, and
thalamotomy) receive dramatically more weight (in the middle
field) when performing Page-rank (among lowest BC). In
analogy of the previous hypothesis, lesion approaches might
be underestimated if incorporating BC only and seem to be
interlinked to a greater extent.
Discussion of Issue-comparisons
The specific comparison involving indications and side-effects
indicates that the description of side effects is clearly dominated
by the ones closely associated with PD, the indication for which
most publications exist (n = 3544, followed by essential tremor,
n = 901). This does not mean that PD is the DBS indication
where most side effects occur, but that side effects are most
frequently described in the context of PD. As outlined above,
the strong connection between PD and hypersexuality only
reflects that within the few papers dealing with hypersexuality,
the term “parkinson” is almost always present. Since the topic
hypersexuality is very infrequent, this result has to be taken
with caution. On the other hand, one also has to take into
account that our data consist of abstracts only, i.e., terms need
to have some importance within a paper in order to appear
in the abstract. Side effects of other indications, especially
neuropsychiatric, are to a far lesser degree discussed. Depression
for example co-occurs only to a minimal extent with personality,
death, and psychosocial issues. As highlighted previously, side
effects in the context of psychiatric disorders are expected to
be (1) much harder to be identified and (2) still have to be
published as such newer indications have only recently been
added to the therapeutic spectrum. OCD with its unconventional
entry into the therapeutic landscape via a humanitarian device
exemption (Fins et al., 2011) is also quite rarely discussed in
the context of concrete side effects [probability of co-occurrence:
hypersexuality (11%), impulsivity (8%), and infection (5%)].
Again, there is a duty to longitudinally follow patients in order to
constantly monitor potential side-effects, besides the great need
for introducing new measures in order to fully capture potential
changes also in the psychosocial/psychiatric domain (Lilleeng
et al., 2015).
The comparison involving indications and neuroanatomical
targets highlights a further interesting result: apart from being
discussed most often with the STN, PD is also quite strongly
connected to the PPN, even more than to the GP—the other
standard target for stimulation apart from the STN. PPN-
stimulation was initially promoted for the treatment of balance
impairments as well as refractory gait freezing and has been
shown to be used as surgical target relatively unspecifically (“the
PPN-area”) and this despite largely unknown clinical usefulness
(Hariz et al., 2013). The high centrality of the PPN together with
such a critical stance toward its usefulness and lack of clinical
evidence further corroborates an apparent tension.
Finally, when comparing side-effects and anatomical targets,
we observe again a dominant description of side-effects in
combination with the STN—one of the most widely used
anatomical targets for the treatment of movement disorders.
The most frequent co-occurrence of the GP is its connection
to apathy, but this happens only in 7.5% of cases in which a
possible co-occurrence is possible. This, potentially driven by
stimulation of ventral and medial subterritories of the STN
(for STN-subterritories see Tremblay et al., 2015; for actions
beyond motor control see Zavala et al., 2015), reflects a described
dominance of side-effects in the context of STN rather than
other (e.g., GPi) DBS targets. Moreover, this could indicate
that side-effects emanating from predominantly ventral STN-
stimulation have overshadowed the description of side-effects
of other anatomical targets such as the GP. Alternatively,
the STN may be intrinsically more prone to (behavioral or
affective) side effects due to its circumscribed connectivity to
limbic areas. There is evidence for a clearer separation of
motor and non-motor functions in the GPi compared to the
STN (Wichmann and DeLong, 2011; Da Cunha et al., 2015).
Additionally, ALIC, an anatomical target with marked BC, is
rarely found in combination with specific side effects. This
imbalance may be problematic or may be the result of the already
mentioned problem of capturing side-effects in the context of
psychiatric disorders. However, if DBS for the neuropsychiatric
domain further expands, the accurate description combined
with the nuanced measurement of psychological changes poses
a bioethical obligation and responsibility for any researcher
involved. It might be an interesting endeavor to once try to
capture the implicit perception of professionals in the field of
DBS regarding such issues. The numerical imbalance of how
e.g., anatomical targets are discussed in relation to side-effects
together with the concrete framing of such issues within the
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most often read articles in the literature supposedly induce
unconscious preferences which do not necessarily display the
situation in an accurate way based on (pre-)clinical evidence.
Bioethical Issues
As the field of bioethics is comparably subjected to a vast
increase of publications, quantitative methods for obtaining a
better understanding might be as important as for neuroscience.
Such an approach is moreover suitable for identifying potential
mismatches between what is currently being discussed and what
might be important ethical topics which are less tangible or more
vulnerable for being overlooked.
Motor-targets and Their Connection to Ethics
Apparently, ethical issues are to a greater extent discussed in
combination with the STN rather than the GP. Is the STN
therefore more thoroughly described in terms of its stimulation-
based ethical consequences or is there evidence that the STN
intrinsically harbors to a greater extent problematic ethical
issues including the potential of inducing undesired effects? The
debate of which target is most appropriate (mostly including
STN and GP, Follett et al., 2010; Krack and Hariz, 2010;
Odekerken et al., 2013) is an old one. But since currently,
there is evidence for a statistical chance selection rather than
one based on (patho)-physiological evidence for either receiving
STN or GP stimulation (Christen et al., 2014; Gilbert, 2014)
[besides clinical considerations such as envisaging drug reduction
(STN) or preexistence of cognitive symptoms (GPi) (Da Cunha
et al., 2015)], this difference might be an important one.
As long as there is no proven display regarding superiority
in terms of therapeutic action, there might be a duty to
investigate ethical issues to a similar extent for all nuclei used
for stimulation.
Depression and Its Connection to Ethics
Another interesting finding is an observed imbalance reflected
in a strong connection between the issue which incorporates
the topic ethics on the one hand and MDD on the other
and a substantially weak connection of the former topic and
the one involving the most often used anatomical targets in
the context of depression. Whenever ethical issues are being
discussed, MDD is most often also discussed. However, the
factual co-occurrence dramatically decreases in the case of
neuropsychiatric anatomical targets: ethical issues co-occur only
in 6.5% of cases when discussing the Nacc, in 3.5% when
discussing the ALIC and in 1.75% when discussing the SG. This
apparent dissociation between indication and anatomical target
is questionable and more pronounced as in the case of PD and
STN. As DBS has not faced a comparably long history regarding
randomized controlled clinical trials for psychiatric disorders,
studies have to be continued in order to identify which nucleus
(or nuclei) shows greatest potential for the treatment of MDD
and other neuropsychiatric disorders but also to identify which
nucleus might be especially vulnerable for (behavioral) side-
effects, psychosocial maladjustments and consequently ethical
issues (e.g., non-maleficence).
Hardware Related Issues
As evidenced in some publications (Kondziolka et al., 2001;
Okun et al., 2005; Fins, 2009) hardware related complications
do impose ethical challenges. This is also backed by our results
highlighting an apparent tension between hardware and ethical
issues. Concomitantly, our data set indicates a continuous
decrease of the discussion of hardware related topics (evidenced
in the trend analysis; data not shown) but also particularly
high BC. The strong link to ethical issues, apart from the mere
description of hardware-related side-effects, might be evaluated
as unintuitive. However, the data suggests that hardware related
issues in the context of social, ethical and moral questions
apparently have already been a topic of debate (e.g., Hilimire
et al., 2015; Fumagalli et al., 2015). Generally, the topic of ethical
and social implications of technological devices is certainly an
important one which, e.g., in the context of emerging closed-loop
devices, will nourish further discussions in the future. Therefore,
closely investigating ethical, social, and clinical aspects of
the follow up process longitudinally, including e.g., the often
challenging postoperative phase for precise DBS parameter
adjustments (Ineichen et al., 2014) as well as fiscal and legal
aspects of hardware replacement apart from ethical issues
specifically in the context of hardware is important. In parallel,
our result may emphasize not only a duty to investigate hardware
related ethical issues which transcend merely and well-known
technical problems (Christen et al., 2014) thoroughly, but also
that ethical duties already instantiated also apply to engineers
which represent key players and which are well-positioned to
support the deployment of innovative hardware in order to
diminish the burden of patients (Fins, 2009). In the general
DBS review literature, hardware-related issues such as the ones
attached to recording devices and the related implications for
patients’ autonomy and responsibility but also the potential use
and abuse of such recorded signals in connection with privacy
issues, the dependency on device manufacturers (Underwood,
2015) and conflicting interests (Clausen, 2011), the long-term
risk of living with implanted hardware (Farris et al., 2008)
apart from psychological issues have in comparison to surgical
complications probably received less attention. The fact that
hardware-related issues receive dramatically more weight in
the context of ethical challenges than impulsivity, concrete
side-effects and death/suicide is certainly surprising and needs
further analysis. Whether this means that hardware-related
issues are already sufficiently discussed in an ethical and social
context or need further exploration has to be identified by a
qualitative in-depth analysis.
Although DBS has alleviated patients suffering tremendously,
many obstacles still remain. Recently, the development of
innovative neuromodulation exemplified by current steering
(Martens et al., 2011; Hariz, 2014b), adaptive DBS (Little et al.,
2014) but also the potential deployment of closed-loop devices
(e.g., Rosin et al., 2011; Grahn et al., 2014; Williams, 2015) have
increasingly gained weight within the discussion of DBS. In the
meanwhile, magnetothermal neuromodulation in translational
models (Chen et al., 2015) shows potential to increase our
knowledge of neuronal microcircuitries (Temel and Jahanshahi,
2015). Apart from technological as well as biological hurdles (e.g.,
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identification of true biomarkers) also ethical issues might arise.
As our data highlights a tremendously weak co-occurrence of the
topics ethics and closed-loop, it might be time to think about
how emerging closed-loop devices may affect already instantiated
guidelines and what differences as well as implications might be
identified both from a theoretical (i.e., philosophical) but also
practical (i.e., what it would mean for patients) perspective.
Limitations
This study, of course, incorporates some limitations. First of
all, as in any quantitative text-network approach, we are unable
to make qualitative statements. This however, is within the
nature of a heuristics approach. Additionally, various topics
might in fact be used in a different context than used as a
basis for interpretation within this study. For example, the
neuroanatomical targets may in fact very well also be mentioned
without referring to a target for stimulation. For example, the
STN may be described within a DBS-publication not as a
target for stimulation but within the context of hyper-reactivity
in the case of hemiballism. Due to the fact that we have
limited our analysis to abstracts, we assume this scenario to
be quite infrequent and would hypothesize such a wording to
be included in a general introduction rather than within an
abstract. Moreover, the Web of Science database is associated
with a language bias. As papers emphasizing psychosocial and
philosophical issues are often published in other languages, they
are likely to be underrepresented in our sample. Finally, topics
which incorporated multiple terms, of course, inevitably have a
greater probability of co-occurrence.
Outlook
The proposed analysis is by no means complete and has no
prerogative of accuracy. It is one additional possibility to read any
text in order to gain new insights about its structure and hidden
messages, suitable to deal with a large number of texts. We are
of the opinion that applying network approaches, visualization
techniques and graph theory to a text corpus might be an
innovative and promising alternative which entails fruitful and
worth considering aspects. The final interpretation of the data,
once visualized as a graph, is certainly open for discussions and
by no means definitive.
Hariz recently wrote in his book chapter “The literature
revisited” that “serendipitous discoveries and advances in
functional imaging are providing ‘new’ brain targets for an
increasing number of pathologies, and the corollary is an
exponentially growing literature on DBS, such that it is simply
impossible to keep track of all papers and books appearing on
this subject.” He then goes on by stating “While most of the
literature constitutes an invaluable wealth of knowledge, a small
but important part gives rise to serious concern and needs to be
revisited and discussed” (Hariz, 2014a). By using a quantitative
network approach, we tackled this issue from another perspective
and tried to identify potentially hidden and underrepresented
issues which might be relevant for further discussions and future
research.
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The benefits of deep brain stimulation for parkinsonian patients are well documented and have
established the method as mainstay in the late stages of the disease (Deuschl et al., 2006). However,
early in the history of the method reports of mental side effects were published. In 1995 Limousin
and colleagues reported transient confusion and hallucinations with one of their first patients
(Limousin et al., 1995). Further reports with disturbing side effects accumulated over time (Krack
et al., 2001; Berney et al., 2002; Herzog et al., 2003a). While cognitive squeals were studied in
numerous papers (Funkiewiez et al., 2004; Contarino et al., 2007) but are generally conceived to
have little impact on the quality of life (Schupbach et al., 2006), the field of psychiatric effects was
more hesitantly explored. Results to the latter remain ambiguous with a tendency toward less severe
side effects in the large series of experienced centers (Deuschl et al., 2006; Weaver et al., 2009).
Adverse events in this domain were largely attributed to acute effects weaning over a short period
(Herzog et al., 2003b).
However, over the years I have seen a considerable number of patients both operated by myself
but also from other experienced centers who showed psychological symptoms that counteracted
the improvements in motor function. This personal experience is in line with patients and
their representatives who voice concern over these phenomena with their deleterious impact
on the wellbeing of patients, their families and caregivers (personal communication, F-W.
Mehrhoff, Geschäftsführer, Deutsche Parkinsonvereinigung, Nov. 2014). Such concerns also appear
quite regularly in patient support group meetings. My impression is, that patients and their
representatives feel their concerns not appropriately reflected in the scientific literature and expert
opinions. This comment responds to such observations with the aim to reposition the defense of
DBS for Parkinson’s disease. Reluctance to delve into this subject may in my opinion eventually
leave those who offer the procedure defenseless toward reproach from patients, referring colleagues
and the general public.
Onemay counter such observations by outlining that, particularly in case of complex psychiatric
side effects, there are no objective means of deciding when a treatment has to be considered a failure
or a success. Patients and relatives have also the propensity to underestimate their preoperative
disabilities (Herzog et al., 2003b). This is further complicated by the fact that PD is a disease with
cognitive, affective, and behavioral symptoms and thus has a neuropsychiatric impact on the patient
as well. DBSmay even in some cases restore the original personality, which then is simply not fitting
any more into the actual social and familial setting. Finally, also medication-based therapies for PD
can have severe neuropsychiatric effects (Cools et al., 2003).
Nevertheless, there remains a substantial proportion of DBS patients with severe and lasting
behavior disturbances, which were credibly not present in the ultimate preoperative phase and that
also has led to critical comments in the literature (Moro, 2009). These comprise reckless driving
or other forms of risk-seeking behavior and even aggressive and contemptuous behavior toward
Abbreviations: DBS, Deep brain stimulation; GPI, Globus pallidus internus; STN, Subthalamic nucleus.
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relatives and spouses. In some cases this can be remedied by
moving the active contacts outside the STN with subsidence of
aggressive behavior within hours. This hints to a direct effect
of stimulation. Unfortunately in some patients stimulation must
be markedly reduced or switched off completely to ameliorate
psychiatric effects. Numerous reports and case series have
contributed to this issue with delineation of alarming psychiatric
disturbances ranging from hypomania to suicidal ideation and
suicide (Herzog et al., 2003a; Morgan et al., 2006; Schupbach
et al., 2006; Witt et al., 2008). At the same time other publications
failed to find relevant changes of personality and behavior
(Schuepbach et al., 2013), considered significant changes as not
relevant for overall quality of life (Morgan et al., 2006) or even
found much higher incidence of psychoses in the control group
compared to the DBS group. I will now elaborate on these issues
in some more detail.
MOOD AND BEHAVIOR
A symptom that may be systematically underestimated in its
frequency is hypomania. It occurs early after the intervention
and may lead to apparent improvement in rating scales like
the Beck Depression Inventory and scales measuring quality
of life. The subjective rating by the patient may however be
a result of direct stimulation of the limbic system and not a
normal joyful response to the improved motor performance.
Hypomania becomes dangerous though impaired judgment of
the own abilities and limits. While the patient (and the surgeon)
may be content or even happy with the result, the patient’s family
may be dismayed about disinhibited and reckless behavior.
After some weeks hypomania may subside but other
alterations in mood and behavior surface. Depression and
Apathy may evolve and stay for years leading to markedly
reduced quality of life not only for the patient but also for his
caregivers. The reasons for both remain unclear and have been
attributed to the stimulation directly or the resulting changes
in medication. The incidence of both is relatively well reflected
in the scientific literature (Drapier et al., 2006) with a minority
finding contradicting results. With few exceptions the burden
resulting from altered mood and behavior on caregivers and
families has not received much attention (Lewis et al., 2015).
SUICIDE
While some studies found markedly elevated incidences of
suicide (Voon et al., 2008) a direct association with DBS surgery
was not found in a recent prospective study (Weintraub et al.,
2013). This may indicate improvements regarding selection
criteria—but the observation time in latter study was however
short and patients were in the close scrutiny of a prospective
setting allowing early detection and intervention if suicidal
ideation occurred. The issue is further complicated by the fact
that suicide after DBS has occurred not only with different
anatomic targets but also with other diseases than Parkinson’s
disease (Appleby et al., 2007). Rare events like suicide are
statistically difficult to assess, however, it is alarming that even in
prospective studies with close monitoring of patients these events
occur (Schuepbach et al., 2013). From a laymen’s viewpoint the
situation remains confusing; patients and their relatives remain
worried due to reports of such events in patient representative
organizations that seem to be in contrast to studies and expert
opinions. To my understanding, a definite proof of the safety of
the procedure in this respect is at present not available and the
matter may eventually only be solved by a comprehensive DBS
case registry.
MORAL COMPETENCE AND
PERSONALITY
These are (in my view) the issues with the most confounding
ethical impact. While hypomania subsides and depression may
respond to treatment, rarely measurements are taken to exclude
less obvious changes in behavior and personality. Fundamental
changes in personality have been relatively seldom been studied
(Florin et al., 2013) although basic research documents the role of
the STN in decision making (Ray et al., 2011). Relatives however
report reckless and risk seeking behavior that lasts well beyond
the postoperative phase. Again, these types of behavioral change
may occur gradually in the natural course of the disease or as
side effect of drugs—but the sudden and seemingly irreversible
alteration of personally after DBS comes as a shock for families.
Probably the most profound, albeit at first sight easily overlooked
effects are changes in moral competences of the patients. Such
changes may result in taking risks for oneself and ignoring the
rights of others, exemplified by car accidents or marital conflicts
(Schupbach et al., 2006). Seminars for management of such
conflicts after DBS are therefore already offered with patients and
spouses reporting their experiences.
Changes in personality or moral competences have so far
not been an issue in recent large studies (Schuepbach et al.,
2013). One reason might be that they are difficult to measure
with the scales presently at hand. Scales using the patient’s own
perception are fated to miss deficits in his ability to cope with
the needs of others. Recently, the issue has come into focus
(Fumagalli et al., 2015), but more appropriate scales to detect
and quantify such complex changes must be implemented in the
future (Witt et al., 2013). Cooperation with specialists in the area
of moral psychology should be considered to adopt scales and
knowledge.
THE STN AS TARGET
One reason for the frequency of psychiatric side effects may be
the stimulated target. As the standard target for DBS in Parkinson
disease the STN must be foremost scrutinized.
One of the basic assumptions in defense of the safety of
the STN is the assumption that it consists of three clearly
separated parts and that electrodes can be reliably steered
into the motor part that exclusively contains motor functions.
This concept while propagated by some researchers (Temel
et al., 2005) has at the same time been questioned by others
(Keuken et al., 2012). Furthermore, with the assumed motor
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division being quite small currents from the presently used
electrodes will almost inevitably spread to other parts namely
the limbic subdivision (taking into account that currents spread
sideways from the electrode into areas outside the intended
target).
Empirically the majority of studies come to the conclusion
that targeting the GPI produces less psychiatric side effects (Liu
et al., 2014) while allowing for almost equal motor improvement.
Only one recent study found a clear advantage for the STN
(Odekerken et al., 2013). Disadvantages of GPI are a smaller
reduction of medication and possibly a weaning of effect over
time. The necessity to keep up a high level of dopaminergic
medication may itself provoke psychiatric events (Volkmann
et al., 2004). Still the GPI may serve as target for a subset of
patients prone to complications by STN-stimulation as outlined
in a recent comment (Krack and Hariz, 2013). As such it
has been advertised as target for patients prone to psychiatric
complications1.
The evaluation search for alternative targets should therefore
be continued. Other promising targets are located in the
subthalamic space within the fiber connections between thalamus
cerebellum and basal ganglia as proposed by Velasco and others.
However, it must been kept in mind that the basal ganglia and
the cerebellum are involved in the processing of cognitive and
emotional tasks and with the effects of stimulation spreading
far complete avoidance of mental side effects is therefore not
possible.
PERSPECTIVES
In summary, the available evidence suggests tomy understanding
that neuropsychiatric effects may be an integral albeit unintended
effect of DBS for Parkinson’s diseases. The ethical issues related
to these effects may be even less trivial compared with DBS
for psychiatric disorders. In the latter case, DBS is used with a
transparent and obvious intention to interfere with the patient’s
psyche (Chabardes et al., 2013). In DBS for Parkinson’s disease,
the neuropsychiatric effects are not an obvious “part of the deal”
with the patient.
Subsequently a sober and unprejudiced discussion about how
far these phenomena can be accepted should evolve. For fear of
1Radio broadcast in Deutschlandfunk covering the work of a implantation center
in Germany www.dradio.de/dlf/sendungen/forschak/1407092/
putting a well-established and beneficial procedure at peril, its
disadvantages shall not be disguised.
The discussion about target points that carry a lower risk of
changing the patient’s personality should continue. Patients must
be informed about the available targets and the risks and benefits
connected with each of them.
Prerequisite for the future development of DBS are diagnostic
tools that are reliably able to detect the long-term consequences
of the operation on behavior, personality and moral competence.
Suitable scales can be developed or integrated from other
disciplines into the clinical assessment and future studies. These
must concentrate on the crucial domains of social interaction and
judgment of own behavior. They should also address caregivers
and family’s perception of the patient and the impact on their life.
In defense of the procedure a reversal in the argumentation
should be considered:
- The existence of psychiatric side effects as integral part of the
treatment should be conceded.
- It should be asserted that DBS is a reversible therapy and
can therefore not be put on a par with irreversible surgical
interventions like the lesioning of brain areas. In analogy to
drug therapy it can be discontinued simply by switching it off.
- The patient should be fully informed about the intrinsic risks of
psychiatric adverse events, possible changes of personality and
the targets at hand. Ideally the patient’s partners and next of kin
are involved and informed about the possible resulting burden
as caregivers. This will counter the reproach of guiding patients
into a treatment with consequences he cannot foresee.
Clearly the issue of psychiatric side effects of DBS involves
a legally and ethically utterly sophisticated discussion. Yet
postponing it beyond the moment the lay press may cover
negative events in an untoward manner will not improve our
position to influence its already unforeseeable outcome.
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The Question
High frequency stimulation of the subthalamic nucleus (STN) is an effective treatment for patients
with Parkinson’s disease (PD) (Odekerken et al., 2012; Kocabicak et al., 2013; Schuepbach et al.,
2013). The technique has been further refined throughout the years by improved magnetic
resonance imaging (MRI) techniques, advanced neurophysiological recording possibilities, and
advances in hardware and software technology (Kocabicak and Temel, 2013). There are at least
two major determining factors for an acceptable therapeutic outcome: patient selection (Deuschl
et al., 2006) and the accuracy of targeting of the relatively small STN (Temel et al., 2005). The
latter requires a state-of-the art stereotactic approach, adequate imaging facilities, and a detailed
neurophysiological mapping of the target area. The preferred area within the STN is the motor
part (thought to be located dorsolaterally in the STN), which can, be to some extent, identified
by intraoperative multi-unit activity analyses, and MRI-based tractography (Zaidel et al., 2010;
Brunenberg et al., 2011).
While the STN could not be visualized on MRI images when modern DBS of the STN surgeries
started in Grenoble in 1993, nowadays its visualization has become a routine procedure for most
centers offering DBS for patients with PD. While using intraoperative electrophysiology was
evident in the beginning, now it is questioned whether it still has an essential added value. In this
opinion article, we aim to provide an answer on the question whether or not electrophysiology still
has a clinically relevant role in this era of advanced neuroimaging technology, which enables us to
visualize both function and structure anatomy.
Old Debate
The discussion of whether or not to use intraoperative microelectrode recording (MER) is not
a new one (Hariz, 2002). This discussion was perhaps less vivid when modern DBS started to
be applied in patients with PD. The STN was an invisible target on MR images in most centers
and MER was considered very helpful to find and delineate the boundaries of the target (Pollak
et al., 1993; Limousin et al., 1995; Shamir et al., 2012). Since then things have changed. However,
currently the STN can be directly visualized on T2 weighed and susceptibility weighed MR images.
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The imaging field progresses rapidly further with ultra-high
field imaging modalities becoming now available for patients
(Plantinga et al., 2014).
It is more than 15 years ago that that the visualization of
the STN for DBS surgeries was described (Starr et al., 1999).
Mostly, T2 weighed and inversion recovery MRI sequences have
been used. In most of the patients, the predefined target on T2
weighed MR images was chosen for implantation after intra-
operative electrophysiology and test-stimulation (Bejjani et al.,
2000; Egidi et al., 2002; Starr et al., 2002). This meant that in most
patientsMRI images could reliably show the STN, except for the y
axis, in which microelectrode recording (MER) indicated that the
STN extended more anteriorly than suggested by MRI (Hamani
et al., 2005). Detailed volumetric analysis of MER-determined
borders of the STN and MRI- defined borders in 22 patients (44
STN’s), showed that MER-determined borders of the STN were
exceeding the MRI signal (Schlaier et al., 2011). In addition, we
examined the entry and exit borders of the STN on MRI images
and with MER, using the probe’s eye trajectory (Kocabicak et al.,
2013). We found that T2 weighed MRI could reliably predict the
electrophysiological entry and exit of the STN. Although these
data confirm the accuracy of MRI in visualizing the STN, there
are also limitations. There are known variations between the
patients with respect to the x, y, and z planes, and the borders
can sometimes be less clear, mainly toward the substantia nigra
pars reticulata (SNr) (Hamani et al., 2005; Kocabicak et al., 2013).
From Atlas-based to MRI Based
Coordinates and from Single-electrode to
Multiple-electrode Recordings
In our previous series of 55 patients with PD who underwent
DBS of the STN, atlas- based coordinates were used and in about
one third of the patients the predefined target (central trajectory)
was used for final electrode implantation, after MER and intra-
operative test-stimulation (Temel et al., 2007). With applying
individually adjusted coordinates based on T2 weighed MRI, the
central trajectory was chosen in about two-thirds of the patients
(Kocabicak et al., 2013; Tonge et al., in press). This has resulted
in a clear reduction in operation time. Similar rates have been
reported by others with atlas-based (Amirnovin et al., 2006) and
MRI-based targeting coordinates (Reck et al., 2012). The change
from 1.5 to 3.0 T has also improved the accuracy of targeting
(Toda et al., 2009; Kerl et al., 2012).
Another development has been the change of single-electrode
to multiple-electrode intra-operative electrophysiological
recordings (Temel et al., 2007). The latter provides more
detailed information about the electrophysiological boundaries
of the STN; however, implantation of several electrodes at one
time might increase the risk of bleeding. We found that the
simultaneous implantation of multiple electrodes did not cause
more bleedings or other major intracranial complication. The
use of multiple electrodes resulted in better motor results when
compared with patients who underwent DBS of the STN guided
with a single recording electrode. There are reports, however,
suggesting increased risk of hemorrhage due to MER (Ben-Haim
et al., 2009; Xiaowu et al., 2010).
Back to the Question
Is intra-operative electrophysiology necessary to find the STN?
Our answer is no based on the advances in MRI technology.
In line with this experienced DBS centers have shown good
outcome with a MRI-guided approach (Ostrem et al., 2013;
Aviles-Olmos et al., 2014). So should we abandon MER then?
In our centers, we have decided not to abandon it for a number
of reasons. Even in experienced centers, in about two-thirds of
the cases, the predefined target is chosen for final implantation.
In one-third, an alternative trajectory is needed. With MER,
alternative trajectories are immediately available. The trajectory
with the second longest and, if needed, the third longest STN
activity can be used as alternative trajectories. Two other less
common reasons to use intra-operative electrophysiology can be
an unexpected error in the stereotactic approach or a shift caused
by excessive CSF leakage or a hematoma (Reck et al., 2012).
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In the wake of deep brain stimulation (DBS) development, ablative neurosurgical
procedures are seeing a comeback, although they had been discredited and nearly
completely abandoned in the 1970s because of their unethical practice. Modern
stereotactic ablative procedures as thermal or radiofrequency ablation, and particularly
radiosurgery (e.g., Gamma Knife) are much safer than the historical procedures,
so that a re-evaluation of this technique is required. The different approaches of
modern psychiatric neurosurgery refer to different paradigms: microsurgical ablative
procedures is based on the paradigm ‘quick fix,’ radiosurgery on the paradigm
‘minimal-invasiveness,’ and DBS on the paradigm ‘adjustability.’ From a mere medical
perspective, none of the procedures is absolutely superior; rather, they have different
profiles of advantages and disadvantages. Therefore, individual factors are crucial in
decision-making, particularly the patients’ social situation, individual preferences, and
individual attitudes. The different approaches are not only rivals, but also enriching
mutually. DBS is preferable for exploring new targets, which may become candidates
for ablative microsurgery or radiosurgery.
Keywords: psychiatric neurosurgery, radiosurgery, gamma knife, DBS, ablative neurosurgery, cingulotomy,
capsulotomy, neuroethics
Introduction
Since 2000, there is a renaissance of neurosurgical treatments of psychiatric disorders. Many
researchers and clinicians hope that modern neurosurgical approaches will be established as treat-
ment options for a growing number of therapy-refractory psychiatric disorders. About 90% of
functional neurosurgeons feel optimistic about the future of psychiatric neurosurgery (Lipsman
et al., 2011; Mendelsohn et al., 2013).
Modern psychiatric neurosurgery includes DBS and ablative neurosurgical procedures (thermal
or radiofrequency ablation, and radiosurgery). DBS and thermal or radiofrequency ablation pro-
cedures require a craniotomy. Radiosurgery (Gamma Knife Radiosurgery) is performed without
craniotomy, mostly as an ambulant treatment. In future, high intensity focused ultrasound might
Abbreviations: ALIC, anterior limb of the internal capsule; DBS, deep brain stimulation; ITP, inferior thalamic pedun-
cule; MRI, magnetic resonance imaging; NAcc, nucleus accumbens; OCD, obsessive-compulsive disorder; SCC, subgenual
cingulate cortex; slMFB, superolateral medial forebrain bundle; VC/VS, ventral capsula/ventral striatum.
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become another option. The worldwide ﬁrst four patients have
been treated with this technique in South Korea (Na et al., 2015).
Many authors consider DBS as the most modern and supe-
rior technology, particularly because of its adjustability and high
degree of reversibility. However, in the wake of DBS develop-
ment, ablative neurosurgical procedures are seeing a comeback,
although they had been discredited and nearly completely aban-
doned in the 1970s because of their frequent serious compli-
cations and their unethical practice. Since modern stereotactic
ablative procedures, particularly radiosurgery are much safer and
more eﬃcient than their historical antecessors, a re-evaluation of
this technique is required.
Until now, ethical discussion about non-DBS psychiatric neu-
rosurgery is scarce, whereas psychiatric DBS is intensively dis-
cussed ethically. This blind spot in neuroethics is astonishing
for several reasons: First, the fraction of ablative procedures in
psychiatric neurosurgery is big: in North America, 50% of psy-
chiatric neurosurgeons use lesioning exclusively or combined
with DBS (Lipsman et al., 2011); outside of North America even
54.9% (Mendelsohn et al., 2013). Second, two expert panels have
aﬃrmed stereotactic ablative procedures as important alterna-
tives for appropriately selected patients (Parkinsonism: Bronstein
et al., 2011; psychiatric disorders: Nuttin et al., 2014). Third, a
clear superiority of any procedure in all relevant aspects can-
not be established. Forth, which approach is optimal, depends
signiﬁcantly on patients’ individual medical and non-medical
properties. Fifth, the much higher costs of DBS, particularly
for long-term treatment, exclude this option for the majority of
patients world-wide.
Therefore, a comprehensive ethical analysis of the pros and
cons of the diﬀerent approaches is necessary, based on clinical
facts, not on ideological prejudices. Particularly, it is not justiﬁed
to characterize modern lesioning procedures as successors of his-
torical psychosurgery, while presenting DBS as something quite
diﬀerent. In fact, both psychiatric DBS and modern ablative psy-
chiatric neurosurgery are signiﬁcantly improved successors of the
historical psychosurgery.
Different Paradigms
The diﬀerent approaches of modern psychiatric neurosurgery
refer to diﬀerent paradigms: microsurgical ablative procedures is
based on the paradigm ‘quick ﬁx,’ radiosurgery on the paradigm
‘minimal-invasiveness,’ and DBS on the paradigm ‘adjustability.’
The purpose of ablative microsurgical procedures is to discon-
nect limbic system circuits related to diﬀerent psychiatric disor-
ders in order to enhance brain function and reduce psychiatric
symptoms (Martinez-Alvarez, 2015).
Radiosurgery is usually considered as an ablative treatment.
However, recent neurophysiological, radiological, and histologi-
cal studies challenge this view. Radiosurgical protocols for neuro-
logical or psychiatric disorders might have diﬀerential eﬀects on
various neuronal populations and remodel the glial environment,
leading to a modulation of function while preserving basic pro-
cessing. Thus, modern functional radiosurgery might be based on
neuromodulatory eﬀects (Régis, 2013).
DBS has been considered as a method to produce reversible
lesions. Indeed, high-frequency DBS has a similar eﬀect as lesions,
i.e., inhibition of targets that are hyperactive in psychiatric dis-
orders. However, its mechanism of action is unclear, and several
hypotheses have been put forward to explain the blocking eﬀect
of stimulation (Lévèque, 2014). Its main advantage is that the
stimulation eﬀect can be adjusted by adapting the stimulation
parameters.
Efficacy
A direct comparison of the eﬃcacy of the diﬀerent approaches is
not yet possible, particularly because of the heterogeneity of the
studies, the small patient numbers, and the fact that most stud-
ies are neither placebo-controlled nor double-blind. The rapid
development of the methods aggravates their comparison: In
psychiatric DBS, many targets (mostly overlapping for diﬀerent
diagnoses) are tested with diﬀerent stimulation parameters. In
radiosurgery, the radiation doses used decreased signiﬁcantly.
Randomized controlled trials would be optimal to directly com-
pare the eﬃcacy of the diﬀerent approaches. However, this sci-
entiﬁc standard cannot be met for practical and ethical reasons.
Nevertheless, studies that directly compare diﬀerent approaches
with matched patients would also provide a valid eﬃcacy com-
parison. In any case, this would be much better than the cur-
rent practice of publishing reviews. The problem with most
reviews is that they summarize only data published in medi-
cal journals in English language. However, this practice does
not represent the clinical reality but presents a distorted pic-
ture. Therefore, we expect a severe publication bias (Schläpfer
and Fins, 2010), leading to a systematic over-evaluation of the
beneﬁts.
The publication bias is no minor problem in psychiatric
neurosurgery, but a fundamental problem, which corrupts the
evaluation of risks and beneﬁts of the diﬀerent procedures. For
example, we have performed a systematic literature search on
psychiatric neurosurgery for treating anorexia nervosa, which
yielded only 27 cases (Müller et al., forthcoming). However, from
presentations on conferences we learned that a multiple of the
patients reported in journals have been treated with ablative neu-
rosurgery. Websites of private clinics in Europe as well as in Asia
oﬀer ablative surgery for a broad spectrum of psychiatric disor-
ders as part of clinical routine. These treatments are not part of
clinical studies and usually not published. Recently, a book of Sun
and De Salles (2015) has been published which presents original
data from several studies with ablative neurosurgery for diﬀerent
psychiatric disorders which had not been published in medical
journals.
That being said, we summarize available data on the eﬃcacy
of the diﬀerent approaches, whereby we refer to the most recent
reviews as well as to the above mentioned book of Sun and De
Salles.
Deep Brain Stimulation
For OCD, data from 25 papers comprising 109 patients and ﬁve
targets (NAcc, VC/VS, ITP, nucleus subthalamicus, and internal
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capsule) have been published (Kohl et al., 2014). The responder
rates ranged from 45.5 to 100%.
For depression, data from 22 papers comprising 188 patients
and six targets (NAcc, VC/VS, SCC, lateral habenula, ITP, and
slMFB) have been published (Morishita et al., 2014). The respon-
der rates ranged from 29 to 92%. However, two multicenter,
randomized, controlled, prospective studies evaluating the eﬃ-
cacy of VC/VS, and SCCDBS were recently discontinued because
of ineﬃcacy based on futility analyses (Morishita et al., 2014).
The failure of two high quality studies in spite of the universally
positive results of reported open-label trials could be attributable
to the typical overestimation of eﬃcacy associated with open
label trials that arises from the failure to control for placebo, and
biases due to lack of blinding and randomization (Morishita et al.,
2014).
For anorexia nervosa, six papers comprising 18 patients and
three targets (NAcc, subcallosal cingulum, and VC/VS) have been
published (Müller et al., forthcoming). Remission (normalized
body mass index) occurred in 61% of patients, and in 88.9%, psy-
chiatric comorbidities improved, too. However, Sun et al. (2015)
have recently published less favorable results: only 20% (3/15) of
their patients treated with NAcc DBS showed improvements in
symptoms. The other 80% underwent a second surgery (anterior
capsulotomy), which improved eating behavior and psychiatric
symptoms in all patients (Sun et al., 2015).
Generally, the current knowledge does not allow for identi-
fying a superior target (Kohl et al., 2014; Morishita et al., 2014;
Müller et al., forthcoming).
Microsurgical Ablative Procedures
For treatment-refractory depression, 40–60% of patients
responded to bilateral capsulotomy or cingulotomy performed
with thermal coagulation or radiosurgery (Eljamel, 2015).
For OCD, response rates between 36 and 89% have been
published (Martinez-Alvarez, 2015). Martinez-Alvarez (2015)
reports own data of 100 OCD patients of whom 71%
responded.
For anorexia nervosa, three papers with nine patients report a
remission rate of 100%, with regard to both weight normaliza-
tion and psychiatric comorbidities. Diﬀerent targets were used
(dorsomedial thalamus, anterior capsula, NAcc; Müller et al.,
forthcoming). Sun et al. (2015) report 150 patients treated with
capsulotomy, of whom 85% experienced an improvement in
symptoms.
Radiosurgical Ablative Procedures
For OCD patients, a response rate of 70% has been reported in
the literature (Martinez-Alvarez, 2015). Martinez-Alvarez (2015)
reported a response rate of 100% in ﬁve own patients.
Adverse Effects
Deep Brain Stimulation
Following DBS, surgery-related, device-related, and stimulation-
related side-eﬀects have been reported. Serious adverse
events during surgery were reported: seizures, intracerebral
hemorrhages (in one case causing a temporary hemiparesis),
a panic attack, and a cardiac air embolus (Kohl et al., 2014;
Morishita et al., 2014; Müller et al., forthcoming). In anorexia
nervosa patients, a high rate of severe complications have been
reported: further weight loss, pancreatitis, hypophosphataemia,
hypokalaemia, a refeeding delirium, an epileptic seizure during
electrode programming, QT prolongation, and worsening of
mood (Müller et al., forthcoming).
In several cases, superﬁcial wound infections, inﬂammation,
or allergic reactions occurred (Kohl et al., 2014). Device-related
adverse eﬀects comprised breaks in stimulating leads or exten-
sion wires requiring replacement, dysesthesia in the subclavicular
region, and feelings of the leads or stimulators (Kohl et al., 2014).
Stimulation-induced adverse eﬀects comprised mood distur-
bances, suicidality, anxiety, panic attacks, fatigue, and hypoma-
nia, partly induced either by a change of stimulation parameters,
or by battery depletion. These eﬀects were either adjustable
by parameter adaption or device exchange (Kohl et al., 2014;
Morishita et al., 2014; Müller et al., forthcoming). Some DBS
patients report feelings of self-estrangement (Gilbert, 2013). A
great problem is the high number of suicides and suicide attempts
after DBS that have been reported in eight papers (Kohl et al.,
2014; Morishita et al., 2014). Further side eﬀects include vertigo,
weight loss or gain, long-lasting fatigue, an increased headache
frequency, and visual disturbance (Kohl et al., 2014).
Microsurgical Ablative Procedures
Adverse side eﬀects of microsurgical ablative surgery for major
depression comprised epilepsy (up to 10%), incontinence, weight
gain, transient confusion, transient mania, and transient incon-
tinence. Further side eﬀects reported by only one or two studies
are personality change (7 and 10%), lethargy, hemiplegia (0.3%),
and suicide (1 and 9%) (Eljamel, 2015). Following microsurgical
ablative surgery for treating OCD, a similar spectrum of adverse
eﬀects has been published. Most side eﬀects were transient, and
included headaches, urinary incontinence, impaired cognitive
function, and confusion. Tardive epileptic seizures occurred in 2–
9% of patients (Martinez-Alvarez, 2015). In case of anorexia ner-
vosa, the journal papers reported only transient adverse eﬀects:
bradycardia, mild disorientation, moderate somnolence, loss of
concentration, apathy, emotional emptiness and mild loss of
decorum, headaches, and centric fever (Müller et al., forthcom-
ing). However, Sun et al. (2015) report intracranial hematomas in
1.9% of the patients (4/216); one patient died thereof (0.5%).
Radiosurgical Ablative Procedures
Side-eﬀects such as fatigue, weight gain, or apathy occurred in
several patients who had received doses of more than 180 Gy. In
newer studies with lower radiation doses, adverse eﬀects did not
occur (Lévèque, 2014).
Recommendations
From a mere medical perspective, none of the procedures is abso-
lutely superior; rather, they have diﬀerent proﬁles of advantages
and disadvantages (see Table 1). The main advantages of DBS are
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TABLE 1 | Comparison of different approaches of modern psychiatric neurosurgery.
DBS Microsurgery Radiosurgery
Paradigm Adjustability Quick fix Minimal-invasiveness
Adjustability Very high Low (through a second intervention
to produce another lesion or to
enlarge the lesion)
Low (second intervention to produce another
lesion) to medium (through a step-by-step
approach)
Addressing different
targets in a single session
No Yes Yes
Reversibility High (exception: permanent adverse effects
due to lesions, infections, bleeding)
No No
Invasive craniotomy Yes Yes No
Onset of action Hours to 12 months Days or weeks 6–12 months
Appropriateness for
patients with special
needs
No Patients who would not comply
with long-term follow-up
Patients
- Who would not comply with long-term
follow-up
- With higher risks of anesthesia
- With higher infection risks
Time and effort of the
procedure
Single surgery; several days in hospital plus
visits for adapting stimulation parameters
Single surgery; several days in
hospital
Ambulatory treatment, single session
Long-term treatment Frequent consultation of specialists required
(parameter adjustment, device exchange)
Not necessary Not necessary
Costs Very high direct and life-long costs Medium Low
Mortality risk Yes Yes No
Short-term risks - Anesthesia
- Infection
- Hemorrhage
- Hardware complications
- Anesthesia
- Infection
- Hemorrhage
- Development of cysts
- Edemas
Long-term risks - Infection risks (due to biofilms and regular
battery exchange)
- Hardware complications
No No
Possible adverse effects - Suicidality
- Mood disturbance
- Anxiety
- Panic attacks
- Hypomania
- Weight loss or gain
- Long-lasting fatigue
- Increased headache frequency
- Visual disturbance
- Suicidality
- Headaches
- Seizures
- Drowsiness
- Urinary incontinence Cognitive
impairment
- Personality change
- Transient cognitive impairment
- Transient apathy
- Radiation dose >180 Gy: fatigue, weight gain,
or apathy
Disadvantages in daily life Device-related problems in daily life (e.g., at
airport controls)
No No
Disadvantages for further
medical treatment
- Exclusion of electroconvulsive therapy
- Special MRI required
No No
Possible problems of
psychosocial adaptation
Self-estrangement, feeling of being
manipulated; burden of normality syndrome
Burden of normality syndrome Improbable
its adaptability and high degree of reversibility; of microsurgical
ablative procedures the rapid onset of action; and of radiosurgery
its noninvasiveness and low rate of adverse eﬀects. Furthermore,
it diﬀers individually what counts as an advantage or disadvan-
tage: For example, the delayed onset of action of radiosurgery
makes it disadvantageous for patients who need a rapid symptom
reduction. However, the gradual development of eﬀects might
be advantageous since it alleviates the psychological adjustment
(Lindquist et al., 1991). This may be protective against feel-
ings of being manipulated, self-estrangement and the burden of
normality syndrome.
We support further research in this area generally, but think
that therapeutic adventurism cannot be justiﬁed. The current
research practice in psychiatric neurosurgery does not fulﬁll the
highest ethical and scientiﬁc standards. We plead for ethical rea-
sons for better safeguards in research and clinical practice. Since
psychiatric neurosurgery has both the goal and the potential to
change core features of the patients’ personalities, these inter-
ventions require a solid scientiﬁc fundament. Particularly, we
recommend the following:
• Case registries should become obligatory for all clinical
studies in order to avoid a publication bias and its neg-
ative consequences, namely faulty evaluations of therapies,
ﬂawed therapy recommendations, unpromising treatment
attempts and unneeded clinical studies (Morishita et al., 2014).
Individual treatment attempts should not be performed.
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• A multi-center, randomized, controlled study should be per-
formed that directly compares DBS, microsurgical ablative
procedures and radiosurgery for diﬀerent psychiatric disor-
ders.
• Since multiple circuits seem to be involved in psychiatric disor-
ders, targets of DBS or ablative procedures, respectively, should
be selected speciﬁcally with regard to the prominent symptoms
instead of using the institution-speciﬁc target for all patients.
• Since no single procedure is absolutely superior, patients
should be informed comprehensively about the diﬀerent
treatment options and their respective beneﬁt-risk-proﬁles.
Individual factors have to be crucial in decision making, par-
ticularly the patients’ social situation, individual preferences,
and individual attitudes (e.g., whether they could tolerate
implanted devices; whether they are more afraid of the irre-
versibility of an ablative procedure or of the medical risks of
brain surgery).
We are convinced that the diﬀerent approaches are not only
rivals, but also enriching mutually. DBS is preferable for explor-
ing new targets, which may become candidates for ablative
microsurgery or radiosurgery.
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The number of depressed patients treated with deep brain stimulation (DBS) is relatively
small. However, experience with this intervention now spans more than 10 years
at some centers, with study subjects typically monitored closely. Here we describe
one center’s evolving impressions regarding optimal patient selection for DBS of the
subcallosal cingulate (SCC) as well as observations of short- and long-term patterns in
antidepressant response and mood reactivity. A consistent time course of therapeutic
response with distinct behavioral phases is observed. Early phases are characterized
by changes in mood reactivity and a transient and predictable worsening in self ratings
prior to stabilization of response. It is hypothesized that this characteristic recovery curve
reflects the timeline of neuroplasticity in response to DBS. Further investigation of these
emerging predictable psychiatric, biological, and psychosocial patterns will both improve
treatment optimization and enhance understanding and recognition of meaningful DBS
antidepressant effects.
Keywords: treatment resistant depression, deep brain stimulation, subcallosal cingulate, therapeutic course,
emotional reactivity
Introduction
Deep brain stimulation (DBS) is being investigated as a potential therapy for treatment-resistant
depression (TRD). The DBS target with the most experience is the subcallosal cingulate
white matter, alternatively referred to as subgenual or Area 25 DBS (SCC; Mayberg et al.,
2005; Lozano et al., 2008, 2012; Bewernick et al., 2010; Kennedy et al., 2011; Holtzheimer
et al., 2012; Puigdemont et al., 2012; Merkl et al., 2013; Ramasubbu et al., 2013). Therapeutic
response has also been reported with DBS of the nucleus accumbens (NAC)/medial forebrain
bundle (MFB; Schlaepfer et al., 2008, 2013; Bewernick et al., 2010, 2012), and ventral
capsule/ventral striatum (VC/VS; Malone et al., 2009; Dougherty et al., 2014). While studies
of DBS at these targets vary in design and rationale, small trials have demonstrated
clear benefit, including long-term sustained antidepressant response (Kennedy et al., 2011;
Bewernick et al., 2012; Holtzheimer et al., 2012). However, pivotal industry-sponsored
trials have not demonstrated efficacy (Dougherty et al., 2014; closure of the BROADEN
trial).1 For DBS to be validated as a reliable treatment strategy for depression, each
1http://www.sjm.com/broaden
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independent approach must clearly define the precise
surgical target, appropriate patient selection, time course
of antidepressant response, and symptom specificity of that
response. Given the small number of researchers with firsthand
experience with DBS for depression, open dialog tomaximize our
collective experiential knowledge of this treatment is encouraged.
Towards this goal, we offer a single lab perspective (Emory
University, Atlanta GA, USA) from 8 years of studies of SCC
DBS for TRD, highlighting the key clinical features of patient
selection and the DBS-mediated therapeutic response in this
target (Table 1; clinicaltrials.gov NCT00367003, NCT01984710).
Patients
Screening and evaluating hundreds of participants with in-
depth assessments (Table 1) has shaped our view that three
factors characterize a DBS responsive patient: (1) history of
clear antidepressant response in early depressive episodes with
evidence of inter-episode functional recovery (job, family,
activities); (2) transformation from treatment-responsive to
treatment-resistant depression; and (3) lack of emotional
reactivity at presentation.
A typical history for those participants who respond to DBS
starts with a depressive episode in their 20s that responded
to antidepressant medication with symptomatic and functional
recovery. In subsequent episodes, more aggressive antidepressant
treatment was required and more medication failures were
experienced. Most underwent electroconvulsive therapy, with
an initial good response that could not be recaptured when
symptoms later returned. Puigdemont et al. (2012) reported a
similar pattern of disease progression. Patients’ descriptions of
their depression often include themes of psychic pain, darkness,
being weighted down, or being in a hole. This is accompanied
by pronounced psychomotor slowing, non-fluent, monotonous
speech, and limited affective range. Consequently, these qualities
have taken on the most weight in our assessments of potential
new subjects.
All subjects must meet a minimum severity score on a
standardized rating scale for study inclusion (Table 1). However,
disease severity cannot be solely defined this way. While a
severity score on a depression rating scale can be informative
and is important for research metrics and study integrity,
assumptions about severity scores may be a confound in this
chronically ill population (Bech et al., 1975; Snaith, 1977; Bagby
et al., 2004). Chronicity, treatment resistance, and functional
impairment define overall disease severity in addition to total
symptom burden.
DBS Lead Placement
Intraoperative testing of DBS contacts is conducted in awake
subjects to explore acute stimulation effects, assess safety,
and confirm electrode placement. In the SCC target, acute
effects to stimulation including ‘‘lightness’’ and ‘‘connectedness’’
were initially reported and replicated in subsequent studies
(Mayberg et al., 2005; Lozano et al., 2008; Holtzheimer et al.,
2012; Merkl et al., 2013), but are not universal (Puigdemont
et al., 2012; Ramasubbu et al., 2013). Our subjects have
not experienced adverse events during intraoperative testing,
although stimulation of many contacts produce no discernable
behavioral effects. While the experiences reported by patients
are highly personal and thus idiosyncratic, the predominant
characteristic is relief from negative rather than induction of
positive mood. Return of negative mood is noted soon after
discontinuation of the stimulation. Acute behavioral phenomena
to stimulation have been reported at other DBS targets and
generally fall into categories of decreased negative mood;
increased positive mood, interest, and motivation; autonomic
changes including increased heart rate, sweating, or flushing;
and unpleasant sensations of anxiety and mental or physical
slowing (Mayberg et al., 2005; Lozano et al., 2008; Schlaepfer
et al., 2008, 2013; Malone et al., 2009; Bewernick et al., 2010;
Holtzheimer et al., 2012; Merkl et al., 2013; Riva-Posse et al.,
2014a). Possible explanations of these phenomena include:
site-specific behavioral biomarkers of antidepressant response,
epiphenomena that may or may not have clinical relevance, or
simply side effects of the spread of electric current to adjacent
structures. In some cases, as in double vision with stimulation
of the MFB (Schlaepfer et al., 2013), the specificity, predictability
(based on local anatomy), and reproducibility of the effect would
point toward this being a side effect. In contrast, smiling has
been reported as asymmetric and time-locked to stimulation of
the VC/VS target (Okun et al., 2004), but may also represent
a positive affective response to the sudden absence of mental
pain (Malone et al., 2009; personal observation). Such an effect
would seem to blur the line between side effect and spontaneous
expression of mood change.
Our observations led us to take a more systematic approach
to intraoperative testing, which confirmed predictable,
reproducible, contact-specific responses in most subjects
(Riva-Posse et al., 2014a). The use of tractography has led us
to optimize electrode placement based on the ability to engage
key white matter tracts within the stimulation zone (Riva-Posse
et al., 2014b). We have observed increased heart rate and skin
conductance with stimulation of appropriately-positioned
contacts, which have greater connectivity to the dorsal anterior
cingulate and subcortical regions (Riva-Posse et al., 2014a).
These autonomic effects are predictable based on the putative
targets of the white matter tracts stimulated, but can tell only
part of the story as additional tracts appear necessary for the
antidepressant response to DBS.
The acute behavioral effects seen with intraoperative
stimulation and described above are typically reproducible
within the immediate post-operative period. In the days
following intraoperative stimulation, it is not uncommon for
our patients to experience some persisting symptom relief
even though stimulation is off. This effect is strongest in
the days after surgery and fades within 3 weeks. Repeating
acute stimulation 1 month after surgery may reproduce the
effects in attenuated form, or they may be absent. These
intraoperative responses are now being evaluated as initial
antidepressant effects, as biomarkers to confirm proper electrode
placement, and as a probe of initial antidepressant physiological
responses.
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TABLE 1 | Emory SCC DBS for depression experience.
Subjects1
• 2080 potential subjects contacted
• 524 completed phone screens
• 274 medical records reviewed
• 76 in-person assessments
• 40 subjects enrolled
 8 failed to meet pre-surgical depression severity criteria2
 1 declined surgery
 1 comorbidity exclusion
• N = 30 implanted
 17 published in Holtzheimer et al. (2012)
 11 manuscript in preparation
 2 in current protocol
Standardized Assessment
• Primary outcome measure: 17 question Hamilton Depression Rating Scale (HDRS-17)
 Response = 50% decrease from baseline; N = 17/30 at one year
 Remission = 7 or less; N = 11/30 at one year
Time Course
• Clinical assessment weekly × 8 months, then tapered to semi-annual assessment by year 2
• 8 years since first subject enrolled
• 1527 subject-months (127 patient-years)
1As of 5/2015, 2HDRS-17 ≥20 averaged over 4 weeks prior to surgery.
Post-Operative Course
A 1-month post-operative recovery period, during which
stimulation is off, is followed by 6 months of continuous
stimulation during which nomedication changes are allowed and
only limited adjustments to stimulation parameters are made.
In our observations, the full antidepressant response evolves
through stereotypic early and late subacute phases before settling
into stable long-term recovery.
Out of the Rut . . .
In the first weeks of chronic stimulation, patients generally
report minimal change, though outside observers notice more
dynamic affect, movement, and speech. Anecdotally, family
members comment that the patient ‘‘looks younger’’ or ‘‘is
more like her old self.’’ Within the first month, patients report
an increase in activity and may notice more things in their
environment. They report little subjective change in mood,
although depression ratings are usually decreasing. Patients
begin to notice that they are having more emotions, including
brief positive moods, before endorsing any significant or lasting
lifting of their depression. Others have similarly observed that
significant subjective improvement in moodmay not be reported
for several weeks of active stimulation (Lozano et al., 2008; Merkl
et al., 2013).
Having chosen the contacts for chronic stimulation on the
basis of tractography and intraoperative effect, we typically do
not make changes to stimulation parameters as this clinical
process unfolds. While it is not uncommon for programming
changes to be required over time in neurodegenerative diseases
like Parkinson’s disease, it is not clear that this level of tuning
is necessary or helpful in depression (Bewernick et al., 2012;
Dougherty et al., 2014). Over time, we have focused on the subtle
signs of improvement, particularly with regard to a patient’s
reactivity. In the absence of a clear biomarker for depression
or DBS treatment effect, it is necessary to rely on clinical
judgment to make such decisions. This task is more difficult in
depression, where a key feature of the illness, negative mood,
is not always pathological nor always attributable to major
depressive disorder. With chronic stimulation, patients learn to
differentiate normal negative emotions from the depressive state.
However, learning to make this distinction and trust one’s ability
to emerge from a sad situation appears to take time and practice
and likely is affected by a patient’s premorbid personality and life
experience.
. . . And Into the Rough Patch
The relatively smooth and progressive improvement in
depressive symptoms seen in the first weeks tends to destabilize
roughly 10–12 weeks after initiation of chronic stimulation.
What follows is a temporary period of subclinical emotional
dysregulation characterized by increased negative affect,
especially flares of anger and irritability, mood swings, and
disproportionate negative emotional reactivity to environmental
stressors. This is often concurrent with increased activity
outside the home and increased frequency and complexity of
interpersonal interactions. This period tends to last around
4 weeks. During this time, patients may report a return of
depressive symptoms with increases in depression rating
scores, although generally they no longer meet criteria for
a major depressive episode. In the Emory experience, these
fluctuations resolve without changes in stimulation parameters.
At a similar time point after starting DBS, Puigdemont et al.
(2012) reported a depressive recurrence in some of their
patients, as well as one suicide attempt. This underscores the
importance of close monitoring of patients during the first
several months of DBS treatment, as this is an expected period
of vulnerability. This phase may also coincide with the timing
of outcome measurements in double-blind controlled clinical
trials (Dougherty et al., 2014), thus confounding a normal
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reemergence of emotional bandwidth with return of true
depressive symptoms as both load onto standard depression
severity scales. Failure to establish clear distinctions between
what appears to be a normal plastic process and the presumed
pathological state has clear implications for evaluating efficacy
and for the design of future trials. In our own studies, once this
stage was recognized, parameter adjustments were halted and
psychotherapy was engaged in earnest.
Recovery Takes More than Stimulation: Chronic
Response and Non-response
After 6 months of chronic stimulation, emotional
hypersensitivity usually abates. Depression rating scale scores
again decrease. Global Assessment of Function scores increase,
as patients become more active and connected with others.
They are able to imagine life further into the future and
entertain longer-term goals, such as a return to employment
or other productive activities. Relationships with loved ones,
especially partners, change in response to the patient’s decreased
dependency. Patients report an increased ability to tolerate
setbacks in life and relationships. We see gradual improvement
in mood and resilience through the first year and beyond,
suggesting ongoing plasticity effects. Long-term follow-up
studies have typically shown that the response at 1 year may
continue to improve in subsequent years (Kennedy et al.,
2011; Holtzheimer et al., 2012). All available evidence suggests
that ongoing stimulation is necessary even in those who have
been in remission for years. With device failure the euthymic
state may hold for a period of time, but usually within weeks
depressive symptoms gradually return. These symptoms are
familiar to patients from previous episodes, although they
rarely have the melancholic features characteristic of the pre-
operative state. When device function is restored, therapeutic
benefit returns, but it may take weeks to fully reach the
previous level of wellness (Kennedy et al., 2011; Merkl et al.,
2013).
Interestingly, even those considered non-responders by study
criteria may nevertheless report meaningful improvement in
their lives and choose to continue the treatment even when
offered discontinuation and device removal, as has been the
experience with other stimulation targets (Bewernick et al., 2010;
Dougherty et al., 2014). In the case of SCC DBS, such a partial
response may be attributable to a failure to stimulate all the
white matter tracts necessary for a full response (Riva-Posse
et al., 2014b). Alternatively, non-response or partial response
may occur as a function of individual disease, biological, or
personality characteristics. It may be that specific depressive
symptom clusters that predominate in an individualmay respond
preferentially to stimulation of one DBS target over another. As
with all psychiatric treatments, personality is bound to play a
role in the nature and timing of therapeutic response or lack
thereof. It is important to note that the core personality traits
of patients who are accepted into DBS studies may be masked
by their chronic depressive illness, such that a full understanding
of their character structure can only be seen after the depressed
state is lifted and the patient returns to previous behavioral
patterns.
Once therapeutic contacts and parameter settings have
been established, they are typically maintained over the years.
Medications are generally not changed significantly once
stimulation is initiated. In some instances, doses have been
reduced, but generally not eliminated. However, since the
protocol does not allow medication changes until after 6
months, it is possible that DBS becomes entrained with the
pharmacological milieu instantiated at the time that DBS effects
evolved. That said, patients do not appear to require medication
to enable a DBS effect as patients on no medications can achieve
clinical response and remission, although this is uncommon.
Discussion
In our experience, patients with the best response to SCC DBS
are those who have a history of treatment-responsive depressive
episodes with good inter-episode recovery, but undergo a
malignant transformation and no longer respond to standard
therapies. The antidepressant response to SCC DBS may be
best described in acute, subacute, and chronic phases. Acute
stimulation of appropriately positioned electrodes is frequently
associated with feelings of relief or increased awareness. These
responses are specific to each individual and highly reproducible
with repeated testing in the intraoperative and perioperative
period.
That said, with chronic stimulation, initial changes are
noticed first by others. Patients notice increased activity
and become more aware of their environment before they
notice improved mood. As patients experience more sustained
improvement in mood and more critically, increased emotional
range, they move from a state of relative stability around a
low negative to relative instability, with heightened emotional
sensitivity and reactivity. Close follow-up and reassurance
during this period of emotional recalibration is warranted,
though frequent stimulation parameter adjustments are not.
This intermediate stage of recovery, generally lasting several
weeks, gives way to increased stability and resilience manifest
by progressive improvement in depressive symptoms that
are maintained over months and years. While the steepest
improvement tends to be seen in the first 6 months, DBS
responders report continued gradual improvement over one or
more years of treatment. Discontinuation of stimulation during
this recovery phase nonetheless leads to a gradual return of
symptoms over several weeks. Current studies are exploring how
rehabilitative strategies may best synergize with these distinct
phases of recovery.
The gradual and predictably bumpy recovery curve in SCC
DBS for depression stands in contrast to the response to DBS
observed in Parkinson’s disease and essential tremor, where
the effect is apparent immediately, maximal effect is reached
within hours, and with discontinuation, primary symptoms
return immediately (Hristova et al., 2000). The response to
DBS for dystonia is more similar to that of depression, as
it develops gradually and maximum effect is seen only after
months of stimulation (Yianni et al., 2003). In dystonia and
depression, neuroplasticity and CNS remodeling may be critical
to the long-term treatment response to DBS (Ruge et al.,
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2011; Gibson et al., 2014). Indeed, changes in serum levels
of brain-derived neurotrophic factor are abnormally low and
increase with antidepressant treatment (Brunoni et al., 2008,
meta-analysis) and in response to chronic DBS in an animal
model (Hamani et al., 2012). DBS-induced plasticity may allow
for changes in regional and network activity that ultimately
result in a normalization of depression-related pathology. PET
scans 3 and 6 months following DBS implantation show activity
changes in depression-relevant regions, including normalization
of hyperactivity in the SCC (Mayberg et al., 2005; Lozano
et al., 2008; Bewernick et al., 2010). Prior to PET scan changes,
autonomic changes accompany the behavioral response to acute
stimulation (Riva-Posse et al., 2014a), and changes in EEG frontal
theta concordance after 1 month of stimulation predict 6 month
response to DBS therapy (Broadway et al., 2012). The time
course varies for different regions, which may reflect both direct
and indirect actions on these networks by acute and chronic
stimulation. Comparable findings have been demonstrated using
EEG, suggesting a differential time course of changes with long-
term stimulation. These findings are consistent with the clinical
observations of phase response characteristics and further they
work toward understanding the mechanism of DBS treatment.
It is hoped that knowledge gained from these small, open-
label, mechanistic investigations will inform the design of
larger scale efficacy trials for DBS. Those who would design
such trials face significant challenges. The heterogeneity of
depression may be obscuring subsets of patients who are
the most appropriate candidates for DBS at each anatomical
target. Inability to effectively quantify the desired patient
characteristics creates a problem for clinical trials, where
everything must be operationalized. Allowances must be made in
treatment decision algorithms for discrepancies between clinical
impression and standardized rating scores. During the transient
period of emotional hypersensitivity in the subacute phase,
depression ratings may worsen, which may trigger protocol-
defined parameter changes that interrupt the natural course
of recovery thus confusing the clinical picture and ultimately,
the demonstration of efficacy. Development of next-generation
closed-loop DBS systems that are capable of monitoring and
responding to changes in neuronal signals may further improve
the conduct of future clinical trials (Afshar et al., 2013; Hosain
et al., 2014; Smart et al., 2015). Such systems will be critical
to identifying biomarkers of DBS-mediated antidepressant
response and hence guide treatment optimization.
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According to the World Health Organization, depression is one of the most common
and most disabling psychiatric disorders, affecting at any given time approximately
325 million people worldwide. As there is strong evidence that depressive disorders
are associated with a dynamic dysregulation of neural circuits involved in emotional
processing, recently several attempts have been made to intervene directly in these
circuits via deep brain stimulation (DBS) in patients with treatment-resistant major
depressive disorder (MDD). Given the promising results of most of these studies, the
rising medical interest in this new treatment correlates with a growing sensitivity to
ethical questions. One of the most crucial concerns is that DBS might interfere with
patients’ ability to make autonomous decisions. Thus, the goal of this article is to evaluate
the impact DBS presumably has on the capacity to decide and act autonomously in
patients with MDD in the light of the autonomy-undermining effects depression has
itself. Following the chronological order of the procedure, special attention will first be
paid to depression’s effects on patients’ capacity to make use of their free will in giving
valid Informed Consent. We suggest that while the majority of patients with MDD appear
capable of autonomous choices, as it is required for Informed Consent, they might still be
unable to effectively act according to their own will whenever acting includes significant
personal effort. In reducing disabling depressive symptoms like anhedonia and decrease
of energy, DBS for treatment resistant MDD thus rather seems to be an opportunity to
substantially increase autonomy than a threat to it.
Keywords: deep brain stimulation, depression, autonomy, informed consent, decision making, neuromodulation,
neuroethics
INTRODUCTION
The introduction of the minimally invasive and highly precise stereotactic method, which is also
the basis of deep brain stimulation (DBS), has most certainly been helped by the desire to overcome
the often gruesome practice of frontal lobotomy (Gildenberg and Krauss, 2009). In 1947, the
American neurologist Ernest A. Spiegel and neurosurgeon Henry T. Wycis were the first to use
the stereotactic apparatus on humans and described dorsomedial thalamotomy for depression
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and anxiety disorders (Gildenberg, 20021). Due to its tendency
to induce cognitive deficits, the dorsomedial thalamus was soon
replaced by other target regions for lesion surgery that have
just recently been investigated for their distant connectivity
(Schoene-Bake et al., 2010). Lozano and Mayberg first applied
DBS technology on treatment resistant major depressive disorder
(MDD) with a formerly unknown efficacy in 2005 (Mayberg
et al., 2005). Over the years, other target regions were tested
(see, Table 1), all with strikingly similar anti-depressant effects1.
Whereas one recently published multicenter study on DBS
of the Ventral Capsule/Ventral Striatum failed to reproduce
the remission rates of the initial studies (Dougherty et al.,
2015), a pilot study using the superolateral medial forebrain
bundle (slMFB) as new target reported heretofore never achieved
anti-depressant efficacy of 85%. Remarkably, this latter target has
been developed in a hypothesis-guided way (Coenen et al., 2011).
Stimulation of this region, which is until today mostly known for
its role in motivated behavior and addiction research (Panksepp,
1998), required even significantly less energy than for all previous
targets (Schlaepfer et al., 2014).
Up to one third of patients with MDD do not show
significant symptom reduction in standard treatment and
therefore have to be considered as treatment-resistant (Rush
et al., 2006). Given the high prevalence of treatment-resistant
major depression (TR-MDD), DBS-treatment of MDD is only
performed in relatively rare experimental instances, which are
generally included into clinical studies. Patients thus necessarily
are research participants at the same time, highlighting the
importance of preoperative valid informed consent. In the above
studies, all included patients had a long history of chronic
1For a current review see Schlaepfer et al. (2014).
depression neither responding to pharmacological treatment,
nor to psychotherapy or electroconvulsive therapy. For instance,
the average length of the current depressive episode of patients
included in one of the largest studies amounts to 10.8 years
(Bewernick et al., 2010). Experimental treatment with DBS,
although not yet approved for depression by the US Food
and Drug Administration (FDA), thus can be considered a
last hope for many patients, if the widely dismissed ablative
neurosurgery is not taken into consideration due to its
irreversibility.
Patient selection for DBS is always preceded by an extensive
multi-professional screening process. The most important
inclusion criteria, apart from diagnosis and treatment resistance,
are the length of the current episode and severity of symptoms,
typically measured with the Hamilton Depression Rating Scale
(HDRS) or the Montgomery Åsberg Depression rating Scale
(MADRS). The main exclusion criteria are current or past
psychotic disorders, abnormal Magnetic Resonance Imaging
(MRI) of the brain and any comorbid psychiatric, neurological
or medical condition that could interfere with patients’
safety or compliance during treatment (Mayberg et al., 2005;
Lozano et al., 2008; Malone et al., 2009; Schlaepfer et al.,
2013).
In the light of DBS target regions associated with higher
efficacy, continuous refinement of DBS-technology and novel
applications on the horizon (Deeb et al., 2016), increasing
medical interest in DBS correlates with a growing sensitivity to
ethical questions raised by the use of invasive neuromodulation
on psychiatric diseases. Accordingly, a consensus guideline
on ethical and scientific conduct for psychiatric surgery has
recently been published by an interdisciplinary group of experts
(Nuttin et al., 2014). One of the principal concerns is that
TABLE 1 | Previous studies on deep brain stimulation (DBS) for major depressive disorder (MDD) with three or more participants (Original table).
Study Target structure Patients treated Results
Lozano et al. (2008) Subgenuale cingulate gyrus
(Brodmann-Areal 25, Cg25)
20 6 months follow up: responsea 12/20, remission 7/20b
Malone et al. (2009) Anterior limb of internal capsule (ALIC) 15 6 months follow up: response 7/15, remission 3/15
Schlaepfer et al. (2008) Accumbens nucleus (NAC) 3 6–23 weeks follow up: response 1/3
Bewernick et al. (2010) NAC 10 12 months follow up: response 5/10
Holtzheimer et al. (2012)c Subcallosal Cingulate Gyrus (SCG) 17 2 years follow up: response 11/12, remission 7/12
Puigdemont et al. (2012) SCG 8 12 months follow up: 5/8 response, remission 4/8
Merkl et al. (2013) SCG 6 24–36 weeks follow up: 2/6 remission
Ramasubbu et al. (2013) SCG 4 6 months follow up: response 2/4
Schlaepfer et al. (2014) Superolateral branch of the medial
forebrain bundle (slMFB)
7 up to 6 months follow up; 6/7 responsed
Dougherty et al. (2015) Ventral Capsule/Ventral Striatum 15 3/15 response within 16 weeks
Accolla et al. (2016) Posterior gyrus rectus region/(Cg 25) 1/(4)e 1/1 response; (0/4 response)
Bergfeld et al. (2016) ALIC 25 12 months follow up: response 10/25
Fenoy et al. (2016) slMFB 4 26 weeks follow up: response 2/3f
aResponse is commonly defined as a reduction of more than 50% of baseline depressive symptoms, measured either with Hamilton Rating Scale for Depression (HRSD)
or Montgomery-Åsberg Depression Rating Scale (MADRS).
bEvery Patient in remission counts at the same time as a responder. Thus remission and response-numbers cannot simply be added.
c In addition to 10 patients with MDD, seven patients with bipolar II Disorder were enrolled.
d In a recently published long time observation over the course of 4 years including one more patient, a stable anti-depressant effect was found in 6 out
of 8 participants (Bewernick et al., 2017).
e In the complete sample of 5 patients, 3 were identical with patients of the study published by Merkl et al. (2013).
fOne patient withdrew from study participation.
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DBS could interfere with the ability of patients to make
autonomous decisions and execute their free will. Consequently,
the goal of this article is to evaluate the impact DBS
might have on the capacity to decide and act autonomously
for patients with treatment-resistant MDD. Special attention
will be paid to the possibly autonomy-undermining effects
depression has in itself, thus also potentially endangering valid
Informed Consent—a key prerequisite for the procedure. Our
approach is based on the conviction that with respect to
the large differences between effects and side-effects of DBS,
depending on the target of stimulation and the condition
treated, a proper ethical evaluation of DBS-treatment should
aim to be performed separately for every single indication,
the target region used and the specific characteristics of
both.
ARE PATIENTS WITH MDD COMPETENT
TO GIVE INFORMED CONSENT TO
INVASIVE TREATMENT?
The autonomy of patients undergoing DBS-treatment is not
exclusively a matter of postoperative care. Since autonomy
is one of the key principles of medical ethics and modern
medical practice is widely based on it, autonomous decisions
are supposed to stand at the very beginning of every medical
intervention. Informed Consent was originally implemented
to ensure that no patient would be harmed by unethical
experiments or treatment against his or her will. From a rather
defensive approach mostly aiming to protect participants of
medical experiments, Informed Consent subsequently evolved
into the main instrument to safeguard autonomous choices
for patients in all matters of personal healthcare (Beauchamp,
2004). As such it has to be respected in the ethical evaluation
of DBS-treatment for MDD as well. Since it is obvious that
no person capable of expressing preferences can undergo
neurosurgery against his or her will, the most relevant ethical
question at this stage is, whether patients with MDD can
be considered as autonomous agents in the sense that they
are effectively able to provide valid Informed Consent. This
is especially critical since there are good reasons to consider
impaired autonomy as a key feature of severe psychiatric
illness (DeGrazia, 1994). Also, it seems worth noting that
DBS is not yet approved as a treatment for MDD in the
United States, nor in Europe, implying that DBS in this
case can only be performed within the framework of clinical
trials. In giving consent to being treated, potential patients
would also have to authorize a research procedure. This would
require a certain appreciation of the experimental nature
of this intervention and its partially unclear risk-benefit-
ratio, posing an additional challenge to both the patient’s
understanding and the quality of disclosure provided by
healthcare professionals.
A wide consensus can be found among ethicists that at least
three criteria have to be fulfilled for valid Informed Consent
(Schöne-Seifert, 2007). First of all, healthcare professionals have
to provide patients with all the information required for decision-
making, including disclosure appropriate for the patient’s level
of comprehension. Second, patients have to be competent to
fully understand the information provided and must be able to
decide on this basis. Finally, their decision has to be voluntary
and free frommanipulative influence or coercion. Assuming that
good medical practice is at least likely to fulfill condition one
and three and it is not ethically controversial that DBS is to be
performed in such a context, our considerations will primarily
focus on whether depressed patients are indeed competent to
consent. This will also help clarify in which way patients with
MDD are able to act autonomously and in which they are
not. New efforts to discuss Informed Consent in the broader
perspective of patients’ vulnerability will not be discussed here
as for the focus of this article. For a concise overview of this
recent attention-gaining approach, we recommend Bell et al.
(2014).
According to the seminal work of Beauchamp and Childress,
competence can be defined by four essential criteria:
‘‘Patients or prospective subjects are competent to make a decision
if they have the capacity to understand the material information, to
make a judgment about this information in light of their values, to
intend a certain outcome, and to freely communicate their wishes
to caregivers or investigators’’ (Beauchamp and Childress, 2009,
p. 113).
Inability to give Informed Consent because of mental disorders
is a very common problem in psychiatric practice and ethics (van
Staden and Krüger, 2003). Several tests have been developed to
assess patients’ competence, among them such well-established
instruments as the MacArthur Competence Assessment Tool for
Treatment (MacCAT-T; Grisso et al., 1997; Dunn et al., 2006).
All in all, in psychiatric literature there has been little doubt about
depressive patients’ competence to consent. In a line of thought
reaching back to Jean-Étienne Esquirol, one of the fathers
of modern psychiatry in the early 19th century, depression
is perceived as a disorder which characteristically affects the
mood and not the mind (Ehrenberg, 2009). Consequently, it is
deemed unlikely to impair cognitive features like understanding
material information or the ability to communicate freely in
a way relevant to patients’ competence (Elliot, 2006). In fact,
clinical experience shows that MDD might be associated with
a slight decline in overall cognitive performance due to lack of
concentration and general tiredness. However, only in the case
of psychotic features, is it common to classify depressive patients
as incompetent. Empirical research points in the same direction.
Studies focusing on understanding and reasoning showed
impairment in only 5.4% (understanding) respectively 7.6%
(reasoning) of depressive inpatients consenting to treatment
(Grisso and Appelbaum, 1995). Depressive inpatients asked to
volunteer for research reached relatively high scores in the
MacArthur Competence Assessment-Tool for clinical research
and were found to be able to distinguish the levels of risk
between studies (Cohen et al., 2004). In a similar vein, two
studies on Informed Consent for ECT could not find any
correlation between depression severity and decision-making
capacity measured with the MacCAT-T (Lapid et al., 2003,
2004). Furthermore, it can be assumed that patients with MDD
would also benefit from strategies to improve understanding and
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thus enhance the Informed Consent process in general. As a
metaanalysis points out, research participants’ understanding of
the information disclosed in the Informed consent process can
be improved by either the use of multimedia or, most effectively,
additional person-to-person contact between participants and
healthcare professionals (Flory and Emanuel, 2004).
Hence, ethical concerns are raised mainly over the
non-cognitive dimension of decision-making. For instance,
it has been argued that MDD could significantly bias the
evaluation of possible treatment results towards neglecting
the likelihood of a positive outcome while overrating negative
outcomes and treatment risks (Rudnick, 2002). In this case,
one could assume patients’ judgment to depend on their overall
negative perspective caused by depression rather than their
true values. However, this argument overemphasizes the role of
rational thinking and consciousness in decision-making. Most
individuals do not decide exclusively by rationally weighing up
pure facts. For the acceptance of a certain treatment, it can be
crucial whether a physician seems trustworthy or if it just ‘‘feels
right’’ to do it. Even if anxiety, a generally pessimistic perspective
and maybe even desperation might have some influence on
decision-making in the case of MDD, it seems questionable
why this should be especially problematic in this context, while
decisions in ‘‘normal’’ daily contexts led by the same irrational
motives are considered adequate. Furthermore, anxiety and
desperation are not at all specific traits of depressive patients,
but in fact—understandably—a common feature of severe illness
in general (Dunn et al., 2006). Thus, excluding patients from
treatment or research primarily because of their desperation or
anxiety could lead to the contradiction, that people who are the
most in need of ultima-ratio interventions are the least likely
to receive them. Apart from that, recent studies on depressive
patients considering enrollment into DBS-treatment programs
indicate that they rather tend to overrate their personal benefits
and underestimate the likelihood of risks than vice versa (Leykin
et al., 2011; Fisher et al., 2012). This widespread bias, known
among ethicist and clinicians as therapeutic misconception, arises
from individuals’ difficulties to distinguish between regular
clinical care and research procedures with unclear therapeutic
benefits (Appelbaum et al., 1982). Interestingly, depressive
patients did not score worse than average non-psychiatric
patients. In a small sample, severity of depressive symptoms even
seemed to correlate with a more precise evaluation of risks and
benefits (Fisher et al., 2012).
In a similar vein, it has been argued that MDD itself can
change patients’ values, preferences and goals in a way that
their decisions are not authentic (Rudnick, 2002; Elliot, 2006).
There are several reasons to be skeptical of this argument. A
general problem concerning authenticity as a criterion for the
competence to consent is that it is only applicable ex-post, which
means that patients’ competence would be verified after they
have already decided. Assuming that this judgment wouldmainly
depend on the content of the decision made, it is probable that
physicians might tend to disrespect non-conforming choices by
judging them to be inauthentic. For this reason, many ethicists
argue that authenticity as a criterion for autonomous decisions
runs the risk of promoting paternalism (Schöne-Seifert, 2007).
Furthermore, severe illness as an extreme experience clearly
has the potential to change someone’s goals or preferences in
a relatively short amount of time. Authenticity, thus, cannot
mean to expect patients to stick to their old opinions while
their whole life is turned upside-down. Given that it is very
natural to change one’s perspective on life in reaction to extreme
situations, authenticity as a criterion becomes rather useless as a
safeguard for competence. It seems neither theoretically plausible
nor practically feasible to separate legitimate changes of mind
from inauthentic shifts of preferences in the light of severe illness
(Bielby, 2008). However, there is a third argument questioning
MDD patients’ competence to consent, which seems to be more
appropriate than the preceding ones. One main symptom of
MDD is a general loss of interest in living, culminating in the
worst case in suicide attempts or completed suicide. An often-
cited example of how a weakened will to live can influence
decision-making in medical matters is presented by Roth et al.
(1977). The authors report a 49-year old woman who was
asked to consent to electroconvulsive therapy because of MDD.
When told that this treatment carries a risk of 1–3000 to die
from complications, she articulated a surprising motivation to
be treated by replying that she hoped to be the one (Roth
et al., 1977). Whereas patients refusing treatment out of fear
or by overrating negative outcomes at least show some concern
for themselves, the patient in this extreme case displays an
alarming lack of this fundamental interest in her own wellbeing.
Choosing a treatment just because of the chance to die from
adverse effects thwarts the very idea of Informed Consent. A
patient using an instrument established to prevent harm in order
to get harmed is not just executing his right of autonomous
choice in a very uncommon way. He is rather refusing to
act autonomously at all and therefore has to be considered
incompetent to consent.
As a result, no argument seems strong enough to exclude
patients with treatment-resistant MDD collectively from giving
Informed Consent to DBS-treatment. Also, empirical data
supports that autonomy in its sense of capacity to consent
commonly seems not to be significantly impaired by MDD itself.
We should take into consideration that expecting depressive
patients to fulfill higher standards than mentally healthy
patients would not only establish unfair access to regular
or experimental treatment, but also reinforce stigmatization
of this already disadvantaged group (Bell et al., 2014). The
well-meant wish for special protection, when not reflected
adequately, can easily relapse into old-fashioned (medical)
paternalism.
On the other hand, regarding the invasiveness of DBS,
the necessarily experimental character of treatment and as a
concession to the current limitedness of empirical data, MDD-
patients’ competence to give valid consent cannot simply be
taken for granted. Individual evaluation of cognitive function,
as should be part of every surgical or experimental treatment
of psychiatric illness, is recommended in this context as well
as extensive psychiatric evaluation, neuropsychological testing
and multi-professional assessment including a thorough look
at possible therapeutic misconception. Additionally, as shown
in the example by Roth et al. (1977) it has to be ensured
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specifically that depressive patients’ decisions are motivated by
the fundamental interest in their own wellbeing, which is the very
essence of Informed Consent.
IS DBS per se AN
AUTONOMY-SUBVERTING TREATMENT?
As the ongoing popularity of literature and movies connected to
the topic shows, the very idea of technical devices implanted in
the human brain seems to cause discomfort to a considerable
amount of people. Although general concerns towards DBS are
by no means comparable to those fears famously expressed
in novels like ‘‘The Manchurian Candidate’’ or ‘‘The Terminal
Man’’, similar questions are touched upon. Far from fictional
scenarios of technically driven mind- and behavior-control,
DBS also has to deal with the preoccupation that it might
affect patients’ behavior in a way that their actions would
no longer count as self-governed (Klaming and Haselager,
2013; Grant et al., 2014; Unterrainer and Oduncu, 2015).
The goal of the following passage is to evaluate whether
evidence can be found that DBS for therapeutical use could
be a threat to patients’ autonomy. Due to a lack of empirical
studies dedicated explicitly to this topic, our main focus
will lie on a philosophically informed critical evaluation of
cases of altered behavior during DBS-treatment. Although
some cases at first sight suggest that DBS might influence
decisional capacity, we hypothesize that it is in fact more
likely for patients with MDD to benefit from DBS-Treatment
with respect to their autonomy, given that MDD itself is a
highly autonomy-subverting condition (see, Figure 1). A similar
claim has recently been made for the treatment of obsessive-
compulsive disorder, in which the overall positive effects of
neuromodulation also seem to increase autonomy (De Ridder
et al., 2016).
Philosophical Background: Harry G.
Frankfurt’s Hierarchical Model of Free Will
Going back to ancient philosophy and as a key concept
of philosophical enlightenment, autonomy is a traditional
issue of philosophy, recently discussed in the debate on free
will and neuronal determinism. Among a variety of largely
overlapping positions, the most prominent modern attempt
to specify the characteristics of autonomous actions has been
developed by US-philosopher Harry G. Frankfurt (Frankfurt,
1988). Frankfurt’s hierarchical model of free will belongs to
the so called internalist wing of the debate. According to
internalists’ point of view, the key feature of autonomous agency
is that the agent’s motives leading to particular actions somehow
cohere with a framework of more general higher motives and
attitudes. The latter can be called internal in the sense that
they are mental states belonging to the agent, which are closely
bound to his or her personality (Buss, 2014)2. They have been
referred to as higher-order desires (Frankfurt, 1988), evaluational
judgments (Watson, 1975), long term plans (Bratman, 2007) or
2http://plato.stanford.edu/archives/win2014/entries/personal-autonomy/
(accessed October 12, 2016).
character traits (Dworkin, 1988). Following this train of thought,
a person who acts in accordance with her own—however
labeled—higher-order attitudes, ultimately acts in accordance
with herself, thus literally being autonomous in the original
ancient Greek translation of self-governing. While internalists
focus on the two-level structure of basic desires or actions
and corresponding higher order desires or attitudes, taking
coherence between the two levels as the benchmark of autonomy,
externalist approaches, representing the other prominent wing
of the debate, place much more emphasis on rationality of the
agents and their higher motives themselves. According to their
shared intuition, agents can only be autonomous, if they are
conscious of and able to articulate logical, sound reasons for
their doing (Fischer and Ravizza, 1993; Nelkin, 2007) or are at
least potentially able to reason about it in an appropriate way
(Christman, 1991, 1993; Mele, 1993). Consequently, for these
authors autonomous action is not primarily a matter of personal
preferences, but most importantly has to fulfill certain external
criteria: to match the objective world and to follow the laws of
logic.
There are several reasons to favor internalist approaches like
Frankfurts’ hierarchical model of free will. Generally speaking,
externalists’ main interest lies in identifying the conditions
under which an agent can be held responsible for his or
her actions, while neglecting engagement with the process of
autonomous decision and action itself. As it is necessary to have
at least a minimal theoretical understanding of how autonomous
actions really take place in order to evaluate possible autonomy-
subverting effects of DBS, it is evident why externalist approaches
are of little use for our purpose.
Frankfurt’s concept of autonomy is not only the most
established internalist approach, it also best matches the
requirements of our endeavor and the kind of data we have
to deal with. Frankfurt suggests a clear and comprehensible
model of autonomous agency, which is remarkably close to the
everyday-experience of self-governed agency. It allows a clear
focus on agents’ behavior and their attitudes towards it. This
is especially important given that we have no other option
than drawing inferences from literature without knowing the
individuals involved personally, thus being unable to verify the
logical soundness of their motives or their ability to reason.
Since there are no specific studies on DBS and autonomy,
our aim is to take a close look at harmful or otherwise
abnormal behavior which occurred under DBS-treatment and
then question it for signs of the agents’ underlying higher-order
attitudes.
According to Frankfurt, persons can be distinguished from
other living beings who are not persons by being capable of
having two different classes of desires and to reflect on them.
Whereas first-order desires have the structure ‘‘A wants to X’’
with X representing a certain action, second-order desires refer
back to first-order-desires a person does or does not want to have.
A person is acting autonomously when her first-order desires
expressed in effective action are fitting to the framework of her
second-order desires. The key feature of free will, therefore, is
that a person identifies with her actions, meaning that she truly
wants to do what she effectively does and, on the other hand,
Frontiers in Integrative Neuroscience | www.frontiersin.org June 2017 | Volume 11 | Article 11 | 47
Beeker et al. Autonomy in Depressive Patients Undergoing DBS-Treatment
FIGURE 1 | The potential effects of deep brain stimulation (DBS) of the different target regions on patients’ autonomy. In STN DBS mania is a rare (ca. 4%) side
effect. Legend: vcvs, ventral capsule ventral striatum; scg, subgenual cingulate gyrus; MFB, medial forebrain bundle; STN, subthalamic nucleus.
really does not want to do what she passes by. According to
Frankfurt, an action is hence autonomous, only if it coheres to
the acting person’s preferences, values and goals as represented
by her second-order desires.
Autonomy Under DBS: A Critical Review of
Empirical Data
Due to a lack of systematic empirical research on autonomy-
subverting effects of any kind of neuromodulation, evaluating
the risks of DBS-treatment to patients’ autonomy in the case of
MDD naturally faces a major difficulty: the only available data
containing information about behavior under DBS indicating
impaired autonomy originate from patients receiving treatment
for different conditions. The predictive power of any evaluation
thus relies on careful selection of cases which are at least in some
respect comparable. The majority of studies and case reports
dealing with troubled decision-making and abnormal behavior
under the influence of DBS are derived from treatment of
Parkinson-Disease (PD). The most relevant subgroup of patients
for our purpose are those receiving DBS of the Subthalamic
Nucleus (STN), which is embedded in similar neuronal circuits
as DBS for MDD aims to modulate. Among several known side
effects of STN-stimulation, the second most frequent psychiatric
side effect (after depression) is hypomania with an estimated rate
of 4% (Temel et al., 2006). According to ICD-10, core symptoms
of hypomania are abnormally increased energy and activity
under persistent elevation of mood, becoming manifest in
behavioral changes such as heightened sociability, talkativeness,
overfamiliarity, increased sexual energy or decreased need for
sleep. Correspondingly, Mandat et al. (2006) report two cases of
hypomania under STN-DBS leading to detrimental behavior of
two male PD-patients. Seventy-two-year-old patient 1 purchased
a new car, ignoring that he would never be able to drive it as
he had been physically disabled for years. He also arranged to
be visited by a prostitute, clearly disregarding the rules of his
nursing home. Forty-five-year old patient 2, lacking any history
of psychiatric disorders or criminal behavior, broke into a parked
car in the middle of a crowded street. Similarly, Romito et al.
(2002) report two male PD-patients with STN-DBS displaying
behavioral changes associated with general symptoms of mania.
Whereas patient 2 showed a wide range of abnormal sexual
behavior, most remarkably inappropriate seductive behavior
toward female staff, patient 1 started writing religious poems
despite never having shown any interest in religion. He also
began to purchase items he did not need, to plan hazardous
business investments and to drive his car in a reckless manner
(Romito et al., 2002, p. 1372).
Although it seems evident that the patients in these cases
are not acting autonomously while in a hypomanic state,
the application of Frankfurt’s model to such reports is quite
difficult. According to Frankfurt, the most important criterion
for autonomy is coherence of the performed actions with the
second-order desires of the agent. Knowing the patients only
by case report, we have no access to the framework of their
second-order desires. For instance, it is hard to tell whether
Romito’s patient 2, when writing religious poems, is just driven
by some spontaneous manic fantasy or if he might be giving
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in to suppressed wishes. Nevertheless, we can assume that at
least some of the abnormal actions displayed contradicted the
higher-order desires of the agents. Wasting money on unneeded
items, risking to die in a car crash or being charged with sexual
harassment are very unlikely to correspond with the preferences
of virtually anyone. Given that this behavior did not occur before,
it appears that patients acting this way thus apparently have
serious problems to act in accordance with their higher-order
desires, following random impulses instead. Mandat’s patient 2,
who broke into a parked car, was later found unable to explain
why he did it. Taking this lack of adequate reasons as a sign
for a lack of second-order desires in favor of breaking into
cars, the best explanation for this patient’s behavior is that he
was unable to resist a sudden impulse. According to Frankfurt,
it is the key feature of personal autonomy to evaluate first-
order desires in the light of second-order desires, which usually
leads to actions compatible with a person’s higher-order desires.
In the cases mentioned, this mechanism seems to be impaired
by impulses bypassing rational assessment. Patients tending to
give in to impulses triggered by external factors (e.g., an empty
highway, attractive medical staff, opportunities for spontaneous
purchases) without evaluating them, thus carry a high risk for
non-autonomous actions.
Having identified decreased impulse control as a possible
autonomy-subverting adverse-effect of DBS, further evaluation
needs to assess, if there are also examples of impaired
autonomous decision-making during DBS-treatment other than
manic or hypomanic states. Indeed, several cases of abnormal
behavior under DBS have been reported which evidently
were associated with impaired impulse control. Sensi et al.
(2004) describe a patient showing explosive-aggressive behavior
undergoing STN-DBS, which they explicitly relate to disturbed
impulse control. On the second day postoperative, the 64-year
old male exhibited spontaneous aggressive outbursts including
physical attacks towards medical staff and his own family.
Furthermore, he displayed kleptomaniac behavior trying to
steal electric wires and bath towels. After they had found
out that his aggressive behavior correlated with the strength
of neurostimulation, the treating physicians eventually gained
control of psychiatric symptoms through a moderate dose of
antipsychotic medication (Quetiapine 100 mg/d). Supporting
Sensi et al.’s (2004) interpretation, both ICD-10 and DSM-IV
rank kleptomania and intermittent explosive disorder among
impulse control disorders. Another kind of abnormal behavior
belonging to this category is pathological gambling, which has
also been found in PD-Patients undergoing DBS-treatment.
According to Frankfurt, who uses the figure of the unwilling
addict as the prime example of deficient autonomy (Frankfurt,
1988), it is highly plausible to consider pathological gambling
an almost paradigmatic example of non-autonomous behavior.
Typically, pathological gamblers not only act against their
assumed second-order desires. In a certain sense one could
argue that they rather act at the expense of their second-order
desires as such, successively destroying their financial well-being
and putting at stake all kinds of interpersonal relationships.
In this regard, Smeding et al. (2007) report a 63-year old
male patient who developed pathological gambling under the
impact of STN-Stimulation. According to his family, the patient
previously was ‘‘as stingy as a Dutchman’’. Within 1 month of
his treatment, he started to gamble away considerable amounts
of money, which resulted in increasing debts, the sale of his
house and his wife wanting divorce. His desperate situation
finally culminated in three suicide attempts, prompting his
admission to the neurological ward, where his urge to gamble
ceased after modification of his Parkinson medication. Apart
from these rather extreme cases of impaired impulse control,
STN-DBS might also impair decision-making in a less obvious
way. A study based on neuropsychological tests suggests that
STN-DBS can interfere with the patients’ ability to stop and
think when confronted with difficult decisions, thus leading
to suboptimal choices (Frank et al., 2007). However, given
that patients tended towards impulsive decisions especially in
win-win-situations, in which only slight extra-benefits could be
gained by careful selection, it seems questionable if this study
actually indicates a severe threat to autonomy in any relevant
sense.
Although there seems to be a wide range of autonomy-
subverting side effects associated with DBS-treatment at first
sight, the role of DBS in all these cases remains controversial.
At least two more factors need to be taken into account for a
proper evaluation. First, every patient mentioned was suffering
from advanced PD and thus from a condition which severely
affects dopaminergic transmission in the brain. PD itself can—at
a certain disease stage—have exactly the same symptoms. Second,
every patient had a history of dopamine replacement therapy
and in the majority of cases medication was still being used
in addition to DBS. The combination of these two factors
was identified as a potential risk for impulse control disorders
years ago (Voon et al., 2011). Dopaminergic dysregulation
syndrome, resulting both from neurodegenerative effects of PD
and longtime dopamine replacement therapy, has been discussed
as a possible explanation for behavioral changes and reduced
impulse control emerging independently of DBS-treatment
(O’Sullivan et al., 2009; Katzenschlager, 2011). Correspondingly,
Smeding et al. (2007) patient’s pathological gambling eventually
resolved after pergolide treatment was stopped, while DBS was
continued. However, there have even been several cases in which
impulse control disorders improved under DBS (Ardouin et al.,
2006). All in all it is hence plausible to regard STN-DBS as
just one of several factors, which, in combination, can possibly
cause impairment of impulse control in some individuals. The
same applies to manic or hypomanic states, which also occurred
mainly among patients who had already been suffering from
conditions affecting the limbic dopamine system. Also taking
into account that the vast majority of patients undergoing DBS
did not show any kind of autonomy subverting complications,
it thus seems appropriate not to generally criticize DBS as a
threat to autonomy. Taking seriously the examples of impaired
decision-making rather should result in raising overall awareness
for this category of adverse effects, including them into Informed
Consent procedures and advancing standards of postoperative
care.
Whereas it is questionable which role DBS has played in the
mentioned cases and to which extent results originating from
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STN-DBS on PD-patients can be applied to DBS of patients
with MDD, the few pilot studies already indicated widespread
positive effects of DBS on the autonomy of depressive patients.
According to Frankfurt’s concept, patients with MDD can be
considered non-autonomous in a very distinct sense: although
depression does not affect most patients’ capability to make
rational decisions, reflected in depressive patients’ ability to
give valid Informed Consent, it is a general feature of MDD
that patients are unable to act as they truly want to. This has
to do with its main symptoms, which are lowering of mood,
loss of interest due to general anhedonia and reduction of
energy with a decrease in activity. A typical patient therefore
might actually wholeheartedly wish to leave his bed, go to
work or meet with friends etc., but still none or just very
few of these desires will lead to goal directed action. For this
reason, patients with MDD can be conceptualized as persons
with an intact framework of second-order desires, who have
a significantly reduced ability to convert them into effective
first-order desires and thus to act autonomously. This very
impairment often entails loss of work, financial problems,
damaged partnerships and social isolation. Given that there
is a negative correlation between depression and autonomy,
response or remission of patients undergoing DBS-treatment can
be regarded as strong indicators for an increase in autonomy
as well. In fact, about half of the patients included in the
main pilots responded to treatment with a decrease of at least
50% on HDRS. Even non-responders have been reported to
show signs of improving goal directed action (e.g., increase of
activity, making new acquaintances, resuming part-time work;
Bewernick et al., 2010). Thus, in the case of patients with
MDD, DBS is more likely to partially restore autonomy than to
subvert it, re-enabling patients to put their desires into action
and leading a life which corresponds at least more closely
to their own preferences than years of depressive stagnation
presumably did.
CONCLUSION: AUTONOMY AS GRADUAL
As a result of our considerations, we propose to regard the
majority of patients with MDD as likely to be capable of
autonomous decision-making but very unlikely to be fully able
to effectively act according to their own will, whenever acting
includes significant personal effort. Taking into account that
MDD is a highly autonomy-subverting condition, DBS thus
rather seems to be a chance to restore some sovereignty in
everyday life than a threat to autonomy. Though there have been
some cases of partially impaired autonomy among PD-patients,
potential risks of DBS in this respect seem to be overcome
by anticipated benefits indicated by the pilot studies of MDD-
treatment.
From a strictly clinical point of view, it is worth noting that
significant improvements in daily and social life (e.g., increase of
activity, establishing a daily structure, reengagement in gainful
employment), which can be seen as major contributions to an
overall increase of autonomy, might not be displayed adequately
in standard outcome measurements. Improvements of this kind
are poorly reflected in commonly used symptom-based rating
scales like HRDS or MADRS. These instruments have been
designed originally to monitor the effects of pharmacotherapy
on ‘‘everyday’’ depressive patients, but not for the extreme
case of treatment-resistant MDD (Bewernick et al., 2010).
Exclusively measuring the effects of DBS with symptom-based
scales thus could result in a paradoxical situation: patients who
subjectively experience benefits of high personal relevance might
be nonetheless considered objective non-responders (Bewernick
et al., 2017). In a similar vein, minor but relevant improvements
might be noticed best by close relatives and consequently also
not be reflected in outcome measurement (Crowell et al., 2015).
In line with the recently published consensus guideline for
psychiatric surgery, this highlights the importance of quality-of-
life measurement for the general outcome assessment of DBS for
MDD (Nuttin et al., 2014). Furthermore, these findings support
the claim to include individually defined treatment goals—which
can of course be diverse and continually evolving—in the
evaluation of overall effects of DBS-treatment (Kubu and
Ford, 2012). A shift towards the individualization of outcome
assessment by using more sensitive tools for improvements
in daily living as well as personally defined treatment goals
would facilitate the proper assessment of a possible increase of
autonomy due to DBS-treatment too. Autonomy in its broadest
and maybe most relevant sense means the capacity to live a
self-governed life which accords as much as possible with the
preferences of the agent, making it a life, which is subjectively
worth living. Therefore, undergoing DBS-treatment in order
to increase quality of life and to reach certain self-defined
goals would not only overlap with the idea of autonomy
but can in itself already be seen as a first step of regaining
autonomy.
From a philosophical point of view, the example of severely
depressive patients being able to decide autonomously while
heavily impaired in their performance of autonomous actions,
underlines that autonomy should be regarded as gradual.
Autonomy cannot be appropriately conceptualized as an ability
which is either completely lacking or fully intact. Both
extremes are located at the very ends of a broad continuum.
Persons reaching one of these extremes presumably are rare
exceptions, given that normal, healthy agents also regularly
perform actions which contradict their second-order desires.
For our case, insisting on autonomy as gradual has two
important implications. First, it would be more accurate to
discuss DBS and its wanted or unwanted effects in terms such
as ‘‘reducing’’ or ‘‘increasing’’ than ‘‘threatening’’, ‘‘losing’’ or
‘‘restoring’’ autonomy, which all implicitly refer to autonomy
as a whole. Second, acknowledging the striking deficits in
autonomy caused by MDD, the main therapeutic goal of DBS
relative to patients’ autonomy can only lie in maximizing their
ability to lead a life according to their own will (Beeker, 2014).
Assuming that severe motor impairments due to PD undermine
self-determined living in a similar way as MDD does, the treating
physicians in the cases analyzed therefore did right to continue
stimulation despite the observed side effects. Having achieved
significant motor benefits, they carefully adjusted stimulation
parameters, optimized additional medication or just waited for
adaption by way of neuronal plasticity, instead of immediately
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ending DBS. Remarkably, in all cases a lasting gain of overall
autonomy finally achieved through successful treatment of
motor symptoms thus was preceded by an episode of partially
diminished autonomy. The same could apply to DBS-treatment
of MDD. An evaluation of the outcome of patients always has
to take into consideration that MDD itself—and therefore the
condition every treatment result has to be compared to—is a
condition which impedes patients living autonomously in any
meaningful sense. For treating physicians, maximizing patients’
autonomy in this context would mean primarily to aim for
remission of depressive symptoms while carefully managing
possible adverse effects. If patients are clinically benefiting from
stimulation, effects which might reduce autonomy to some
degree should be tolerated as long as there is reasonable hope
of eventually reaching overall and long-term gains of autonomy.
Even moderate persistent side effects could be tolerated, if in
accordance with the will of a patient or if negligible from a
broader quality-of-life perspective on autonomy. A slight overall
increase in impulsiveness or a tendency towards suboptimal
choices in win-win-situations might look like small disturbances
to most patients, if in exchange chronic symptoms remit and
theses patients are enabled to lead a relatively normal life
again.
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This paper provides an overview of current progress in the technological advances
and the use of deep brain stimulation (DBS) to treat neurological and neuropsychiatric
disorders, as presented by participants of the Fourth Annual DBS Think Tank, which
was convened in March 2016 in conjunction with the Center for Movement Disorders
and Neurorestoration at the University of Florida, Gainesveille FL, USA. The Think Tank
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discussions first focused on policy and advocacy in DBS research and clinical practice,
formation of registries, and issues involving the use of DBS in the treatment of Tourette
Syndrome. Next, advances in the use of neuroimaging and electrochemical markers to
enhance DBS specificity were addressed. Updates on ongoing use and developments
of DBS for the treatment of Parkinson’s disease, essential tremor, Alzheimer’s disease,
depression, post-traumatic stress disorder, obesity, addiction were presented, and
progress toward innovation(s) in closed-loop applications were discussed. Each section
of these proceedings provides updates and highlights of new information as presented
at this year’s international Think Tank, with a view toward current and near future
advancement of the field.
Keywords: deep brain stimulation, Parkinson’s disease, Alzheimer’s disease, closed-loop, depression,
post-traumatic stress disorder, Tourette syndrome, DARPA
INTRODUCTION
The Fourth Annual Deep Brain Stimulation (DBS) Think
Tank convened in Gainesville, FL, on March 9–11, 2016.
In this summary we provide the meeting topics and
expert updates, as well as important highlights in each
area. DBS use has expanded in many neuropsychiatric
areas and there is a need for an interdisciplinary approach
incorporating neurologists, neurophysiologists, neuroscientists,
neurosurgeons, psychiatrists, rehabilitation specialists, ethicists,
members of industry, and engineers. The DBS Think Tank
aims to be an annual forum that facilitates sharing, discussing,
and debating the latest innovations and challenges in the field.
This year’s Think Tank focused on the regulatory process and
advocacy; innovative techniques and indications; updates in
the field of responsive DBS (closed-loop systems), as well as
updates on associated advances in electrophysiology and sensor
technology.
Abbreviations: 3-D, Three dimensional; AD, Alzheimer’s disease; ADD, Attention
deficit disorder; BCI, Brain computer interface; BLn, Basolateral nucleus of
the amygdala; CM, Centromedian thalamus; CMS, Centers for Medicare and
Medicaid services; CUA, Cost Utility Analysis; DARPA-SUBNETS, Defense
Advanced Research Projects Agency - Systems-based Neurotechnology for
Emerging Therapies; DBS, Deep brain stimulation; DTI, Diffusion tensor imaging;
ECoG, Electrocorticogram; EQ-5D, European quality of life 5 dimensions;
FDA, Food and Drug Administration; FDG, Fludeoxyglucose; GDP, Gross
Domestic Product; GTS-QoL, Gilles de la Tourette Syndrome quality of life;
HDE, Humanitarian device exemption; HFS, High frequency stimulation; HR-
QoL, Health related quality of life; ICER, Incremental cost effectiveness ratios;
IDE, Investigational device exemption; IIR, Investigator initiated research; IRB;
Institutional review board; LFP, Local field potential; LFS, Low frequency
stimulation; MCID, Minimal clinically important difference; mPFC, Medial
Prefrontal cortex; NINA, Neurological information non-discrimination act; NNTI,
National neurotechnology initiative; OCD, Obsessive-Compulsive disorder; PET,
Positron emission tomography; PTSD, Post-traumatic stress disorder; QALY,
Quality adjusted life year; QoL, Quality of Life; RNS, Responsive neurostimulator;
ROR, Right of Reference; SCC, Subcallosal cingulate; SF-36, Short-form 36-item;
STN, Subthalamic nucleus; TAA, Tourette Association of America; TRANSFORM
DBS, Transdiagnostic Restoration of Affective Networks by System identification
and Function Oriented Real-time Modeling in Deep Brain Stimulation; TRD,
Treatment resistant depression; TS, Tourette Syndrome; TSA, Tourette Syndrome
Association; UCSF, University of California at San Francisco; VNS, Vagal nerve
stimulator; YGTSS, Yale Global Tic Severity Scale.
The overarching goal was not to produce an evidence-based
summary or practice guidelines, but rather to engage participants
toward addressing and solving unresolved issues that impede
current and near-term research and translation of DBS. This
approach has the potential to expand collaborative research,
improve care and strengthen the field. The meeting, conducted
in a think-tank style, afforded equal time to key speakers’
presentations, and group roundtable discussions. The current
proceedings of the Think Tank provide a summary and review of
the developments, challenges, and opportunities in DBS research
and its clinical translation.
DEVELOPMENT OF AN INTERNATIONAL
REGISTRY AND DATABASE OF DBS FOR
TOURETTE SYNDROME
Update
Tourette Syndrome (TS) is a complex neuropsychiatric disorder
with multiple motor and vocal tics that can incur difficulty
with social engagement and communications that can often be
debilitating (Cheung et al., 2007; Kenney et al., 2008; Hanks et al.,
2015). DBS has been explored in a subset of TS subjects with
severely disabling symptoms. An international TS DBS registry
and database was established in 2012 by investigators in the
TS DBS field and the Tourette Association of America (TAA;
previously the Tourette Syndrome Association, TSA; Deeb et al.,
2016). The need for the registry and database was based on the
relatively low number of cases of TS patients who have received
DBS. The registry and database were therefore developed to
facilitate pooling information on these cases to define and refine
anatomical targets, develop management strategies, improve
therapeutic outcomes, inform, and support regulatory agency
approval, and ultimately, improve the quality of patient care.
Data are registered and securely stored at the University
of Florida, which serves as the hub site. The registry and
database enable collaborators to safely access and use the data
for research and practice improvement. The project collects cases
of TS who receive DBS from network sites, and encourages
investigators to submit complete treatment and follow up data on
every case. Data from multiple domains, including demographic
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information, pre- and post-operative clinical measures, surgical
measures, lead placement, DBS programming, and adverse events
are registered.
Multiple brain sites have been targeted for DBS in TS
(Figure 1; Malaty and Akbar, 2014).
By March, 2016 there have been 149 cases from 16 different
institutions registered. There were 94 cases targeting thalamic
regions (centromedian, parafascicular nuclei); 23 cases with
anteromedial pallidal targets; 41 cases with posteroventral
pallidal targets; and 2 cases with nucleus accumbens/ventral
capsular/ventral striatum targets. Interestingly, the age at the
time of surgery has been decreasing for TS DBS. This has
been reflected in development of revised guidelines, which now
no longer advocate that TS patients be a minimum age of
25 in order to be considered as viable candidates for DBS.
Indeed, TS patients younger than 18 years of age have had good
clinical outcomes following DBS treatment (Schrock et al., 2015).
However, data also reveal that multiple co-morbidities, including
obsessive-compulsive disorder (OCD), major depressive disorder
and attention deficit disorder (ADD), exist in the TS population,
and it is intended that the database and registry will provide
further information to elucidate how these conditions affect, and
are affected by DBS intervention.
To date, one of the most significant barriers to accruing
a relatively complete evidence base has been difficulties in
acquiring longitudinal datasets. Many records are missing
information regarding co-morbid conditions and motoric and
phonic tic follow-up scores at 6, 12, and 24 months. Additionally,
sub-score collection has been incomplete for tic scales (Yale
Global Tic Severity Scale YGTSS), and more data are required
on the actual DBS settings and their changes over longitudinal
follow up.
Developing a more finely grained understanding of the
problems with the technology, physiological effects, and adverse
events will be critically important to map the future of DBS
therapy, and new forms for effect and event recording matching
the Food and Drug Administration (FDA) standards have been
implemented. Adverse event reporting has included surgical,
psychiatric, cognitive and general events. Preliminary data
have revealed a higher than anticipated number of device
explantations and issues precipitating device removal and these
need to be further explored. Servello et al. (2016, 2011) have
shown TS DBS to be associated with increased infections and
hardware issues, but in some cases, the devices were removed due
to resolution of symptoms. In a limited number of cases, post-
operative lead location measurements have been made available,
and increasing such data will be important to the registry.
Multiple approaches have been suggested and implemented to
improve the collection of data across the numerous centers and
groups that provide DBS treatment for TS. For example, quarterly
reminder messages will now be sent to contributors in order to
acquire heretofore-missing data fields, and a dashboard has been
developed to allow secure, multi-site access to data.
The registry and database effort has been initially successful
in collecting information on safety of DBS in the TS population,
understanding preliminary effectiveness, and in driving better
outcomes. A planned objective is to explore if and how the
database could—and should—be utilized to inform and support
more a more facile method for obtaining of humanitarian
device exemptions (HDE), or other approval for DBS use from
other international regulatory agencies. Here a number of
key questions were posed that were regarded as important to
leveraging DBS in other potential areas of clinical application, as
well. These questions included: What obtaining HDE approval
would mean to scope and extent of research in the field. What
lessons can be learned from the OCD HDE experience? If
HDE approval does not prove to be a viable next step, how
might the registry and database be employed to help refine
large randomized clinical trials? What types of metrics [e.g.,
predisposing features; clinically response measures; quality of
life (QoL) indicators] will be important to characterize a good
responder? Is there a role for subjective narrative input from
each participating subject?
Highlights
- The TS DBS registry and database effort started in 2012 to
bridge the knowledge gap in the use of DBS in TS subjects.
- More consistent and extensive data collection is needed
to improve clinical outcome assessments, lead locations,
programming parameters and adverse event reporting.
- Future areas of effort include:
◦ Studying the viability and impact of obtainingHDE approval
in TS DBS and its implications.
◦ Characterizing TS subject phenotypes and meaningful
clinical metrics.
◦ Comparing outcomes of different surgical targets and
stimulation paradigms.
Registering Lead Locations and How to
Use the Data
The registry and database can serve as an expansive resource
of diverse types and levels of information that will be essential
to further define and refine the possible use(s) of DBS. For
example, there is an important role for data from functional
magnetic and diffusion tensor and kurtosis-imaging studies to
further systematically depict lead location(s), and changes in the
activity of anatomical nodes and tracts that may be involved in,
and/or subserve observed clinical outcomes and effects.
There are several laboratory-based tools for predicting and
reconstructing DBS effects. However, these tools are often
difficult to use and incur a relatively steep user-learning curve.
Developing simple systems to disseminate three-dimensional (3-
D) interactive models could provide means toward more useful
and user-friendly toolkits. One proposed approach toward this
objective is to incorporate plotting and predictive functions
into an interactive 3-D model. The method would employ
a visualization component that provides volume rendering
as well as surface renderings. The results would reveal the
effect-size on specific clinical outcomes (such as bradykinesia)
and would represent results as a function of stimulation-
location. The informatics component allows the user to use
a widget to query a position in space that will reveal
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FIGURE 1 | Schematic (cartoon) representation of potential therapeutic targets of DBS for Tourette Syndrome. Figure is not drawn to scale. ALIC, anterior
limb internal capsule (From Malaty and Akbar, 2014; with permission).
different visualizations of the outcome data associated with
stimulating a specific point in space. Clinical effect sizes
for various effects can also be extracted from the data
obtained.
A composite figure of actual lead locations in the subthalamic
nucleus was produced using data from a multi-center DBS
clinical trial. It revealed significant variability in lead location
and trajectory across the different centers, despite targeting the
same structure, and region (subthalamic nucleus). Analyzing the
variability in lead location will be critical, as it will allow more
accurate site specific correlation of lead placement and clinically
relevant (objective and subjective) effects of DBS in treating
different signs and symptoms of various disorders.
Future steps in developing imaging databases include
measures for insuring patient (and clinician) anonymity,
consideration of a data-use embargo period, and defining the
terms of use of information in the database. Participants in
the Think Tank proposed the possibility of a central data
repository of images and lead locations, to which practitioners
could upload individual scans to be used for comparisons and
benchmarks.
To be sure, the collection and assimilation of various types
and extent of data represent challenging tasks, and opportunities.
At present, a number of computational tools are available to
facilitate data collection and sharing. One such tool, developed by
the Center for High Performance Computing at the University
of Utah, enables use of a protected data environment platform
to allow collection of sensitive, personal health information. This
organized, scalable infrastructure can be used to host RedCap R©
and imaging software that enable differing types of data from
providers, patients, and caregivers to be entered and analyzed.
Ongoing efforts will be focused upon developing this and other
big data platforms to optimize collection, integration, use, and
modeling of diverse information.
Highlights
- Any database effort needs to establish the short-term, medium
term, and long-term goals.
- Lead location in the TS DBS database effort is a bedrock in
understanding outcomes.
- Steps are needed to improve collaboration and eliminate
obstacles.
◦ Tools are available to facilitate sharing of interactive and
predictive 3-D models.
◦ The think tank participants recommended the development
of a central data repository of lead location images.
Quantifying Economic Impacts of Deep
Brain Stimulation
Since 1999, a small number of patients worldwide have received
DBS for severe TS (Ackermans et al., 2008). Although, clinical
results have been promising, establishing clinical effectiveness
is not always sufficient to ensure investment in new medical
technology.
The Center for Movement Disorders and Neurorestoration at
the University of Florida maintains an international database of
patients with severe TS who have received DBS (n≈ 150). While
clinical data is collected pre- and post-DBS, to date economic
data have not been collected. When medical treatments must
compete aggressively for a limited pool of healthcare resources,
well-designed economic evaluation is essential to ensure that
necessary resources are directed toward treatments that offer
the best outcomes. In light of this, a comprehensive economic
evaluation of DBS for TS is planned.
A survey of patients and treating medical practitioners
will be undertaken to collect data necessary for economic
evaluation. Patients will be surveyed for indirect medical costs,
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including workforce participation and health related quality
of life (HRQoL) using a validated instrument (e.g., SF-36 or
EQ-5D). The treating medical team will be asked to report
direct medical costs and relevant post-operative clinical data
(e.g., verification of the neuroanatomical location of the DBS
electrodes, etc.). Direct medical costs will include the costs of
DBS hardware, surgery, inpatient stay, neurostimulator titration,
and post-operative complications. Quality-adjusted life years
(QALYs), a generic metric of HRQoL, is routinely used as a
summary measure of health outcomes in cost-utility analyses
(CUA) (Drummond et al., 2015). A QALY of one denotes a year
of life lived in perfect health. Years lived in less than perfect
health are scored less than one. Health policy analysts deem cost
per QALY ratios, less than some designated threshold, as being
cost effective. Thresholds between nations will vary, and can be
approximated by the gross domestic product (GDP) per capita
(Marseille et al., 2015). For example, ratios of US $50,000 per
QALY (Grosse, 2008) and £20,000–£30,000 per QALY (McCabe
et al., 2008), are used in the United States and United Kingdom,
respectively. Post-operative QALYs will be derived from reported
HRQoL sub-item scores. Pre-operative QALYs will be hindcast,
using coefficients obtained from statistical analysis, which regress
clinical variables on post-operative QALYs (Dodel et al., 2010;
Müller-Vahl et al., 2010). Costs and QALYs will then be analyzed
and incremental cost effectiveness ratios (ICERs) reported.
Other methods of analysis, such as the Minimal Clinically
Important Difference (MCID) may be valuable. We believe that
such findings will represent an important first step to elucidating
health outcomes’ afforded by DBS, and to informing appropriate
investment in DBS technologies and practices.
Highlights
- It is planned that economic data should be collected to establish
the cost-effectiveness of DBS as a treatment for severe TS.
- Technical (e.g., post-operative electrode placement), as well
as direct and indirect health costs plus a generic measure of
HRQoL data should be collected.
Regulatory Processes and Translational
Viability: Time for a Change?
Investigational Use of DBS in Clinical Practice
The overarching goal of the US Food and Drug Administration
(FDA) regulation process is to establish that any and all drugs and
devices provided for medical care are safe and technically sound.
In the United States, device trials utilizing either a non-approved
or an approved device to be used for a non-approved indication
require an investigational device exemption (IDE) to be granted
from the FDA. Failure to obtain an IDE will preclude most
Institutional Review Boards (IRBs) from approving prospective
studies of off-label use of devices. Both the IDE and HDE entail
considerable detail in scope, application, review and guidance,
and such stringency is necessary and important to determine
and to assure probity in applications of technology. Moreover,
whereas IDEs can be obtained (by industry) for industry-
sponsored device trials, investigators are required to obtain the
IDE in non-industry sponsored trials; this can be- and frequently
is—an arduous, and time- and cost-expensive process.
In recent years, IDE and HDE applications, review and
approval have become considerably more facile and efficient; this
is a notable improvement—and a step in the right direction.
However, as regards to DBS, it may be that aspects of the overall
structure and certain specifics of the IDE and HDE are not
well suited to meet the contingencies (and exigencies) of actual
clinical use, particularly in light of interest in exploring if and
how DBS may be of clinical benefit in the treatment of an
expanding number of neuropsychiatric conditions (as detailed
elsewhere in this report). For example, the current regulatory
framework necessitates filing and securing an IDE as a first step
in investigator-initiated research (IIR) and/or other off-label use
of DBS in those cases where other approaches have been shown
to be ineffective or untenable, and for which DBS may prove
to be viable as “humanitarian care.” In such instances, it may
be that the proverbial cart precedes the horse, and the HDE
might be more practical and valuable given both the nature of the
disorder and treatment, and the value of the HDE in establishing
a basis for further (and/or expanded) application, as supportable
by an IDE.
Moreover, while both IDE and HDE establish parameters
for using DBS in practice, neither regulatory mechanism
establishes or enforces a basis for provision of economic support
necessary for right and good use-in-practice. As recent work
has demonstrated, non-payment of insurance costs for pre-
certified DBS interventions has been, and remains a problem
of considerable concern (Rossi et al., 2016a,b). Absent resources
to provide: (1) DBS as a demonstrably-important or necessary
treatment option for those subjects with conditions that are non-
responsive to, or not candidate for other therapeutic options, and
(2) continuity of clinical services as required, the sustainability
of this neurotechnology may become questionable (Rossi et al.,
2014). We see this as contrary and counter-productive to recent
federal incentives to maximize benefits of translating extant and
new neurotechnologies into clinically-relevant and affordable
care and to implementing precision medicine.
In the main, we applaud actions taken by the FDA to date
that have streamlined the IDE and HDE process. Yet, while
certain aspects of the IDE and HDE mechanisms may be in
order, apt, and valuable for regulating use of DBS, others may
require re-examination, revision or replacement, so as to remain
apace with developments in the field, and needs and necessities
(of both subjects and clinicians) in practice. In this vein, we
recommend further study of: (1) the scope and tenor of the
IDE and HDE mechanisms to determine their independent and
interactive benefit (as noted above); (2) whether and which
aspects of the current IDE/HDE process are effective and
efficient, and which are not; (3) what aspects need to be retained
and fortified, revised or replaced; (4) what is entailed in these
revisions/replacements; and (5) if and how regulatory, policy and
legal processes can and should be aligned with, directive toward,
and supportive of and by concomitant changes in standard
of care guidelines and federal insurance structure (Fins et al.,
2012). A number of possible alterations to the IDE process
were addressed, which may streamline application and granting
of regulatory approval. These include: removal of the right
of reference letter (ROR) requirement; improved alignment of
federal grant mechanisms and regulatory process, and institution
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of mechanisms for Centers for Medicare and Medicaid Services
(CMS) and private insurance payment to support costs incurred
by patients involved in these trials. Proposed alternatives to IDE-
sponsored trials were also addressed, including the viability and
value of retrospective analyses of multiple case series, and large
scale, multi-site single case analyses, which could be facilitated
through the use of currently available computational tools
(e.g., the AvesTerra System; see: http://osvpr.georgetown.edu).
that enable massive data assimilation and integration, both
in concert with, and independently of a registry mechanism.
Important to this effort would be the development of both a
governmental-commercial enterprise to guide industrial efforts
in neurotechnology (e.g., a National Neurotechnology Initiative;
NNTI), as well as the establishment and enactment of federal laws
(e.g., a neurological information non-discrimination act; NINA)
to govern potential use(s) of information obtained through DBS
and related neurotechnologies together with extant and novel
big data initiatives (Kostiuk, 2012; DiEuliis and Giordano, 2016).
We believe that while establishing this “translational estate” will
require significant effort; it represents a worthwhile endeavor
toward the achievement of genuine and durable progress in the
development and use of neurotechnology in clinical practice.
DBS INNOVATIONS
Tourette Syndrome
As noted, much of the more innovative work to date has
(and remains) focused upon studying the viability and value
of DBS for the treatment of Tourette syndrome. While the
exact causes of TS remain unknown, recent neuropathology
neuroanatomical investigations have collectively implicated
dysfunction of corticostriatal and thalamocortical circuits
thought to play a role in the generation of abnormal motor
programs, possibly due to aberrant thalamic disinhibition (Albin
andMink, 2006). The collection of neural activity from the awake
and behaving human TS patients will offer new and vital insights
to the underlying neurophysiology of tic generation. To this end,
next generation DBS devices, such as the Neuropace RNS and
Medtronic Activa PC+S enable recording of electrophysiological
signals from both the implanted depth electrodes, as well as
acutely placed electrocorticography (ECoG) strips.
An unpublished study was presented that examined the
effects of DBS on two patients with severe, medication refractory
TS. Patients were implanted with bilateral Medtronic Activa
PC+S devices. Depth leads were placed in the centromedian-
parafascicular nucleus of the thalamus (CM) and ECoG strips
were placed over the precentral gyrus to cover the hand
primary motor cortex (M1). Experiments consisted of separate
interleaved trials in which patients were instructed to: (1) tic
freely, (2) suppress tics (baseline), and (3) execute volitional
movements (e.g., shaking hands rapidly, opening and closing
hands, raising arms up, and down, talking). Post-operatively
recorded data suggested that M1 yields a general motion detector
(15–30 Hz), whereas CM yields tic-specific features (1–10 Hz).
A human tic detector, based on support vector machines was
constructed during each post-operative visit (for a period of 6
months). Three types of tics were recorded including simple,
complex, and long complex tics. Long complex tics were shown
to be concurrent with a consistently detectable thalamocortical
signature. Short complex tics were more difficult to detect
than long complex tics, and simple tics were the most difficult
to detect. Acute trials of closed loop stimulation using the
Medtronic Nexus-E platform are currently underway. The
proposed system is presented in Figure 2.
Highlights
- The initial RNS study in TS patients revealed that good benefit
in tic control can be achieved with scheduled stimulation as
compared to continuous stimulation.
- LFP-ECoG neurophysiological testing identified a correlation
between tic activity and appearance of a 10 Hz narrow band
signal.
- Targeted stimulation using the 10Hz band as signal resulted in
tic improvement (preliminary results).
Summary of Use of DBS to Treat Epilepsy
Epilepsy, the result of the hyper-synchronization of firing
of neurons, creates “fragile” neurological networks that tend
to cycle. Multiple modalities of neurostimulation have been
developed to modulate burst and cycling activity in epileptic
patients (Krishna et al., 2016). In addition to DBS, techniques
such as vagus nerve stimulation (VNS), which engages afferents
of peripheral nervous system input to activate vagal pathways,
can alter firing patterns of brain networks involved in ictal
discharges and cycling. As well, the use of other neuromodulatory
techniques, such as responsive neurostimulation (RNS), has been
explored (Chang et al., 2015).
These approaches differ in their modulatory effects upon
cycling time, burst duration, frequency, and amplitude. In
addition, the locations of the VNS and DBS electrode placement
(at the anterior nucleus of the thalamus) are the same in all
patients while RNS employs a variety of possible placement sites.
The site of RNS is dependent upon identifying the epileptogenic
locus of nodes involved in a specific patient. In most cases, this
has been shown to be cortical gray matter. However, patients
with long-standing refractory epilepsy have been shown to
develop areas of secondary epileptogenesis, possibly through
kindling. To better manage multiple epileptogenic loci in this
population, stimulation of the affected circuitry (white matter)
rather than the epileptogenic gray matter is being considered
(Girgis and Miller, 2016). In these studies, it has been shown
that microelectrode recording and modification of the area of
stimulation can achieve differential, acute and chronic effects
on the involved neurocircuitry. Chronic effects appear to be
related to stimulation-induced plasticity, and may engage trophic
mechanisms in that they subserve (at least some component of)
the therapeutic outcomes of neurostimulation in this patient
population.
Highlights
- Studies of the mechanisms and effects of DBS in treating
epilepsy can be useful to both an expanded understanding of
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FIGURE 2 | Diagrammatic depiction of the University of Florida approach to implementing chronic responsive DBS therapy for Tourette Syndrome.
Current experience with two patients with TS, who received bilateral centromedian (CM) thalamus depth leads and bilateral subdural grid implantation over their hand
motor cortex (A), led to the discovery of tic specific features in CM thalamus (1–10Hz) and motion detection features in hand motor cortex (15–30Hz; beta rhythm)
(B). A combination of these two features yielded highest detection of tics and differentiation from voluntary movements in linear discriminant analysis classifiers (C).
These classifiers are embedded in PC+S and send control signals to Nexus- E stimulation engine (D). Once the detectors sense presence of tic related activity,
stimulation will be activated to deliver stimulation to optimize therapeutic effects/outcomes.
DBS and brain pathology, and can synergize the development
of other types of neuromodulation.
- Studies of DBS (and VNS and RNS) reveal the importance of
determining and identifying anatomical targets (gray matter)
vs. circuit targets (white matter).
- Brain stimulation can exert acute and chronic effects, the latter
being related to neuro-plasticity and trophic effects.
- The role of multi-site, multi-electrode pre- and intra-operative
recording is essential to advancing understanding and
improvement of neuromodulation approaches to the treatment
of epilepsy; however, how findings from studies of the use of
DBS, VNS, and RNS may translate to broader applications of
these techniques remains a subject of continuing speculation.
Novel DBS Settings—Biphasic Pulses and
Beyond
DBS signal delivery is a rapidly progressing field. Recent
innovations in DBS signal delivery (Fasano and Lozano, 2015)
include regulated current vs. regulated voltage waveforms
(Lempka et al., 2010; Preda et al., 2016), differing stimulation
waveforms (Foutz and McIntyre, 2010; Wongsarnpigoon and
Grill, 2010), and different temporal patterns of stimulation
(Brocker et al., 2013; Adamchic et al., 2014).
Studies have repeatedly demonstrated the enhancement of
the therapeutic window with lower DBS pulse widths (Moro
et al., 2002; Volkmann et al., 2014). High frequency stimulation
(HFS; >100Hz) has generally been considered to be effective for
mitigating certain signs and symptoms of Parkinson’s disease
(PD), but low frequency stimulation (LFS; <100Hz) has yielded
contradicting results. LFS <50Hz has been shown to be harmful
resulting in worsening bradykinesia and tremor (Moro et al.,
2002). Stimulating at individualized gamma frequencies (30–
90Hz) improved PD symptoms, with outcomes that were similar
to those produced by HFS (Tsang et al., 2012). These findings
suggest that LFS can be effective provided that it is appropriately
matched to subject’s individualized gamma frequency patterns
associated with movement. Irregular patterns of stimulation
have also been studied in computational models, non-human
primates, and human patients. While there are some irregular
patterns that seem to be as effective as—or more effective
than—regular HFS, evidence for human testing remains limited.
A recent randomized, blinded pilot study of nonconventional
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DBS patterns and pulses—the first reported study of its kind—
tested 3 essential tremor and 8 PD clinically-optimized patients
in a clinic setting (Akbar et al., 2016). Of the settings tested,
the nonconventional biphasic pulse (equal and opposite, active
recharge phase) was shown to bemore effective than the clinically
optimized settings. Of course, it may be premature to draw firm
conclusions about the effectiveness of this pulse shape based
upon the results of this small pilot cohort, but such findings are
both of great interest and promising in their implications for the
viability and effectiveness of novel pulse and pattern parameters.
Additional studies to further investigate these possibilities and to
address the potentially short washout interval are underway.
Highlights
- A number of techniques of stimulation are available including
differing stimulation waveforms and current.
- There is a differential therapeutic effect of the various
stimulation parameters in DBS that appears to be related
to the underlying disease process (e.g., PD, dystonia). A
recently published pilot trial to assess different stimulation
parameters in PD and essential tremor subjects revealed
significant improvement induced by symmetric biphasic pulse
stimulation.
- Ongoing unresolved issues include the effect of differing pulse
and pattern settings on battery drain, requisite washout time,
and biophysical changes induced in affected neural nodes and
circuits.
Development of DBS Sensors
DBS surgery provides an investigational opportunity for use of
electrophysiological and/or neurochemical recording techniques.
Such approaches can: (1) aid in DBS lead placement, (2) provide
additional information about disease states, and (3) potentially
enable future development of techniques to better control
and fine-tune DBS therapies including closed-loop control
(Herrington et al., 2016). In addition, DBS surgery provides a
vector to introduce stem cells, autologous transplants, and/or
gene modification. We have termed the conjoined use of these
approaches DBS Plus.
Future directions in DBS have been proposed to incorporate
real-time monitoring of field potentials/unit activity, and in vivo
assessment of neurotransmitter release and turnover (Paek et al.,
2013). Such combinatory approaches could be used to further
define brain networks affected in disease processes, which could
serve to elucidate target sites for current and future applications
of DBS (including closed-loop systems) to more effectively—
and automatically—program, control, and modify stimulation
parameters (Grahn et al., 2014).
These iterations are currently under development. For
example, RNS for epilepsy and a new DBS variant manufactured
by Medtronic, the Brain Radio, implement simultaneous field
potential recordings that are coupled to neural stimulation. The
use of simultaneous DBS and neurotransmitter measurement is
being studied by Lee and coworkers in a Phase I investigation
using fast-scan cyclic voltammetry recordings coupled to carbon
fiber or boron doped diamond-like carbon microelectrodes
(Bennet et al., 2016). Gerhardt, van Horne and colleagues
are investigating (personal communication) the possible use
of glucose and glutamate as chemical biomarkers for control
of DBS. Current preclinical studies support that oxygen and
glutamate measures can be used to reveal both tonic and
phasic changes in neuronal systems that may be indicative of
trait- or state-dependent properties (Stephens et al., 2014). A
persistent technical impediment to these types of studies is the
difficulty of long term monitoring of neurochemistry in vivo.
As well, it remains unclear if and how in vivo neurochemical
monitoring can be durably yoked to DBS. The combined use
of electrophysiological recordings and real-time neurochemical
monitoring show considerable value for closed-loop control
of RNS technology for epilepsy, and for closed-loop control
of DBS therapy for PD. Nevertheless, given the early stage of
these developments, it will be important to continue studies
of real-time neurochemical monitoring for use in both open-
and closed loop DBS applications pursuant to advancing these
approaches toward more broadly applied clinical translation.
Highlights
- We introduce the concept of DBS Plus to describe the
incorporation of additional treatment and recordingmodalities
(e.g., stem cells, gene modification, neurochemical monitoring,
etc.) during DBS surgery.
- Multi-modality monitoring can be important to identifying
neural circuity involved in various pathologies and DBS effects,
and in these ways can facilitate more accurate electrode target
placement.
- These DBS Plus approaches show promise in the further
development of closed-loop systems.
DBS for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia
worldwide (Scheltens et al., 2016). Current focus of treatment
for AD treatment has pharmacotherapy aimed at modifying
acetylcholinesterase activity, N-methyl D aspartate receptor
activation, and more recently, production or deposition of beta-
amyloid or tau proteins. The limited evidence for symptomatic
benefit or slowing of disease progression from these approved
and investigational treatments, as well as the side effects reported,
support pursuing other avenues of intervention (Winblad et al.,
2016).
The importance of developing approaches to modulate
cortical and hippocampal circuits affected in AD was the
impetus for a phase I study of DBS targeting the fornix (Laxton
et al., 2010). The choice of the fornix as the target was based
upon serendipitous observation of improved spatial and verbal
learning and memory functions in patients who received DBS
leads in the hypothalamus for obesity management. In the
phase I study, continuous fornical stimulation produced
sustained increases in cortical metabolism at 1 month
and 1 year post-operatively. Further, increased functional
connectivity was observed in two orthogonal networks: a
frontal-temporal-parietal-striatal-thalamic network and a
frontal-temporal-parietal-occipital-hippocampal network. These
increases in functional connectivity were greater than effects
produced by 1 year of pharmacotherapy (with cholinesterase
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inhibitors) and were in contrast to metabolic reductions and
decreased functional connectivity seen in the 1 year course of
AD. Higher cortical metabolism prior to initiation of DBS, as
well as increased metabolism after 1 year of DBS, were correlated
to better outcomes in global cognition, memory, and quality of
life indices (Smith et al., 2012). A multi-center, double-blind,
randomized, and controlled Phase II trial of 42 mild probable
AD patients—the ADvance trial—was conducted (Lozano et al.,
2016). In this study, the mean age of subjects was 68.2± 7.8 years
(younger than the AD population, but similar to the age range
of AD patients enrolled in clinical trials; Leinonen et al., 2015).
Average disease duration since diagnosis was 2.3 ± 1.7 years.
Electrodes were implanted in all patients, but half of the patients
did not receive stimulation for the first 12 months, and were
subsequently crossed over to active stimulation. The trajectory
was trans-ventricular and implantations of Medtronic hardware
were bilateral (Ponce et al., 2016). Stimulation was applied using
extant PD protocols, with a frequency of 130 Hz, pulse width of
60µs, and voltage set at 50% of that at which side effects (e.g.,
autonomic or cognitive changes) were seen, with a maximum
test voltage set at 7 V and maximum continuous voltage of 3.5
V. There was no noted acute decline in cognition after 1 month
of surgery. Consistent with results of the prior Phase I study,
persistent increases in metabolism were observed in the group
receiving stimulation (i.e.,- the ON group) after 6 and 12 months
of DBS of the fornix, in contrast to the OFF group that showed
decreased metabolism (7–13%) across all regions assessed. The
primary goal was safety; the safety profile of the procedure was
acceptable and comparable to pharmacologic therapies. There
were some short-term side effects related to the surgery, as well
as some psychiatric side effects (as expected following DBS).
None of the subjects had persistent side effects or complications
at 12 months follow-up.
Secondary goals were to evaluate the preliminary efficacy of
therapy. These secondary end points were notmet, although post-
hoc analysis of subgroup evaluations based upon age showed that
when patients 65 years of age or older were analyzed separately,
greater increases in metabolism were observed in the ON group
compared to those under age 65 (14–20% across regions over
age 65). The subgroup aged <65 years had worsening clinical
scores, while the subgroup aged >65 years showed improvement
in clinical scores. The clinical scores used for this analysis
included the Clinical Dementia Rating (CDR) and Alzheimer’s
Disease Assessment Scale—cognitive subscale (ADAS-Cog). In
this older cohort, increased metabolism with fornical DBS was
observed in the temporal and parietal cortices and hippocampal
regions affected by AD, as well as in sensory and motor cortical
regions that are relatively spared in this disorder. Functional
connectivity and correlational analyses are currently in progress
to determine the networks affected by DBS that are involved with
clinical improvement, and the relationship between themetabolic
and structural brain alterations associated with DBS to the
fornix.
Other potential targets for DBS treatment of AD have been
assessed and include the nucleus basalis of Meynert and the
entorhinal cortex. Further studies are needed to: (1) clarify
stimulation parameters for various brain regions and networks
that can be targeted to mitigate signs and symptoms of AD; (2)
define mechanisms through which DBS produces therapeutic
and side effects in AD patients, and (3) to enable more accurate
subject identification and selection.
Highlights
- DBS of the fornix has been shown in phase 1 studies to be
associated with metabolic and clinical changes.
- TheADvance trial, a recently completed phase 2 study, assessed
the safety of fornix DBS in AD, that demonstrated:
◦ No significant long-term complications,
◦ No acute cognitive decline after DBS surgery,
◦ Age-dependent effects with patients over age 65 achieving
better outcomes,
◦ Concerns about bilateral simultaneous implantation,
◦ The need to further identify “optimal” stimulation
parameters,
◦ Need for further study before considering fornical DBS as a
viable treatment for AD in clinical practice.
CLOSED-LOOP DBS
Introduction
Existing DBS devices continuously stimulate their target
structures regardless of the actual level of pathological
activity. This can result in stimulation induced adverse effects,
habituation, short battery life, and the need for labor-intensive
programming sessions by a neurologist. Closed loop DBS
enables simultaneous feedback and feedforward control of
stimulation parameters that can afford a high level of precision
and individual modification to variations in brain state. A
major consideration of closed loop DBS is determination of the
input signal. Recording brain signals in different therapeutic
conditions (on and off DBS; on and on medication) has led to
a better understanding of pathophysiology underlying PD, TS
(discussed above) and major depression. This work results in the
identification of disease markers that might be used as control
signals for closed-loop DBS algorithms.
Parkinson’s Disease
Published work has focused on the use of a beta-band signal
(13–30Hz) as a control signal (Little et al., 2013). However,
the beta band is somewhat limited as a control signal by the
influence of normal movement upon the signal fidelity. In light
of this, current work is aimed at identifying oscillations that are
outside of the beta-band that may be useful as markers. One,
a narrow band gamma signal that has been defined as between
60 and 90 Hz, has been previously assessed as a surrogate signal
using local field potential measurements (LFP) of the subthalamic
nucleus (STN) (Brown et al., 2002; Cassidy et al., 2002). However,
further study is required to more fully define the value of this,
and other signals that can be utilized for optimized closed-loop
control. Pursuant to such study, extensive neurophysiological
work will be required.Work currently underway involves cortical
recording with ECoG at the precentral gyrus/primary motor area
and depth electrode recording at the level of the basal ganglia.
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For example, to assess control signals in PD subjects
with dyskinesia, researchers at the University of California at
San Francisco (UCSF) group have implanted 5 patients with
Medtronic Activa PC+S neurostimulators attached to a DBS lead
(Medtronic 3389) in the STN and a 4-contact cortical ECoG strip
(Medtronic Resume paddle) placed over the M1. Cortical and
subcortical signals were collected over 2 years while patients were
on and off therapeutic DBS as well as on and off dopaminergic
therapy. During these recordings patients were resting with eyes
open or engaged in a cued arm-reaching task (de Hemptinne
et al., 2015). M1 and STN signals were recorded in a bipolar
configuration at 800 Hz, stored and the PC+S downloaded non-
invasively via telemetry and analyzed in the frequency domain.
Using this unique data set (unpublished data), they found that
periods of dyskinesia are associated with an increased neuronal
synchronization in the gamma band (60–90Hz; Figure 3). This
excessive synchronization is reflected as a narrow band peak
in the spectral power density of both M1 and STN signals,
although less reliably detected in the latter. The emergence of
this excessive synchronization occurs only in the presence of
dyskinesia suggesting it as a marker of dyskinesia rather than
a marker of the dopaminergic state. Interestingly, the cortical
narrow-band gamma signal was shifted to half of the stimulation
frequency when DBS was turned on, in the presence of dyskinesia
only, which might be explained by a partial entrainment of
axonal activity to stimulus pulses (Li et al., 2012). Contrary
to broadband gamma activity, a non-oscillatory signal strongly
affected by movement, the narrow-band gamma signal studied
here was independent of the subject’s “normal” voluntary non-
dyskinetic movements. Othermarkers were studied including the
coherence between the cortical and basal ganglia signal, as well as
phase-coherence (unpublished data).
Narrow gamma band signals are part of a normal motif in
brain connectivity allowing communication between multiple
brain areas and alteration of these oscillations might results in
dyskinesia as suggested by this study. Recordings in the motor
cortex of a rodent model of PD identified a remarkably similar
phenomenon in dyskinetic rats versus non-dyskinetic animals
(Halje et al., 2012).
FIGURE 3 | The graphs depict the results of analysis of the M1 signal in
the frequency domain in PD patients with dyskinesia. It shows, in the
graph on the left, that dyskinesia is associated with an increased neuronal
synchronization in the gamma band (blue line) reflected as a narrow band
peak. The graph on the right shows that this gamma-band signal is related to
dyskinesia and independent of the functional state (rest, walking, or voluntary
arm movement).
Given the predictable frequency at which this marker occurs,
the simple method used to calculate it and the small impact of
stimulation artifact of cortical signals, this biomarker is the ideal
candidate to develop a closed-loop DBS algorithm. Therefore,
the next step of this study is to develop closed-loop paradigms
using this narrow-band gamma signal as a control signal and
test it in PD patients with dyskinesia using the Medtronic Activa
PC+S with the Nexus-D and E updates that allow for real time
sensing and stimulation updates.
Highlights
- The use of beta-band subcortical oscillations in PD as a control
signal is limited by the effects of voluntary movements and
stimulation.
- Narrow gamma-band signal (60–90 Hz) appears to correlate
with the dyskinetic state in PD subjects, is less affected
by stimulation artifact and is independent of voluntary
movements.
- Ongoing study to use the identified narrow gamma-band as
a control signal for closed-loop DBS in PD patients for better
control of dyskinesia.
Depression
It has been ∼10 years since the first proof-of-principle report
supporting the efficacy of subcallosal cingulate (SCC) DBS to
reduce signs and symptoms of treatment resistant depression
(TRD; Mayberg et al., 2005). Initial selection of the SCC as
a putative DBS target was principally based on converging
findings from resting-state positron emission tomographic (PET)
imaging studies of conventional antidepressant interventions,
localization of depression-related circuits, and nodes using
standard structural imaging methods, and trial-and-error
behavioral testing of chronic stimulation at individual contacts
on each implantedDBS electrode. As testing of DBS for treatment
resistant depression has matured and expanded, neuroimaging
continues to play a crucial role, with recent work now focused
on refinement and optimization using multimodal methods
combined with real-time behavioral and physiological metrics.
These combinatory approaches affordmore precise identification
of optimal target locations in real time (Smart et al., 2015).
One proposed mechanism of DBS in reducing features
of treatment resistant depression is modulation of a multi-
region network converging at the SCC (Figure 4). Structural
connectivity analysis of SCC DBS confirms the SCC as a
critical node within this specified “network,” as small differences
in stimulation location can generate substantial differences in
activated fibers. Recent studies have further confirmed which of
these pathways are necessary for clinically significant effects of
DBS. These pathways can now be prospectively characterized
in individual patients using DBS parameter models coupled to
structural connectivity analyses (Riva-Posse et al., 2014; Choi
et al., 2015).
Close clinical monitoring and systematic long-term follow-up
using small experimental cohorts outside of industry-sponsored
trials have further provided new perspectives on the time course,
trajectory and sustainability of DBS-mediated effects (Crowell
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FIGURE 4 | The panes depict (from left to right) the evolution of surgical targeting of SCC in depression from, an anatomical “gray matter” target to
identification of the “white matter” tracts activated, and finally tractographic data allowing identification of the involved pathways that elicit differing
effects when targeted by DBS. This approach allows individualized target refinement and produces improved therapeutic outcomes. Genu, genus of the corpus
callosum; Mid-SCC, mid subcallosal cingulate; Ac, anterior commissure; mF10, medial frontal Brodmann Area 10; ACC, anterior cingulate cortex; aTh, anterior
thalamus; vSt, ventral striatum; Fr-st, frontal striatal fibers.
et al., 2015). Notably, patients often experience contact-specific
changes in mood, attention, psychomotor speed, and autonomic
reactivity with initial testing during electrode implantation
surgery. Importantly, these acute behavioral effects appear
predictive of long-term response. Recent implementation of
real-time recording of SCC LFP during acute testing and ongoing
therapeutic DBS using the prototype Activa PC+S DBS system is
providing a first-in-human view of differential SCC LFP changes
mediating immediate, sub-acute, and chronic DBS-induced
antidepressant effects at the neural level. LFPs measured at
the site of stimulation combined with concurrent high density
EEG will further enable characterization of clinically relevant
network-wide effects. Findings from this small exploratory study
will potentially provide new metrics to further improve precision
of surgical targeting as well as new algorithms for DBS delivery
beyond current methods. Validation of relationships between
local and network-wide changes with the differential time course
of recovery in specific clinical features will lay the foundation for
sensing signals for next generation neurostimulation systems.
Highlights
- Initial selection of the SCC as a putative DBS target
was principally based on converging findings from resting-
state PET imaging studies of conventional antidepressant
interventions.
- Recent work now is focused on refinement and optimization
using multimodal methods combined with real-time
behavioral and physiological metrics, providing a more precise
identification of the optimal target location in real time.
- Modulation of a multi-region network converging at the
SCC is a proposed mechanism of action for DBS in reducing
features of depression.
- Validation of relationships between local and network-wide
changes with the differential time course of recovery in specific
clinical features will lay the foundation for sensing signals for
next generation neurostimulation systems.
Clinical Assessment and Management of
Tremor
Tremor-dominant PD patients have been shown to have a
functional correlation of their tremor and beta-band signals
as measured by LFP. The resting state beta band may be
attenuated during periods of tremor in PD. Resolution of tremor
results in re-emergence of the beta band (Little and Brown,
2012). This suggests that beta band power may be viable as a
kinematic control variable to drive closed loop DBS for tremor,
as diminished beta band power during tremor could be assumed
to signal a decrease in closed loop DBS. However, the activity-
dependent fluctuations in the beta-band power limit its use a
sole control for closed loop DBS in PD tremor. Bronte-Stewart
and colleagues (Malekmohammadi et al., 2016) reported the
efficacy of closed loop STN DBS to control resting tremor, using
a kinematic measure of tremor power from use of a wearable
Bluetooth enabled smart watch (LG G-watch; Figure 5).
In their study, baseline tremor recordings were performed,
from which maximum tremor power was calculated. Closed loop
DBS was driven by real-time measurement of tremor: when
tremor intensity exceeded 50% of the maximum baseline tremor
power, the control policy algorithm commanded an increase in
DBS voltage at a predetermined safe ramp speed; when tremor
intensity fell below 25% of the maximum tremor power, voltage
was decreased. Using this model it was noted that the rate
of change in stimulation voltage (if decreased quickly) could
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FIGURE 5 | (A) Example of adaptive stimulation voltage (top row) and tremor power with 25% (magenta) and 50% (cyan) thresholds of the control policy algorithm
(bottom row). Black horizontal lines above upper panel indicate timing of calibration and closed loop DBS (aDBS). Dashed black line shows level of clinical stimulation
voltage. (B) Comparison of mean tremor power at baseline and during aDBS across the group. (C) Comparison of average stimulation voltage during open loop
continuous (cDBS) and aDBS for the group. (D) Insert to (A) showing the timing of the aDBS decision tracking. When tremor power exceeded the upper threshold
(red triangles), the stimulation voltage increased. When tremor power fell below the lower threshold (blue triangles), stimulation voltage decreased. Stimulation voltage
remained unchanged if the tremor power level remained between lower and upper thresholds.
be correlated to occurrence of rebound tremor. Consequently
the rate of decreasing voltage was set at 0.5 times the ramp
(or increase) rate. Overall, the mean tremor power significantly
decreased by 36.6% (p = 0.014) during closed loop DBS, and
the mean voltage used was 76.4% lower than that used during
continuous open loop DBS (p = 0.02). On average, closed loop
DBS was “on” for only 51.5% of the time (p = 0.002), but there
was a significant variation among subjects in the duration and
average voltage required for effective stimulation.
This study provided proof of concept that real time
kinematic measurement of tremor represents a safe, tolerable and
efficacious method to drive STN DBS for tremor in PD. This
strengthens prior findings of pilot trials using a neural control
variable to drive closed loop DBS in the treatment of PD (Little
et al., 2013; Rosa et al., 2015), and provides further support for the
use of kinematic controls to supplement LFP input in developing
personalized closed-loop DBS systems.
Development and Use of Algorithms in Closed Loop
Systems—A Focus on Tremor
In current clinical practice, DBS treatment involves open loop
control. The stimulation parameters are pre-set for each patient,
and do not automatically adjust to the presence or absence of
symptoms, side effects or other patient-specific variables. The
result is excessive battery consumption, as well as the possibility
for undesirable side effects. Work by Chizeck and colleagues has
produced a platform for investigating the control of DBS (Herron
and Chizeck, 2014), which has now being employed by other
Frontiers in Integrative Neuroscience | www.frontiersin.org November 2016 | Volume 10 | Article 38 | 65
Deeb et al. Fourth DBS Think Tank Proceedings
groups. One mobile, wireless version consists of a set of worn
inertial and electromyography sensors that communicate via
Bluetooth to a host application running on a smartphone, smart
watch or laptop. Using sensed data, the host application initiates
control decisions, including enabling or disabling stimulation
or modifying individual stimulation parameters (voltage, pulse
width, frequency). These control signals are then transmitted
by Bluetooth to a Medtronic NexusTM system, which relays
packets and control on a hardware and software modification of
the clinician programming unit, driving a FDA approved and
implanted DBS system (the Medtronic Activa PC+S)TM (Herron
et al., 2015; Houston et al., 2015; Malekmohammadi et al., 2016).
An alternative, fully implanted system that is currently under
development uses implanted cortical electrodes (connected to
the DBS) to measure local field potentials (along with the deep
brain electrode), as indicators of tremor and/or patient intentions
and stimulation adjustment requests. These systems are being
evaluated on patients with essential tremor and PD (Houston
et al., 2015). This represents a practical implementation of a
brain computer interface—BCI (i.e., which can be used for
voluntary BCI-triggered stimulation adjustment by the patient;
Thompson et al., 2016). These platforms also provide an
opportunity for collection of tremor and stimulation data for
extended periods of time, which will be vital toward gaining
further insight to both the neurological basis of tremor, and
issues related to the long term viability and use of these devices
(Brown et al., 2016).
Highlights
- Activity-dependent fluctuations in the beta-band power in STN
limit its use a sole control for closed loop DBS in PD tremor.
- Kinematic input can be processed by a laptop or smartphone
that produces control signals that are then transmitted via
Bluetooth to a Medtronic Nexus
TM
system, which relays
packets and control on a hardware and software modification
of the clinician programming unit, driving a FDA approved
and implanted DBS system.
- Combination of kinematic input in a closed-loop DBS system
resulted in tremor control, but there was considerable variation
among patients.
- Future directions include the development of fully implanted
closed loop DBS systems.
Development of a Closed Loop System for
Tourette Syndrome
(See Section Tourette Syndrome).
DARPA SYSTEMS BASED
NEUROTECHNOLOGY FOR EMERGING
THERAPIES (SUBNETS) RESEARCH
PROGRAMS UPDATES
Introduction
The goal of the Defense Advanced Research Projects Agency
(DARPA) Systems-Based Neurotechnology for Emerging
Therapies (SUBNETS) project is to develop closed-loop DBS
projects that will address the multiple neuropsychiatric problems
occurring in the veteran and general population, including
post-traumatic stress disorder (PTSD), traumatic brain injury,
depression, anxiety, chronic pain, and substance abuse. In a
recent article, Vigo and colleagues estimate from published data,
that the global burden of mental illness is 32.4% of years lived
with disability (Vigo et al., 2016).
Currently available treatments (e.g., pharmacological
and psychological therapies) can be helpful for some
patients. However, some patients are left with partial or
no response to such intervention(s). Brain stimulation
offers notable promise in treating these patients, as there
are already FDA approved indications for the use DBS in
treating other neuropsychiatric conditions such as OCD (see:
http://www.accessdata.fda.gov/cdrh_docs/pdf5/H050003b.pdf).
To address this clinical problem, DARPA currently supports East
Coast and West Coast Research Teams that are engaged in key
projects focusing upon one or more areas of state-of-the-art DBS
techniques and technologies. Sections East Coast Research Team
Updates and West Coast Research Team Updates summarize
their unpublished work.
East Coast Research Team Updates
Transdiagnostic Restoration of Affective Networks by System
identification and Function Oriented Real-time Modeling in
Deep Brain Stimulation (TRANSFORMDBS), the DARPA 5 year,
funded program at Massachusetts General Hospital (MGH) is
currently in its second year.
A recurring concern when attempting to categorize
neuropsychiatric disorders is that most patients have co-
morbid conditions that present with considerable variability.
To decrease the effects of co-morbidity on analysis, the
TRANSFORM DBS group employed a trans-diagnostic
FIGURE 6 | Vector diagram illustrating the difference between a
categorical diagnosis (in this instance MDD or major depressive
disorder) and a symptom based or behavioral based domain
assessment. The limitation of the categorical diagnosis analysis is that it can
average and thereby diffuse genuine subgroup (behavioral domain) therapeutic
effects.
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approach that focuses on behavioral domains rather than
categorical diagnosis or co-morbidity assessments (Figure 6).
Behavioral tests were developed to quantitate the severity
of each domain, and these findings were used to guide
treatment.
In collaboration with Draper Laboratory (Cambridge, MA),
the group developed a modular, flexible implantable system that
allows 320 simultaneous recordings. The identification of the
deep electrode implantation site is determined by structural and
functional assays relating to the different behavioral components.
Studies thus far have been on non-human primates, with plans
to extend investigations to humans in the epilepsy-monitoring
beginning in summer 2016.
West Coast Research Team Updates
Recent animal and human studies of brain connectivity have
fostered a mesoscale network approach to interpreting and
understanding mechanisms of neurocognitive function and
dysfunction (Yuste, 2015).
This network-based construct suggests that psychiatric
disorders may be related to changes in the function and/or
structure of particular neural nodes and inter-nodal connectivity.
Given the plasticity that has been demonstrated in neural circuity,
a basic premise of SUBNETS is that DBS can be employed as a
tool to facilitate re-modeling of brain architecture on micro to
mesoscales.
The West Coast Team—at the UCSF—presented their initial
work “mapping” the frontal and pre-frontal cortical areas by
advancing an electrode grid under intra-operative fluoroscopy in
PD patients undergoing DBS. At each cortical area, they stimulate
and record the electrophysiological and clinical changes (mood
states). The results show significant variability among patients,
but indicate a possible correlation between the recorded signals
and different mood states.
The next phase of this DARPA project will focus on chronic
recording and stimulation in PD patients who have moderate
psychiatric co-morbidities.
Highlights
- The goal of the DARPA’s SUBNETS project is to develop closed-
loop DBS projects for multiple high-burden neuropsychiatric
disorders: PTSD, anxiety, depression, substance abuse, and
pain.
- Two projects were discussed with different approaches in
identifying DBS closed-loop systems:
◦ East Coast Group
Using behavioral domains (avoidance, perseveration, etc.)
rather than categorical diagnoses (depression, anxiety,
PTSD, etc.) as endpoints.
Using a custom-built modular and flexible implantable
system allowing 320 simultaneous recordings.
Work so far has been on non-human primates with
human studies planned to start in summer 2016.
◦ West Coast Group
FIGURE 7 | Diagrammatic representation of a possible closed-loop
DBS system comprised of sensors (e.g., - ECoG, neurochemical
sensors and local field potential sensing through the implanted
electrodes) that influence the stimulator (actuator) signal. The sensed
signal is classified, and with use of an implementation algorithm, can influence
the stimulator output to induce therapeutic effects.
Using intra-operative grid mapping of the frontal and pre-
frontal cortical areas to assess their effect on affective states
in patients with PD undergoing DBS.
Noted significant variability among the different patients.
Work so far has been on intra-operative recording, next
phase will use chronic recordings.
DEVELOPMENT IN TECHNOLOGY AND
APPLICATION
Closed-Loop DBS
Much of the hardware of DBS technology has been adapted from
the cardiology field. A major limitation to ongoing refinement
of DBS technology is a somewhat limited understanding of
its mechanism(s) of action (Herrington et al., 2016). As noted
in Section Introduction, open loop DBS does not respond to
variations in the patient’s state and disease progression but
rather produces a pre-programmed output stimulation. This
can result in a suboptimal outcome as optimization of the
output stimulation has to be done by separate visits to provider
clinics, usually many weeks apart. The closed-loop DBS system
offers a solution by allowing integration of feedback signals
to continuously modulate the output stimulation using an
algorithm. The development of these advanced systems involves
the construction of a number of components that are reliant,
at least in part, upon feedback and feed-forward integration.
The system comprises sensors that are connected to an actuator
through a classifier and control policy (Figure 7).
Recent technological advances allow multi-modality sensing.
Many of these modalities were discussed in prior sections
and include LFP, ECoG, and neurochemical sensing modalities.
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There are multiple limitations to the current recording/sensing
implantable technology. One, the signal sensed and recorded by
implantable sensors has a lower quality than the one measured
by stand-alone devices that are non-implantable and can be
used only intra-operatively for a short period of time. Two,
the signal measured is of relatively low amplitude. Three,
identification of the appropriate signal to sense is still evolving
and not clear for most indications (refer to Sections Tourette
Syndrome, Development of DBS Sensors, Parkinson’s Disease,
Clinical Assessment andManagement of Tremor). Four, there is a
need to develop mechanisms to distinguish between the feedback
and stimulation signals.
The feedback signal is transmitted from the sensors to a
classifier system. The role of this system is signal processing,
converting the raw signal into classified data that will be
recognized by the algorithm. The latency of the signal
transmission for analysis, though improving, is still a limiting
factor in building closed loop DBS systems. The most complex
component of developing algorithms for closed loop DBS is to
modulate the output signal from the actuator (DBS stimulation)
in order to affect the outcome toward the desired state. This
is an area of considerable research. Section Clinical Assessment
and Management of Tremor exemplifies the development of a
classifier system based on the amplitude of the tremor and a
relatively simple algorithm that modulates the output signal.
As with any biomedical technology, safety is an important
aspect of closed loop DBS, and therefore a first objective is
determining safety limits for the algorithms. A second and
related consideration is the development of facile mechanisms to
allow the patient and/or clinician to deactivate the closed-loop
system, and/or engage a “default—safety mode” open loop
system.
Highlights
- The DBS field is moving from the use of systems of continuous
stimulation to more adaptive, closed-loop systems.
- To facilitate such progress, it will be important to address and
resolve a number of issues, including:
◦ Improving recording and feedback signal acquisition.
◦ Improving latency time from signal sensing to analysis.
◦ Developing classifier systems that allow signal processing.
◦ Generating valid and safe algorithms of closed-loop
function(s).
◦ Identifying markers of neural response.
◦ Identifying appropriate stimulation responses.
◦ Understanding and developing patient specific parameters
for precision closed-loop DBS.
Electrical Current Shaping
The most commonly used lead design in DBS systems includes
four (4) ring-shaped contacts. In monopolar settings, each
of these contacts produces a spherical electrical field. This
can be problematic in cases when the lead is not optimally
positioned in the target zone, as resultant stimulation induces
side effects evoked by stimulation of off-target tissue(s) (Deuschl
et al., 2006). To maintain clinical benefit while minimizing side
effects, practitioners tend to modify the shape of the electrical
field. Different approaches have been used, including bipolar
stimulation, double monopolar stimulation, and/or interleaving
settings.
Given the demonstrated importance of site and directional
specificity of DBS electrical fields, new lead designs that
allow current shaping/steering have been developed. The
“directSTIM” lead, a design by Aleva Neurotherapeutics
(Lausanne, Switzerland), divides each contact ring into 3
sub-compartments that can be individually stimulated (Hariz,
2014). Another, “SureStim,” developed by Sapiens (Eindhoven,
the Netherlands), has 32 contacts distributed evenly (Contarino
et al., 2014). A third, Vercise PC, produced by Boston
Scientific and recently approved for use in Europe (September
2015), uses an 8-contact directional lead—the VANTAGE study
(Timmermann et al., 2015). These designs allow current to
be shaped away from unintended targets while maintaining a
larger therapeutic window to the intended target site(s). Some
limitations to these designs arise from the electrical properties
of the system. For example, decreasing the surface area of the
active contact will result in increased impedance and therefore
increased power consumption. As well, impedance variation
between different smaller contacts will passively dictate current
distribution whenmore than one contact is simultaneously active
if independent current sources are not employed.
To date, published data, as derived from use of the
commercially available Vercise PC, has been limited to acute
intraoperative settings, with only limited information available
about the effects and efficacy of current steering in clinical care.
However, unpublished data were presented at the Think Tank
that illustrated the feasibility and improved therapeutic window
of steered current, STN DBS in PD patients using the Vercise PC
system in the clinic setting.
We posit that current steering/shaping approaches offer
promise to improve the clinical outcomes of DBS, by allowing
a wider therapeutic stimulation window, especially in those cases
where lead placement may be difficult, and/or less than precise.
For example, if a lead is targeting the STN in a PD patient
but was noted post-operatively to be more lateral than initially
planned, conventional stimulation will not only stimulate STN
but also the adjacent internal capsule. This will produce a low
threshold of stimulation to side effects thus providing only sub-
optimal control of PD symptoms. By steering the current away
from the internal capsule, a higher threshold of stimulation can
be tolerated resulting in a better clinical outcome (Hariz, 2014).
Highlights
- A challenge facing the use of conventional DBS leads is delivery
of the electrical current to the desired region while avoiding
side effects by stimulating undesired areas.
- One approach proposed to decrease the undesired area
stimulation is by using current steering
◦ Multiple lead designs are now being investigated.
- Unpublished results of prospective in-clinic current steering
testing were presented that showed improved outcomes with
STN current steering.
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Neurosurgical Technique Updates in DBS
The accuracy of surgical placement of the DBS electrode(s) at the
specified anatomical targets is important. Although stereotactic
techniques combining preoperative image-based planning
with intraoperative recording and test stimulation are well-
developed, these approaches carry risks including intracranial
hemorrhage (1–3% both symptomatic and asymptomatic with
<1% symptomatic), seizures (∼1%), leak of cerebrospinal fluid
(1–2%), and infection (2–3%) (Videnovic and Metman, 2008;
Patel et al., 2015). While rates of adverse events appear to be
quite low, in reality, these rates have been shown to increase to
∼5% when data are prospectively and systematically collected
(Burdick et al., 2010). Innovations in the surgical delivery of DBS
include the use of intraoperative magnetic resonance imaging
(Ostrem et al., 2013; Chabardes et al., 2015) to identify and
guide electrode placement, and the use of frameless stereotaxy
to enable more accurate surgical access and reduce burden and
risks incurred by the operative hardware (Khan and Henderson,
2013). These are yet nascent, and the benefit and effect(s) of such
innovations remains unknown.
Another surgical innovation in DBS lead implantation is the
development of intravascular DBS electrodes. The feasibility
of intravascular electrodes for both neural stimulation and
recording and stimulation has been demonstrated. Electrodes
positioned temporarily within intracranial vessels enabled
recording of both spontaneous and evoked EEG-like electrical
activity (Driller et al., 1969), and this work was recently extended
to multi-electrode recordings using a chronically implanted
stent-like device (Oxley et al., 2016). Stimulation through the
blood vessel wall is also possible, an example being endovascular
stimulation of the vagus nerve (Nabutovsky et al., 2007), and a
recent simulation analysis demonstrated comparable patterns of
model nerve fiber activation between an intravascular electrode
and traditional stereotactically-positioned DBS leads (Teplitzky
et al., 2014). This is not to suggest that intravascular methods
are without risk; however, such innovations may provide a
less-invasive approach to both record and stimulate deep in the
brain and thus, represent new way to deliver DBS.
Highlights
- Significant advances have improved neurosurgical techniques
of DBS implantation, but the complication rate remains∼5%.
- Intravascular stimulation may prove to be a viable, alternate
method for delivering DBS.
NEW CLINICAL APPLICATIONS OF DBS
DBS for Treatment of Addiction
This year, a case was presented at the Think Tank of a female
patient with severe OCD (displaying excessive cleaning behavior)
who gained appreciable therapeutic benefit (i.e.,—reduction of
compulsive behaviors and obsessive ideation) following nucleus
accumbens DBS (Mantione et al., 2010). Of particular note
however, was that this patient also was able to quit smoking and
lost an appreciable amount of weight (she was obese) following
DBS implantation. Although, it remained unclear whether these
latter two effects were directly due to DBS or were artifacts, it was
speculated that DBS may have effected change in neural circuitry
mediating obsessive ideation and/or compulsive-type behaviors
that subserve over-eating and smoking. The effect of the nucleus
accumbens stimulation on addiction (cigarette smoking) in this
OCD patient prompted interest in considering this target for
treatment of addiction without co-morbid OCD. This has been
reinforced by the identification of nodes and networks in the
brain associated with addiction (Volkow et al., 2016).
This has prompted a funded trial of DBS targeting the
nucleus accumbens to treat 8 heroin-addicted patients. Multiple
cortical and deep brain recording sessions were performed while
exposing the patients to either neutral or addiction-themed
images. Change in signal intensity with cortico-basal coherence
was used to identify the appropriate stimulation contact.
Identifying the appropriate stimulation setting was achieved by
asking the patient to engage in heroin “freebasing” behavior
(using real heroin), and to rate his/her experience with each of
the different settings used. At this writing, two patients have
been treated, and decreased addiction behavior was noted in
both patients with DBS stimulation. To be sure, these results are
preliminary, and continued work in this study—and others—will
be required to more accurately address and define the role and
value of DBS in treating addition disorders.
Highlights
- The “optimal” target for DBS in addiction is not established;
however, given extant data supporting the efficacy of nucleus
accumbens-directed DBS in treating OCD, and similar
cognitive and conative features of compulsive and addictive
behaviors, the nucleus accumbens has been considered as a
possible target.
- A study in the Netherlands that employed bilateral nucleus
accumbens DBS implantation to treat heroin addiction
demonstrated possible therapeutic benefits. At this point,
results are preliminary, and continued work in will be required
tomore accurately address and define the role and value of DBS
in treating addition disorders.
Use of DBS to Treat Post-Traumatic Stress
Disorder
Dis-inhibition and propagation of fear responses appear to
be cardinal neuro-cognitive features of PTSD (Furini et al.,
2014). Extinction of fear responses involves engagement of
the basolateral nucleus of the amygdala (BLn) and the medial
prefrontal cortex (mPFC) (Marek et al., 2013). Fear responses
(to even inert stimuli) can become heightened if this network
is compromised. In this event, progressive psychotherapeutic
approaches, such as progressive desensitization and/or stimulus
immersion are less likely to succeed. Pharmacotherapy using
benzodiazepines, while somewhat effective, is burdened by
side effects (inclusive of sedation, tolerance, and withdrawal),
and other pharmacological approaches (e.g., azapirones; beta-
receptor antagonists) have been shown to be only nominally
effective (Ravindran and Stein, 2010). In these cases, DBS of the
amygdala may be useful to suppress abnormal activity within
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amygdalar-prefrontocortical circuits, and “re-set” the inhibitory
tone necessary for fear extinction and reduction of PTSD
symptoms.
Langevin presented results of a 1-year study of a patient with
treatment-resistant PTSD who received BLn DBS. The patient
exhibited and reported significant improvements in all domains
of PTSD assessed (Langevin et al., 2016). In particular, the
patient reported and evidenced improved quality and quantity
of sleep (without nightmares), overall reduction in anxiety, fear
and irritability, and improvement in interpersonal interactions
with family members and work colleagues. Patient scores on
the clinician administered PTSD scale decreased in excess of
40%. There have been no treatment-related adverse events and,
in particular, monthly EEG studies have shown no evidence
of seizure or epileptiform activity. In addition, the monthly
EEG has shown progressively more sleep activity and improved
sleep architecture, with the patient showing increased deep
sleep that consistently occurs earlier in the patient’s sleep cycle.
Pre-operatively, the patient had undergone a fludeoxyglucose
(FDG) PET imaging studies, both at rest and under symptomatic
conditions during an exposure therapy session. These studies
revealed increased metabolic activity in the amygdala during the
symptomatic phase, as compared to the resting phase (Langevin
et al., 2016). The FDG PET study was repeated 1 year after
initiation of BLn DBS; post-treatment PET showed no difference
in amygdalar metabolic activity between the resting and the
symptomatic phase. This finding is consistent with patterns of
amygdalar activity during fear extinction, suggesting the efficacy
of BLn DBS in restoring a more normal pattern of activity in
amygdalar networks involved in cognitive and behavioral aspects
of fear that are representative of PTSD. The study is continuing,
with ongoing recruitment toward a target enrollment of six
patients.
Highlights
- A case was presented to support the possibility of using DBS
targeting the amygdalar BLn to reduce signs and symptoms of
PTSD
◦ Prior to DBS, the patient had disrupted sleep quality and
quantity, night terrors, OCD-like symptoms, and manifest
social disturbances. Following BLn DBS, the patient reports
feeling calmer, evidences improvement in sleep architecture
and quality (as demonstrated by EEG and described
through self-report), and describes improvement in social
interactions.
- FDG PET studies revealed post-DBS normalization of
metabolic activity in the amygdala metabolism.
Use of DBS to Treat Clinical Obesity
Clinical, morbid obesity is a significant public health problem,
both in the United States, and worldwide (Nangunoori et al.,
2016). The current standard of treatment for morbid obesity
that is not responsive to dietary and lifestyle modification, or
pharmacotherapy is bariatric surgery. However, bariatric surgery
although certainly of clinical value, also poses a number of risks,
and is not uniformly successful (Ho et al., 2015). In seeking
alternatives to gastro-intestinal surgery, DBS has been proposed
as a viable approach to affect hypothalamic mechanisms of
hunger and satiety that may be dysfunctional in morbidly obese
patients (Nangunoori et al., 2016).
To explore this possibility, three (3) patients with a history
of bariatric surgery were recruited; each with a current body
mass index (BMI) greater than 40 Kg/m2. The DBS target was
the bilateral lateral hypothalamus and post-operative images
confirmed successful electrode implantation in all cases. The
patients were followed for 2.5 years. The primary goal of this
study was to assess safety. There were no serious adverse effects
reported and no evidence of autonomic dysfunction. There was
a subjective report of decreased urge to eat. Although, the study
was not designed to assess efficacy, the resting metabolic rate was
measured using a metabolic chamber. It was noted that contacts
centered in the lateral hypothalamus were associated with an
increase in the resting metabolic rate. This, however, did not
correlate with a consistent weight loss (Whiting et al., 2013).
Long-term follow-up data were presented; one patient
dropped off due to delayed bariatric surgery complications.
During the long-term follow-up period, multiple DBS settings
(9 settings/day) were used to determine the optimal stimulation
parameters required to elicit the greatest increase in resting
metabolic rate. In one patient, BMI decreased from 46 to 38,
while the other patient did not show any weight loss or change in
BMI. However, both patients showed an increase in their resting
metabolic rate. The effects of any stimulation paradigm were
short-term. This was attributed to the “hedonic component of
food seeking and the motivational processes that drive eating”
(Whiting et al., 2013).
Future directions for studying the potential viability and value
of DBS to treat certain forms of clinical, morbid obesity are
centered upon the identification of other neurological targets
(e.g., the nucleus accumbens; see also Section DBS for Treatment
of Addiction, above; either singularly, or in combination with
stimulation of the lateral hypothalamus), and the potential utility
of employing closed-loop systems.
Highlights
- DBS to treat clinical morbid obesity has targeted the lateral
hypothalamus in an attempt to restore balance in hunger and
satiety states.
- In a limited study (n = 3), obese patients who had previously
undergone bariatric surgery and still maintained a BMI
> 40 Kg/m2 underwent DBS surgery targeting the lateral
hypothalamus.
- The procedure was noted to be safe in the 3 patients tested.
- Two years post-operatively, assessments indicate an increase
in the resting metabolic rate though this did not translate to
consistent weight loss.
- Future directions are focusing upon identification of other
and/or additional neuroanatomical targets for DBS to treat
clinical, morbid obesity.
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CONCLUSION
Herein we have summarized the presentations and discussion(s)
of the Fourth Annual DBS Think Tank. Policy and regulatory
issues and proposed optimizations were discussed, multiple
advances in the field were addressed, including updates on the
state of research, database and data registry, developments in
closed-loopDBS, themost current and novel applications of DBS,
and advances in electro-neurochemical sensing systems. In sum,
the field and applications of DBS are expanding, and to some
extent this expansion may represent a change in the status and
trajectory of DBS research and use in clinical practice. To assess
participants’ perspectives and attitudes toward the current and
near-term future development in the field, an anonymous 40
question poll was sent online at the conclusion of the Think Tank.
The questionnaire assessed the respondent’s perceived position of
DBS applications in disease states, neurotechnological principles,
and emerging applications on the hype cycle graph.
Thirty-six participants responded to the poll. These responses
are depicted in Figure 8. Of note is in contrast to last year,
participants’ current perception of some uses/indications for DBS
have slipped from the plateau of productivity to the slope of
enlightenment (e.g., Parkinson’s disease), others moved from
the trough of disillusionment to the contraction phase (e.g.,
Depression), still others moved from the expansion slope to the
peak of inflated expectations (e.g., Obesity).
In conclusion, the fourth Annual DBS Think Tank provided
a nexus for the presentation of new developments and findings,
discussion about the technology, research and practice of
DBS, and speculation about—and proposals for—the future
of the field. The future of DBS therapy will rely on
continuing innovation and cooperation of key stake and
shareholders, inclusive of scientists, engineers, physicians,
ethicists, administrators and policy makers. The aim of the
DBS Think Tank is to remain an important component of, and
resource for contributions to this process and progress.
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Many investigators now consider psychiatric disorders to be neural circuit disorders
(Lozano and Lipsman, 2013). Cognitive, emotional and volitional symptoms of major depression,
generalized anxiety, obsessive-compulsive disorder and other conditions are traceable to dysfunc-
tion in critical nodes of circuits in cortical, limbic and subcortical pathways of the brain. Guided
by functional imaging, the ability of deep-brain stimulation (DBS) to probe and modulate spe-
cific circuits in real-time has elucidated the pathogenesis of these disorders. DBS has validated the
neurobiological underpinning of normal and abnormal states of mind. This and other develop-
ments in clinical neuroscience discredit a dualist theory of mind and brain that takes psychological
properties to be conceptually distinct from and capable of functioning independently of neural
properties. Instead, they support a materialist theory of mind that explains mental phenomena in
terms of their neural correlates.
A materialist theory of mind suggests that mental illnesses are just diseases of the brain
(Fuchs, 2012). This idea is generally consistent with the aim of the Research Domain Cri-
teria (RDoC) initiated by the US National Institutes of Mental Health (NIMH), which
is to identify brain mechanisms that can explain the causes of psychiatric disorders and
predict treatment responses and outcomes (Insel et al., 2010; Casey et al., 2013). There
are, however, reductive and non-reductive versions of materialism (Baker, 2009). Accord-
ing to reductive materialism, phenomena at one level can be completely explained in terms
of more basic elements at a different level. On this view, normal and abnormal men-
tal states can be completely explained in terms of brain function and dysfunction. Accord-
ing to non-reductive materialism, the brain necessarily generates and sustains mental states
but cannot account for all of their properties. By themselves, probing and modulating neu-
ral circuits of people with psychiatric disorders fail to capture how the content and phe-
nomenology of the mind can affect the brain in how these disorders develop and respond to
treatment.
Psychiatric disorders are multifactorial disorders resulting from interaction among genes, neu-
rons, immune and endocrine systems and the affected person’s psychological response to the
natural, social and cultural environment. Describing these disorders at a brain-systems level
is necessary but not sufficient for understanding their etiology or how they can be controlled
through different types of neuromodulation. It is not dysfunctional neural circuits but people
who have these disorders. Persons are constituted by their brains but are not identical to them.
The conscious and unconscious mental states that emerge from the brain and define persons
are influenced by a dynamic and interacting set of factors both inside and outside of the brain.
Mind and brain are shaped by the fact that persons are embodied and embedded in differ-
ent environments. Our brains alone do not determine everything about who we are and how
we experience the world (Churchland, 2013). These considerations suggest that non-reductive
materialism is a more plausible theory than reductive materialism for explaining the mind-brain
relation in psychiatry and a more helpful model for diagnosing and treating psychiatric disorders.
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Neuropsychiatrist Todd Feinberg’s conception of the mind as
a process emerging from the brain in a nested hierarchy supports
non-reductive materialism as a theoretical basis of the mind-
brain relation (Feinberg, 2001, pp. 129–131). Higher-level pro-
cesses associated with conscious and unconscious mental states
are compositionally dependent on, or nested within, lower-level
processes associated with circuits in the brain. Feinberg’s idea
of constraint can be used to explain how interacting neural and
mental processes promote homeostasis within an organism and
its adaptability to the external world. Constraint refers to the con-
trol that one level of a system exerts over another level of the same
system. The “system” at issue is a human organism, and the rel-
evant “levels” are brain and mind. Constraint operates in both
bottom-up and top-down directions as brain and mind mutu-
ally influence each other in a series of re-entrant loops. Neural
functions constrain mental states to ensure that they accurately
interpret information from the environment. Mental states con-
strain neural circuits to ensure that they are neither underactive
nor overactive. Beliefs with heightened emotional content can
over-activate the limbic fear system, disable cortical constraint
on this system and lead to depression, anxiety or panic disorders.
Disabled constraints on belief content from dysfunctional audi-
tory and prefrontal cortices can result in the hallucinations and
delusions in the positive subtype of schizophrenia.
Proponents of non-reductive materialism hold that men-
tal properties are part of the material world. They also hold
that mental properties can be causally efficacious without being
reducible to material properties. Critics of this position argue
that if mental events are not reducible to physical events, then
they are epiphenomenal (Kim, 1998, p. 81). Mental events are
the effects of material or physical causes but cannot cause any
material or physical events to occur. If mental processes associ-
ated with beliefs, desires and emotions are not reducible to their
neural correlates and are epiphenomenal, then presumably they
do not influence the etiology of psychiatric disorders or patients’
responses to therapies.
But there are many examples in psychiatry where mental
states are causally efficacious in disrupting and modulating neu-
ral pathways. Persistent psychological stress can cause a cascade
of adverse biochemical events in the brain and body, including
hyperactivation of the amygdala fear system and dysregulation
of the hypothalamic-pituitary-adrenal (HPA) axis and sympa-
thetic nervous system. This can disrupt frontal-limbic connec-
tivity mediating cognitive and affective processing and result in
impaired cognition and mood. The contents of a person’s beliefs
and emotions may play a causal role in the pathophysiology of
this disorder. In obsessive-compulsive disorder, excessive con-
scious reflection on motor tasks ordinarily performed as a matter
of course can have a similar disruptive effect on frontal-limbic-
striatal pathways and impair sensorimotor and cognitive func-
tions (Melloni et al., 2012; Figee et al., 2013). Yet mental states
can be part of a therapeutic process as well. In cognitive behavior
therapy (CBT), patients with depression can be trained to reframe
their beliefs and emotions in a way that can re-wire some regions
of the brain and result in significant improvement in depressive
symptoms. Studies have shown that CBT can modulate func-
tion in specific sites in limbic and cortical regions mediating
mood and cognition (Fuchs, 2004; Goldapple et al., 2004). Dis-
ruptive bottom-up effects on mental functions by dysregulated
neural functions can be reversed to some degree by top-down
modulating effects of this therapy on these functions.
Neurofeedback (NFB) is another example of how mental
states can modulate brain activity. With this technique, par-
ticipants can be trained to down-regulate brain hyperactivity
through their cognitive and emotional responses to the sensory
feedback of neural function they receive from EEG or fMRI
(Linden et al., 2012; Linden, 2014, chapter 3). This type of self-
regulation can restore some degree of control of thought and
behavior for those who successfully perform the technique and
relieve symptoms associated with attention deficit-hyperactivity
disorder (ADHD), anxiety, depression, posttraumatic stress dis-
order (PTSD) and other conditions. It may also be possible
for depressed subjects with anhedonia and avolition associated
with an underactive nucleus accumbens in the reward system
to use NFB to up-regulate activity in this region and improve
motivation (Linden, 2014, chapter 3). NFB demonstrates that
participants can induce changes in their brains through their
own mental states without having to rely on psychoactive drugs
or devices implanted and stimulated in specific neural circuits.
Moreover, the fact that the cognitive and emotional responses
that induce these changes depend on indices of brain activ-
ity fed back to the subject shows that mind and brain are
not independent but interdependent and interacting processes
necessary for flexible and adaptive behavior. It highlights the
erroneous assumption that non-reductive materialism implies
dualism between mental properties and neural properties and
that the first cannot influence the second. It is because of interac-
tion between brain and mind in NFB that this technique can pro-
duce its therapeutic effects. Indeed, some investigators describe
NFB as “a holistic approach that overcomes bio-psychological
dualisms” (Linden et al., 2012, p. 8).
Psychological factors are also significant in brain-computer
interfaces (BCIs) used as a form of neurofeedback for neurolog-
ical disorders. These systems may use scalp-based electrodes to
record EEG or a microelectrode array implanted in the motor
cortex. More and less invasive forms of BCIs are designed to
enable subjects paralyzed from spinal cord or traumatic brain
injuries to bypass the site of injury and translate signals from
the motor cortex through a computer into actions such as mov-
ing a cursor or robotic arm. In addition, BCIs have been studied
to determine whether individuals with complete locked-in syn-
drome can communicate when they are unable to do this ver-
bally or gesturally by activating signals in brain regions mediating
semantic processing. Subjects have to be trained to perform these
neural and mental acts in manipulating the interface, and there is
considerable variation among them in the capacity to be trained.
Success in learning how to use the system and activate and trans-
late signals in the motor cortex depends on operant conditioning,
which requires sustained motivation, attention and persistence.
Not all locked-in subjects have the requisite degree of these psy-
chological capacities to manipulate the interface. One explana-
tion for the failure of researchers and practitioners to train these
individuals to communicate with a BCI is that the complete loss
of control from paralysis undermines the motivational basis for
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operant conditioning (Birbaumer et al., 2008, 2014; Linden, 2014,
p. 22). They may experience not only physical fatigue but also
mental fatigue in repeatedly attempting and failing to activate
the cortical regions necessary for communication. Theoretically,
though, participants who are sufficiently motivated and have the
necessary cognitive capacity could be trained to translate signals
in these regions into actions that realized their intentions. Psy-
chological properties of the participant play a causal role in the
success or failure in using the technique to induce the desired
brain responses. In both NFB and BCIs, the role of the trainer in
enabling the participant to exercise the critical mental capacities
and induce changes in the brain is one aspect of environmental
influence on these capacities and changes.
In treatment-refractory depression and obsessive-compulsive
disorder, DBS can modulate dysfunctional circuits enough to
make them amenable to CBT. As in NFB, this underscores the
complementarity of brain-based and mind-based techniques in
controlling symptoms in these disorders. Mind-brain dualism
would conceive of these techniques as unrelated or even incom-
patible. The reductionist view that everything about the mind
can be explained by appeal to neural circuits and that mental
states are epiphenomenal would also fail to appreciate the causal
efficacy of beliefs and other cognitive states on neural function.
Dualist and reductive materialist models of the mind and brain
both fail to recognize the salutary effects of combined neural
and psychological therapies for these disorders. It is thus mis-
taken to assume that non-reductive materialism in clinical neu-
roscience implies that mental states have no influence on the
brain.
Rather than focusing exclusively on neural mechanisms, a
holistic model of psychiatric disorders that explains them in
terms of interaction among genes, neurons, mental states, the
body and the environment is more helpful in understanding
them. The success or failure of different forms of neuromodula-
tion for these disorders demonstrates that interdependent mental
and neural processes influence the extent to which they can be
controlled. These considerations support a non-reductive mate-
rialist model of the mind-brain relation in psychiatry. This rejects
the reductionist view that mental illnesses are just diseases of the
brain and that how we experience the world is completely deter-
mined by neural structure and function. Theoretical models such
as the RDoC and techniques such as DBS alone may be too lim-
ited to provide an adequate account of mental health and mental
illness. They are components of a broader set of factors that shape
mind-brain interaction and need to be included in diagnosing
and treating psychiatric disorders.
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In order to gain insight into the public’s perspective on using the minimally invasive
technique transcranial direct current stimulation (tDCS) as an enhancement tool, we
analyzed and compared online comments in key popular press articles from two different
periods (pre-commercialization and post-commercialization). The main conclusion drawn
from this exploratory investigation is that public perception regarding tDCS has shifted
from misunderstanding to cautionary realism. This change in attitude can be explained
as moving from a focus on an emergent technology to a focus on its applications,
benefits, and risks as the technology becomes more grounded within the public
domain. Future governance of tDCS should include the concerns and enthusiasms of
the public.
Keywords: cognitive enhancement, neuroethics, public understanding, transcranial direct current stimulation,
brain stimulation, public policy
Introduction
Brain stimulation techniques are emerging as methods of neuroenhancement. Among these
techniques, transcranial direct current stimulation (tDCS) is one that is gaining public attention as
a potential neuroenhancer. This portable technology, which involves applying weak direct currents
to the scalp via saline-soaked sponge electrodes, appears rather safe with medical supervision,
reasonably effective across a range of brain functions, and accessible to an interested public. These
features have led to its growing implementation in both research and clinical settings, as well as with
home users (Dubljevi´c et al., 2014).
Given the impact that home use of tDCS may have for individuals and society, changes in public
perceptions warrant careful attention, as these may be consequential. In order to gain insight into
the public’s attitudes towards tDCS as an enhancement tool, we used thematic analysis to compare
online comments on popular press articles from two different time periods: before and after the
introduction of the first widely available commercial product. The main conclusion is that the
public’s perception regarding tDCS has shifted from misunderstanding to cautionary realism. This
change in attitude suggests that as the technology has become more grounded within the public
domain, there has been a shift from a focus on an emergent technology to one on its applications
and risk-benefit profile.
Trends in Public Attitudes Towards tDCS
Information on tDCS is growing substantially (Dubljevi´c et al., 2014). While acknowledging
that public opinion formation, patterns, and trends can be analyzed and understood
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through different paradigms, our primary focus here is on
attitudinal and perceptual trends as revealed through online
comments (Capstick et al., 2014).
Methods
We conducted a temporal comparison of online comments
addressing the use of tDCS as an enhancement tool. Comments
on online articles is not a representative sample of the general
population, but are available to large numbers of readers
from a range of different backgrounds, who can express their
opinions by posting comments online. Thus, online communities
‘‘offer a mechanism through which a researcher can gain
access to people who share specific interests’’ (Wright, 2005)
and diverse opinions (Faridani et al., 2010). We compared
two time periods. For our first time period, the EARLIER
PERIOD, we only included articles that were published between
August 2007 and May 14, 2013, dates that preceded the first
offer of a widely available commercially tDCS product to
the general public.1 We restricted our search to widely read
English-language U.S. and U.K. popular media sources that
were accessible to readers without a subscription and which
had online reader comments. For our second time period, the
LATER PERIOD, we included articles from May 15, 2013 to
August 2014.
For both time periods, a search was carried out of the
Lexis Nexis Academic database and Google using the following
terms for newspapers or online magazines: ‘‘transcranial
stimulation’’ ‘‘tDCS’’ ‘‘neural stimulation’’ ‘‘neurostimulation’’
‘‘brain stimulation’’. The initial search yielded 38 articles for
the EARLIER PERIOD and 36 for the LATER PERIOD. Each
article was read and checked it for relevance according to
pre-established exclusion and inclusion criteria: (1) a focus
on tDCS as a cognitive enhancer; and (2) 10 or more
comments. The 10 comments inclusion criterion was chosen
in order to ensure that the popular media article at hand
had generated a good level of discussion. For the EARLIER
PERIOD, 13 newspapers (N = 8, 61.5%) and magazines
(N = 5, 38.5%) articles were included for analysis, while
for the LATER PERIOD 14 newspapers (N = 10, 71.42%)
and magazines (N = 4, 28.57%) articles were included (see
Figure 1).
We employed thematic analysis (Chi, 1997; Braun and Clarke,
2006), with comments coded in an interactive manner, in which
themes were developed as the coding process progressed. Themes
were grouped into categories. Author replies and comments that
were duplicated or irrelevant were excluded, leaving a sample
of 248 comments for the EARLIER PERIOD and of 465 for
the LATER PERIOD. Inter-rater reliability was determined by
randomly selecting 10% of the comments and assigning them to
a second coder (Lombard et al., 2002); Cohen’s Kappa was 0.82
for the EARLIER PERIOD and 0.98 for the LATER PERIOD.
Descriptive statistics were used to characterize the composition
and properties of the sample.
1Invitations to pre-purchase a device from foc.us were sent out on that date.
FIGURE 1 | Distribution of articles according to year published.
Limitations
Anonymity of comments can threaten their reliability. Relatively
little is known about the demographics of people in online
communities (Wright, 2005) which facilitates the posting of
polemic, charged and untruthful comments (Lefever et al., 2007).
Moreover, we cannot be sure that the posted comment is a result
of reading the article or merely responding to the comment
thread. Posting of comments is based on volunteer sampling
rather than probability sampling (Lefever et al., 2007), and
certain websites attract people with like-minded viewpoints,
reinforcing biases (Faridani et al., 2010). Finally, our sample
composition is limited to English language sources in the United
States and United Kingdom, as well as digital natives with
access to the Internet. In spite of these limitations, this research
provided us with the opportunity to grasp trends and themes
regarding the use of tDCS as a cognitive enhancer.
Results
Personal position and Technology issues were the two most
frequent categories of codes for both periods of analysis. Figure 2
displays the comparison between the EARLIER PERIOD and the
LATER PERIOD from comments addressing specific categories
and themes.
Early Stage on Public Perception Around tDCS:
A Misunderstood Technology
The EARLIER PERIOD was a point in time at which the overall
level of understanding of tDCS was limited and there was often
conflation with other similar technologies. In many instances,
comments addressed tDCS either as an extension of other
electricity delivering technologies (such as tasers) or as a form
of electroconvulsive therapy (ECT). Technical misinterpretation
represented another form of misunderstanding. For instance,
there were comments implying unsupported assumptions, such
as the more current or voltage used, the better the results of
cognitive enhancement. There were also comments implying that
the current administered by tDCS (generally between 1–2 mA)
could lead to ‘‘fried brains’’ or even death.
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FIGURE 2 | Comparison of Subjects Addressed within tDCS Online
Public Comments. χ2 ∗∗p < 0.001 and ∗p < 0.05. For bar charts y axis
represents percentage of the overall coded data points. (A) Comparison of
categories earlier and second period. Comparison of themes within Category:
(B) Personal Position (C) Technology Issues (D) Benefits and Risks (E) Ethical,
Social and Political Implications (F) Target Population.
The other main theme addressed in the comments during
the EARLIER PERIOD was their polemic and controversial
tone (14.67%, N = 55). That enhancement is controversial
may have contributed to the controversial tone of many
Frontiers in Integrative Neuroscience | www.frontiersin.org April 2015 | Volume 9 | Article 30 | 80
Cabrera and Reiner Understanding public (mis)understanding of tDCS for enhancement
comments, as well as the fact that online comments enable
commentators to remain anonymous, creating a space
for polemics (Faridani et al., 2010). In addition people’s
perceptions are likely to be biased by their hopes, fears,
needs and immediate emotional states which can give rise
to polarized opinions in pluralistic societies (Pronin et al.,
2002).
Even at this early point in time, respondents reported safety
concerns in relation to the use of this technology (7.47%,
N = 28). Ethical issues were not a main category in this
sample. For example, even though justice is one of the major
concerns regarding cognitive enhancement (Fitz et al., 2014)
and tDCS is rather inexpensive compared to other brain
stimulation technologies, comments addressing this topic were
infrequent. Similarly, comments regarding policy and regulation
were also infrequent, despite the fact that a few articles in
our sample mentioned the possibility of do-it-yourself (DIY)
approaches.
Second Stage on Public Perception Around
tDCS: Cautionary Realism
Whereas the EARLIER PERIOD was marked by a growth
in basic awareness and misunderstanding about tDCS, the
LATER PERIOD entailed a sustained growth of cautionary
concerns overall, a steady polemic and controversial stand,
and the proliferation of doubts and skepticism regarding
tDCS’s enhancement potential. Comments in this LATER
PERIOD focused on subjects about technological based
enhancement not being substitution for effort nor the solution
for human improvement, the existence of other of non-
technological and less risky methods (such as meditation
or exercise) for enhancement, and that people can misuse
this technology, all captured under the theme cautionary
realism.
The overall growth in cautionary concern (χ2 = 11.07,
p < 0.001) mirrors a rise in media attention about the use
of tDCS as a cognitive enhancer and in particular as a DIY
technology. Whereas no single commenter in the EARLIER
PERIOD mentioned DIY, this had risen to almost one in ten
comments for the LATER PERIOD. Comments mentioning
DIY reflected polarized views, as half of the commenters
expressed concerns about this practice and the other half
enthusiasm.
Skeptical comments centered most prominently on
questioning the value of tDCS as an enhancer (N = 54)
and its scientific validity (N = 49). In this LATER PERIOD,
comments portrayingmisunderstanding diminished (χ2 = 26.03,
p < 0.001), as expected in a more mature stage of public
awareness of the technology.
Compared to the EARLIER PERIOD, comments mentioning
technical issues (χ2 = 26.01, p < 0.001) and use of tDCS for
political leaders (χ2 = 8.42, p < 0.05) and children (χ2 = 3.94,
p < 0.05) were less frequent, whereas comments mentioning
commercialization (χ2 = 6.97, p < 0.01), therapeutic benefit
(χ2 = 7.8, p < 0.01) and policy and regulation (χ2 = 5.29,
p < 0.05) were more frequent. While most comments on policy
and regulation reflected concerns about the lack of regulation
(N = 29), a minority of these explicitly mentioned being against
any regulation of tDCS as an enhancer.
Discussion
A New Phase for Public Perceptions?
Our results are consistent with other temporal analyses of
technology and public understanding, such as those on climate
change (Capstick et al., 2014). Before 2012, when the technology
was still new in the public sphere, we found widespread
misunderstanding of tDCS. In both periods but even more
so in the LATER PERIOD, we found that in spite of
the loaded and often inadequate representation of tDCS in
the media, some commenters distinguished sharply between
different brain stimulation techniques and openly criticized
the inadequate language and analogies used in the media
articles, questioning not only the scientific validity of the articles
discussed in the popular media but also the domains to be
enhanced.
The availability of tDCS as a consumer device, as well as
the vivid online exchange of experiences with tDCS as well as
instructions for DIY use (cf.: http://www.reddit.com/r/tDCS/;
http://www.diytdcs.com) may be explanatory factors shaping
the change in public attitudes towards tDCS, The observation
that in the LATER PERIOD misunderstanding was reduced
can be regarded as evidence that the public was developing
a more mature understanding of tDCS. In view of the
past trends, it appears important to inform the public
accurately on the short- and long-term consequences of
tDCS on healthy individuals and on the plausibility of
enhancement effects. In addition, detailed knowledge of
the current practice and prevalence of DIY tDCS is also
needed.
Why Public Understanding Around tDCS Matters
Our findings have several implications. As tDCS becomes
assimilated into public’s consciousness, beliefs, attitudes,
intention and usage of tDCS are likely to change. For example,
a flawed understanding of the risk involved could lead to
the increased home use. Clear understanding is also of key
importance for making informed choices, in this case as
a potential consumer of tDCS (Bauer et al., 2006). This
becomes a pressing issue if we consider the number of online
resources and companies already advertising and promoting
a home use of tDCS as a cognitive enhancer. On the other
hand, greater familiarity with tDCS and related scientific
findings has helped the public to resist pseudo-scientific
information, to scrutinize the plausible from the implausible,
and to be cautious about using this technology as a cognitive
enhancer. Despite the decrease in misunderstanding, the fact
that tDCS continues to be confused with ECT may obfuscate
the discussion regarding regulation of tDCS. In this view,
online comments—ranging from sound counterarguments
to the claims made in the article, to personal stories, to
seemingly random remarks irrelevant to the article—enable
a dynamic construction of meaning and frames in which
tDCS can be understood. We invite policy makers to take
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into account public attitudes and (mis)understanding of
tDCS in order to maximize the benefits of innovation while
minimizing harms.
Conclusion
Analyses of comments in online discussion forums are a
relevant source to study public attitudes towards tDCS. As
this technology continues to mature and more applications
become available, researchers have the opportunity to explore
trends in public understanding as well as to determine the
factors shaping these changes. Our results show that while
misunderstanding has decreased as the technology matures, the
public seems to become more cautionary and at times skeptical
of this technology as a cognitive enhancer tool. From a public
policy perspective, analysis of public perceptions over time can
help to better inform governance and regulatory frameworks
for tDCS.
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